

© Copyright 2017

Shannon Leigh Newman

**H-NS Counter-silencing as a Primary Regulatory Mechanism of
Curli Gene Expression in *Salmonella* Typhimurium**

Shannon Leigh Newman

A dissertation
submitted in partial fulfillment of the
requirements for the degree of

Doctor of Philosophy

University of Washington

2017

Reading Committee:

Ferric Fang, Chair
Edith Wang
Beth Traxler

Program Authorized to Offer Degree:
Molecular and Cellular Biology

University of Washington

Abstract

H-NS Counter-silencing as a Primary Regulatory Mechanism of
Curli Gene Expression in *Salmonella* Typhimurium

Shannon Leigh Newman

Chair of the Supervisory Committee:
Professor Ferric C. Fang
Departments of Microbiology and Laboratory Medicine

Incorporation of horizontally acquired genes into transcriptional networks is essential for regulated expression of virulence in the bacterial pathogen *Salmonella enterica* serovar Typhimurium. The nucleoid-associated protein H-NS is able to recognize and bind AT-rich horizontally acquired genes, such as the *csg* regulon required for curli synthesis, and silence their expression. While previous studies have implicated a role of the alternative sigma factor σ^S in directly disrupting H-NS silencing, our system reveals that σ^S plays a more indirect role, acting through transcriptional regulators such as CsgD, IHF, and MlrA. I have identified an essential role of CsgD as a direct counter-silencer to H-NS silencing. Using a suite of footprinting techniques *in vitro*, I was able to determine that CsgD causes a topological distortion to disrupt the H-NS nucleofilament and reinstate RNA polymerase open complex formation. While σ^S appears to be required for *csgD* expression *in vivo*, *csgD* is σ^S -independent *in vitro*. Analysis of

regulators further upstream in the pathway suggest that both MlrA and IHF are required for *csgD* expression *in vivo* and are also dependent on σ^S . Initial studies *in vitro* suggest that MlrA may serve as a counter-silencer of H-NS, although the mechanism for this process awaits further characterization. Additionally, we identified a previously uncharacterized input for biofilm regulation. Vitamin B₁₂ likely serves as an allosteric regulator of MlrA and may serve as a photosensor to trigger biofilm formation in response to harmful UV irradiation. Characterization of counter-silencers in *Salmonella* can help us understand mechanisms of gene regulation that can be extrapolated to other organisms and provide new insights into the evolution of regulatory networks in bacteria.

Table of Contents

List of Figures	iii
List of Tables	v
Acknowledgements	vi
Dedication	viii
Chapter 1: Introduction	
Horizontal Gene Transfer as a Driver of Evolution.....	1
<i>Salmonella</i> as a Model Organism	3
Basic Prokaryotic Transcriptional Regulation	4
Nucleoid-Associated Proteins	5
H-NS	6
Counter-silencing.....	8
Scope of this Dissertation	9
Chapter 2: Materials and Methods	
Bacterial strains and plasmids.....	14
RNA isolation and quantitative PCR analysis of <i>in vivo</i> gene expression	17
Phenotypic Analyses	17
Western Blotting	18
Protein Purification	18
<i>In vitro</i> transcription	22
DNase I Footprinting and Fluorescent Primer Extension	23
KMnO ₄ Footprinting	23
Circular Permutation Assay	24
<i>In vitro</i> Vitamin B ₁₂ Transcription Assays	25
Chapter 3: Role of σ^S as a Transcriptional Regulator and Counter-silencer	
Summary	34
Introduction.....	34
Results	
H-NS depletion restores <i>spvB</i> expression in <i>rpoS</i> mutant <i>S. Typhimurium</i>	37
$E\sigma^S$ is unable to counter-silence <i>spvAB</i> <i>in vitro</i>	39
$E\sigma^S$ is unable to counter-silence <i>csgB</i> <i>in vitro</i>	40
Discussion	42
Chapter 4: CsgD Serves as a Transcriptional Regulator and Counter-Silencer at the <i>csgB</i> locus	
Summary	55
Introduction.....	55

Results	
H-NS depletion restores <i>csgB</i> expression in <i>rpoS</i> and <i>csgD</i> mutant <i>S. Typhimurium</i> ...	58
H-NS depletion restores RDAR phenotypes in an <i>rpoS</i> mutant	59
CsgD alone can counter-silence <i>csgB</i> <i>in vitro</i>	60
Biochemical analysis of CsgD-mediated counter-silencing	61
Discussion	64
Chapter 5: MlrA Antagonizes H-NS Silencing at the <i>csgD</i> promoter	
Summary	84
Introduction	84
Results	
H-NS depletion restores <i>csgD</i> expression in <i>rpoS</i> and <i>mlrA</i> mutant	
<i>S. Typhimurium</i>	87
MlrA is able to serve as a counter-silencer to H-NS independently of	
IHF <i>in vitro</i>	89
MlrA shows sequence similarity to other MerR-family members sensitive to	
vitamin B ₁₂	90
Light Exposure of the vitamin B ₁₂ -MlrA complex leads to high levels of	
transcriptional activation and counter-silencing <i>in vitro</i>	91
Discussion	92
Chapter 6: Significance and Future Directions	107
References	110
Supplemental References	126
Vita	130

List of Figures

Figure 1.1. Major horizontal gene transfer events in <i>Salmonella</i>	11
Figure 1.2. H-NS Silencing and Counter-Silencing Mechanisms.	12
<hr/>	
Figure 3.1. Depletion of H-NS using an inducible asHNS construct.	46
Figure 3.2. H-NS and σ^S play distinct and independent regulatory roles in <i>spvA</i> expression <i>in vivo</i>	47
Figure 3.3. <i>In vitro</i> transcription assays with different target promoters exhibit regulatory factor specificity.....	48
Figure 3.4. Neither $E\sigma^S$ nor $E\sigma^{70}$ show resistance to H-NS silencing <i>in vitro</i>	49
Figure 3.5. Crl does not mediate sigma-specific counter-silencing nor promoter selectivity at <i>csgB</i>	50
Supplementary Figure 3.1. The asHNS transcript does not directly deplete σ^S	51
Supplementary Figure 3.2. H-NS and σ^S exhibit little regulatory overlap in <i>Salmonella</i> <i>Typhimurium</i>	52
<hr/>	
Figure 4.1. CsgD and σ^S up-regulate <i>csgB</i> in stationary phase	68
Figure 4.2. Constitutive <i>csgD</i> expression <i>in trans</i> stimulates σ^S -independent <i>csgB</i> transcription.....	69
Figure 4.3. Depletion of H-NS restores biofilm formation in σ^S -deficient <i>S. Typhimurium</i>	70
Figure 4.4. CsgD counter-silences the <i>csgB</i> promoter <i>in vitro</i>	71
Figure 4.5. DNaseI Differential DNA Footprint Analysis (DDFA) of the <i>csgB</i> promoter region.....	72
Figure 4.6. KMnO ₄ Differential DNA Footprint Analysis (DDFA) at the <i>csgB</i> promoter region.....	73
Supplementary Figure 4.1. Alignment between <i>S. enterica</i> 14028s and <i>E. coli</i> K12 <i>csg</i> intergenic region.....	74
Supplementary Figure 4.2. H-NS depletion and mutation of <i>rpoS</i> or <i>csgD</i> have distinctive regulatory effects.....	75
Supplementary Figure 4.3. DNase I footprinting at the <i>csgB</i> promoter	76

Supplementary Figure 4.4. Circular Permutation Analysis of the DNA bending induced by CsgD binding.....	77
Supplementary Figure 4.5. Sense-strand DNase I Differential DNA Footprint Analysis (DDFA) of the <i>csgB</i> promoter region	78
Supplementary Figure 4.6. Sense-strand DNase I footprinting at the <i>csgB</i> promoter.	79
Supplementary Figure 4.7. KMnO ₄ footprinting analysis of the <i>csgB</i> promoter region	80
Supplementary Figure 4.8. Sense-strand DNase I DDFA of RNAP at the <i>csgB</i> promoter	81
Supplementary Figure 4.9. CsgD does not counter-silence its own promoter <i>in vitro</i>	82
Supplementary Figure 4.10. CsgD counter-silences the <i>csgB</i> promoter <i>in vitro</i> under varying conditions.....	83
<hr/>	
Figure 5.1. MlrA and σ^S up-regulate <i>csgD</i> in stationary phase	96
Figure 5.2. Constitutive <i>mlrA</i> expression <i>in trans</i> stimulates σ^S -independent <i>csgD</i> transcription	97
Figure 5.3. <i>ihfB</i> expression is dependent on σ^S and is required for <i>csgD</i> transcription in the presence of H-NS	98
Figure 5.4. MlrA counter-silences the <i>csgD</i> promoter <i>in vitro</i>	99
Figure 5.5. MlrA protein structure is similar to CarH.	100
Figure 5.6. Modulation of MlrA activity by vitamin B ₁₂ is light-dependent	101
Figure 5.7. Model of B ₁₂ -modulated regulation of <i>csgD</i> expression by MlrA and IHF	102
Supplementary Figure 5.1. σ^S -dependent curli expression does not result from SsrB or OmpR regulation	103
Supplementary Figure 5.2. MlrA and H-NS do not influence the expression of other <i>csgD</i> regulators.....	104

List of Tables

Table 1.1. AT-content of horizontally acquired pathogenicity islands	13
Table 2.1. Strains, Plasmids, and Primers	26
Supplementary Table 3.1. The H-NS- σ^S co-regulon in <i>S. Typhimurium</i>	53
Supplementary Table 5.1. Molecules most structurally-related to MlrA retrieved by the PHYRE server.....	105
Supplementary Table 5.2. Molecules most structurally-related to MlrA retrieved by COACH.....	106

Acknowledgements

My experience in graduate school was a kind of war of attrition, in which the emotional ups and downs of the science gradually wore away at me, and like most graduate students, I think there were plenty of moments in which I doubted my ability to finish what I had started. However, while the work presented in this thesis is my own, I think the only way it came to fruition was through the efforts of many, and as a result, I must acknowledge their contributions.

First and foremost, I need to thank Ferric. Ferric to me was always this kind of impossible human being that could be on top of everything professionally and still have an enriched personal life, and his ability to be exceptional at so many things was inspiring to me because it emulated the kind of personal-professional balance I hope to have and know is possible. His blanket knowledge of the field, clinically and scientifically, was useful in directing my project and placing it into a context that previously I didn't fully appreciate, and his perseverance in all facets of research will serve as a model for me as I go forward.

Secondly, it is pertinent that I recognize Ryan Will. Ryan served as my postdoc mentor when I joined the lab and because of his tireless efforts to develop techniques and analyses to characterize some of molecular mechanisms I will be discussing, my job in lab was made incredibly easier. I think I could say confidently that I would be here at least another couple of more years were it not for the ground-work that he did to set up the project.

Steve Libby, or "Father Steve" as I sometimes called him, was also instrumental to my graduate school career. Ever full of wisdom and support, Steve would encourage me to "Press on!" when things became challenging and helped me to trust in my knowledge and abilities, fostering a degree of self-confidence that I am still surprised by.

Briefly, I want to personally acknowledge all of the other Fang Lab members, past and present – Elaine Frawley, Joyce Karlinsey, Taylor Stepien, Rudy Urbano, Helen Warheit-Niemi, Anshika Singhal, Lacey Bingham-Ramos, Smirla Ramos, my bay-mate Traci Kinkel, and especially Larissa Singletary. I was extremely fortunate to have found myself in the company of extraordinarily intelligent and fun co-workers, many of whom became some of my closest and most reliable friends in Seattle. They knew the day-to-day struggles and they could empathize, so in a way that nobody else really could, they could help get me through the most challenging of times, because they had lived them as well.

I want to recognize my alma mater, Lawrence University, and more specifically, thank all of my dedicated professors. Lawrence really shaped who I am, both intellectually and personally, and I can't overstate the value of a liberal arts education in making me a well-rounded, open-minded, creative human being. I attribute my scientific curiosity and my devotion to teaching to my professors, as they served as role models for how important and influential a supportive instructor can be.

Finally, I need to acknowledge my parents, Jim and Colleen Newman, to whom this dissertation is dedicated. Growing up, I know that I didn't appreciate them nearly as much as they deserved. They have forever and always been my biggest champions. They have

unquestionably been there for me, always, and were on my side under every circumstance. I don't think it was until halfway through graduate school, a time when I thought I could be entirely independent, that I realized how much I needed them and how much they are willing to attend to my needs to ensure my safety, well-being, and happiness. It was the first time when I can identify my dependency on them to be beyond parental but as friends as well. As embarrassed as I am regarding the pride they take in me, I know it is just a measure of their love, so I will endure it and hope to show the same level of love and thereby, say I feel the same levels of pride toward them.

Dedication

To my parents, James and Colleen Newman

Chapter 1: Introduction

I. Horizontal Gene Transfer as a Driver of Evolution

Horizontal gene transfer, also referred to as lateral gene transfer, is broadly defined as the process by which genetic material is non-genealogically transmitted from one organism to another (1). This process is a potent driver of evolution among all biological kingdoms, including eukaryotes (2), plants (3) and bacteria (4), occurring both among and between these domains (5,6). However, this process is most significant and best understood in bacteria, in which the horizontal acquisition of new traits accounts for up to a third of all genes in some bacterial species (7). The significance of horizontal gene acquisition first came to light in the 1950s when multi-drug resistant bacteria began to emerge worldwide (8). Heavy antibiotic use following the discoveries of penicillin and sulfonamides was followed by the emergence of resistant strains. Newly acquired genes allow bacteria to adapt to ever-changing environments and exploit new ecological niches. Gene acquisition and loss promote speciation over time.

Horizontally transferred genes may be acquired through transformation, conjugation, or transduction (9). Transformation allows an organism to take up naked DNA from the environment. In transduction, genes are transferred from one bacterium to another by bacterial viruses, referred to as bacteriophages, and the DNA is subsequently integrated into the chromosome of the recipient. Conjugation requires direct contact between two viable bacteria. A mating bridge forms between the bacteria, and DNA in the form a plasmid is transferred across this bridge. Horizontally transferred genes exhibit both genetic and functional biases, and these biases facilitate the identification of horizontally-acquired genes. Within the genome, these genes are often integrated near tRNA loci or found in close proximity to phage/transposon genes (7).

Recently, horizontally acquired genes have been shown to exhibit promoter architecture distinct from that of classically regulated core genes (10). Horizontally acquired genes may exhibit unusual codon usage or exhibit a nucleotide compositional bias, often being relatively rich in AT-content compared to the host genome (11). In *Salmonella*, the AT-content of the genome is approximately 48%, whereas the AT-content of horizontally-acquired genomic islands and plasmids ranges from 53% to 63% (12) (Table 1.1).

While there are multiple mechanisms that mediate DNA uptake, novel genes are infrequently incorporated into a host genome (13). Genes that confer new traits such as virulence, stress resistance or cell surface alterations may be more likely to be retained. Some horizontally-acquired elements include genes that aid in integration and self-regulation, which are found in some of the *Salmonella* pathogenicity islands. A classic example is the *csg* locus. Organized as two divergently transcribed operons, the *csg* region consists of *csgBA*, which encodes the major structural subunits of the fibrous polymers, and *csgDEFG*, which encodes the major biofilm transcriptional regulator (CsgD) and the protein components required for secretion and assembly of the curli structures (CsgEFG). However, for most horizontally-acquired genes, incorporation into existing regulatory networks to allow coordinately regulated gene expression within the context of the existing genome is essential. The acquisition of horizontally-acquired genes drives both evolution and genetic diversity. Examination of horizontally-acquired genes has provided insights into the evolution of regulatory networks over time.

II. *Salmonella* as a Model Organism

Salmonella enterica has in particular served as a useful model organism for understanding the regulation of horizontally-acquired genes. This gastrointestinal Gram-negative pathogen is of global importance, most commonly causing enteric fever (typhoid) and enterocolitis/diarrhea, resulting in as many as 1.3 billion cases of infection and over 3 million deaths annually (14). *Salmonella* genetics are often compared to those of the related bacterium *Escherichia coli*. However, given that between 10-20% of the *Salmonella* genome consists of material absent from *E. coli*, it is believed that most of the phenotypic traits that distinguish the two are acquired through lateral gene transfer (15).

Unlike *E. coli*, which can serve as a gut commensal, all *Salmonella* are pathogenic, able to invade the intestinal epithelium and multiply within gut-associated lymphoid tissues (16,17). Virulence determinants acquired over time in the form of pathogenicity islands, mobile genetic elements and plasmids (Figure 1.1), distinguish *Salmonella* from its ancestors and generated diversity. For instance, *Salmonella* Pathogenicity Island-1 (SPI-1) has enabled *Salmonella* to invade epithelial cells (18), while SPI-2 has facilitated intracellular survival (19).

Oftentimes, the incorporation of newly-acquired genes has required integration into existing regulatory networks to coordinate appropriate expression. For instance, the magnesium ion-sensing PhoPQ system controls SPI-1 (20), while the stationary phase-associated sigma factor RpoS regulates expression of genes on the *Salmonella* virulence plasmid (21). Conservation of these common regulators across many gram-negative species has facilitated transfer events and increases the likelihood that new bacterial lineages may arise via horizontal gene transfer.

Current studies are attempting to better understand the mechanisms of *Salmonella* virulence, with a particular focus on pathogen evolution through horizontal gene transfer. Understanding this process in *Salmonella* will have broad implications for other bacterial species.

III. Basic Prokaryotic Transcriptional Regulation

Gene expression is a fundamental and universal process, allowing specific genetic programs to respond to changing environmental and growth conditions. In bacteria, transcription is a multi-step process with RNA polymerase (RNAP) as the primary driver of classical gene activation. While recognition of specific promoter sequences by RNAP regulates transcriptional initiation at the most basic level, a combination of transcription factors and other regulatory proteins act at promoter regions to silence or enhance transcription in response to environmental and biochemical cues, creating a system of integrated regulatory networks. Basal levels of transcription occur when RNAP coupled to a sequence-specific sigma factor recognizes and binds a promoter sequence to initiate transcription through the formation of an open complex (22). Transcription can be inhibited by binding of a repressor protein or enhanced through directed binding of a transcriptional activator that promotes RNAP-DNA interactions.

Gene transcription is also extensively affected by DNA supercoiling. The ability of RNAP to interact with a promoter to form an open complex is dependent on DNA topology and the constraints created therein (23-25). The superhelical density of DNA is regulated by topoisomerases I and II (gyrase), which can relax DNA or induce negative supercoils, respectively (26,27). Introduction of negative supercoils causes DNA twisting around the helical axis and DNA writhe around the superhelical axis (28). Writhe promotes long-range DNA

interactions, facilitating proximal positioning of regulatory proteins and genes with their promoter targets (29). Twisting may induce the formation of single-stranded bubbles, which enable the movement of RNAP from a closed to an open transcriptional initiation complex to enhance promoter clearance and transcriptional levels at certain genes (30,31). Environmental and growth conditions influence topoisomerase activity such that the superhelical density of the chromosome at any given time is highly dynamic (23). In addition to affecting RNAP-binding preferences, topological structure may also influence binding preferences by important regulatory proteins such as nucleoid-associated proteins (32).

IV. Nucleoid-Associated Proteins

Global gene regulation is best understood as an integrated model that includes elements of nucleoid architecture in addition to regulatory proteins. Bacteria must package their DNA in a way that is compact yet allows the DNA to be accessible for gene expression and regulation. Lacking a nucleus, prokaryotes package their DNA within the confines of the "nucleoid," a macromolecular complex in which genetic material and associated proteins are located (33-35). Compaction within this structure is implemented via three main mechanisms including molecular crowding (36,37), negative supercoiling (38) and interaction of DNA with nucleoid-associated proteins (39). Additional superstructures, including 400 looped domains and six macrodomains, provide further organization (40). Dynamic nucleoid architecture allows adaptation to modifications introduced by newly-acquired bacterial genes, influencing their expression and ability to become incorporated.

Nucleoid-associated proteins (NAPs) are integral to the regulation of existing and newly-acquired genes. This family of proteins exerts pleiotropic effects on gene expression through reversible local modulation of chromatin structure (41,42) as well as through direct promoter binding. Sensitivity to environmental and growth conditions allows tuned temporal regulation of gene expression. Factor for inversion stimulation (Fis) is the most prominent NAP during exponential phase, serving to up-regulate or repress many genes directly through promoter binding and indirectly through interaction with the topoisomerase genes (43,44). During post-exponential growth, levels of Fis decline due to auto-regulation, making way for other prominent NAPs in stationary phase, including DNA protection during starvation protein (Dps), and the histone-like nucleoid-structuring protein (H-NS). Interplay between NAPs adds an additional layer of regulatory complexity and greater precision. Fis and heat-unstable protein (HU) antagonize the activities of H-NS (45), while integration host factor (IHF) is required for *dps* transcription (46). Because NAPs have low DNA-sequence specificity, they are well-suited to the regulation of new horizontally-acquired genes, as foreign promoters do not necessarily contain specific regulatory sequences that are recognized by existing transcriptional regulators in the new host. One NAP that has been recognized to play an essential role in this process is H-NS, which is able to silence recently-acquired DNA.

V. H-NS

At about 20,000 copies per cell (47), H-NS is one of the most abundant chromatin-associated proteins. It binds DNA ubiquitously, controlling expression of over 200 genes through interaction with DNA topology, environmental cues, and other regulatory proteins. At a structural level, H-NS has two discrete and functionally independent domains, separated by a

flexible linker. The C-terminal domain mediates DNA-binding, while the N-terminal domain is essential for H-NS oligomerization (48). H-NS primarily forms tetramers, but higher levels of oligomerization may occur following binding and nucleation of DNA (49). DNA-binding by H-NS is specified by AT content. AT-rich tracts are recognized by a structural Q/RGR motif in H-NS that targets the minor groove of DNA (50). Oligomerization in response to divalent cation concentrations can lead to either DNA stiffening, wherein the H-NS-DNA complex forms a rigid nucleoprotein filament, or bridging, wherein relatively distant regions of H-NS-bound DNA interact, forming a DNA loop (51). This function is theorized to play a role in trapping RNAP (52). However, the stiffening mode of oligomerization has increasingly been associated with transcriptional silencing *in vivo* (53,54).

A strong correlation between H-NS binding and AT-rich horizontally acquired genes suggests a mechanism to allow self/non-self DNA-discrimination in bacteria (55,56). In a process called "xenogeneic silencing" (55), newly-acquired genes are silenced to protect a cell from potentially detrimental effects of unregulated expression, which can be relieved under appropriate conditions by other regulatory proteins. H-NS-mediated repression primarily occurs through direct transcriptional silencing (57,58) as well as through the modulation of DNA topology (32) (Figure 1.2). H-NS nucleation and oligomerization along a promoter region may be sufficient to occlude RNAP binding, thereby preventing transcription (10). In other instances, H-NS binds to regulatory regions both upstream and downstream of a promoter and alters superhelicity by constraining negative supercoils (59). In this scenario, RNAP is still able to bind but is unable to form an open complex. In some cases, RNAP may bind and form an open complex when H-NS is present, but structural loops formed by bridging prevent clearance of the promoter and thus

inhibit transcriptional elongation (52,60,61). H-NS is also able to bend DNA during bridging (62), bringing otherwise distant segments of DNA into close proximity. This may not only affect downstream topology, but may also facilitate silencing.

VI. Counter-silencing

In order to be useful to the recipient cell, newly-integrated DNA sequences silenced by H-NS must also be able to be appropriately expressed. Disruption of H-NS-mediated silencing by counter-silencing is a means by which repression can be reversed (Figure 1.2) (54,55). Oftentimes, counter-silencing factors consist of proteins that act as transcriptional activators at other loci, which are already able to respond to environmental cues. Exploitation of existing regulatory networks is one way in which horizontally-acquired genes can be regulated under appropriate conditions. Environmental changes in temperature, pH, and osmolarity can have a profound impact on DNA curvature, and at certain promoters, have been shown to affect H-NS binding (63).

Other regulatory proteins may also disrupt DNA-binding by H-NS. Fis is able to compete for binding sites and disrupt H-NS-stabilized complexes, promoting a switch from repression to stimulation at certain loci (64). In some instances, one protein may mediate both counter-silencing of H-NS and direct transcriptional activation. SsrB, a response regulator in the *Salmonella* SsrAB two-component system, both directly competes with H-NS for binding at virulence gene promoters and also induces a DNA conformational change that is unfavorable for H-NS-mediated stiffening (53). Other proteins may work in concert to achieve counter-silencing. For example, the MarR family regulatory protein SlyA competes with H-NS for DNA-binding

and alters the structure of H-NS bound DNA to allow another regulatory protein, PhoP, to bend DNA and facilitate open complex formation (10). H-NS homologs may serve as counter-silencers by disrupting the oligomerization capabilities of H-NS. H-NST, for example, is a truncated form of H-NS that lacks a DNA-binding domain but dimerizes with full-length H-NS molecules to disrupt their DNA-binding activity (65). More recently, a possible role of alternative sigma factors as counter-silencers has also been suggested (66-68).

VII. Scope of this dissertation

The overall goal of this dissertation is identify the scope of counter-silencing in the context of curli gene regulation. Chapter 2 contains specific details of the methods used throughout the dissertation. In Chapter 3, I consider a long-held hypothesis regarding the role of the alternative sigma factor σ^S as a potential counter-silencer. Other researchers have hypothesized a role for this sigma factor as an H-NS counter-silencer at the *spv* and *csg* loci, but this possibility has only been tested indirectly in *in vivo* studies. For the first time, I have used recently developed tools to directly characterize the nature of σ^S -H-NS regulatory interactions at these loci *in vitro*. Contrary to previous findings, I have found that σ^S lacks counter-silencing activity and have been able to demonstrate that σ^S exerts its actions indirectly via regulation of upstream pathways. In Chapter 4, I identify CsgD as the protein that is directly responsible for counter-silencing of the *csgBA* operon. I provide both *in vivo* and *in vitro* evidence for this finding and further define the mechanism of CsgD-mediated counter-silencing through DNase I and KMnO₄ footprinting. In Chapter 5, I describe studies to characterize the direct site of σ^S regulation, with a particular focus on the *csgD* locus. I show that σ^S is not directly required for transcription or counter-silencing of *csgD*, but rather, the σ^S -controlled regulators MlrA and IHF are responsible for

relieving H-NS repression at this promoter, leading to the expression of a downstream cascade of curli genes. In the final chapter, I discuss my work in the greater context of virulence gene regulation and the implications of my findings for the current understanding of transcription mechanisms within both *Salmonella* and other bacteria. In addition, I point to future directions for this work and address remaining unanswered questions.




Figure 1.1. Major horizontal gene transfer events in *Salmonella*. Filled arrows represent acquisition points of *Salmonella* virulence genes. Notable events include acquisition of *Salmonella* pathogenicity island 1 (SPI-1), *Salmonella* pathogenicity island 2 (SPI-2) and the *Salmonella* virulence plasmid (*spv*). Adapted from (69).




Figure 1.2. H-NS Silencing and Counter-Silencing Mechanisms. Left: Proposed mechanisms of H-NS-mediated silencing include nucleofilament formation to occlude promoter recognition (i), nucleofilament obstruction of elongation (ii), and trapping of RNAP in the bridging conformation (iii). Right: Four different mechanisms of counter-silencing have been proposed, including (i) competition for nucleation sites by promoter-specific transcription factors, (ii) topological distortions induced by promoter-specific transcription factors or environmental stimulation, (iii) activation by alternative sigma factors, and (iv) multimer disruption by protein antagonists. Adapted from (54,55).

Genetic Element	%AT-content
SPI-1	53.0%
SPI-2	55.4%
SPI-3	52.7%
SPI-4	55.2%
SPI-5	56.4%
Plasmid Virulence Genes	54.3%
<i>Salmonella</i> Genome	47.8%

Table 1.1 AT-content of horizontally acquired pathogenicity islands. The *Salmonella* pathogenicity islands and virulence plasmid genes exhibit AT-content substantially above the host genomic average, a hallmark characteristic of horizontally-acquired genes.

Chapter 2: Materials and Methods

Bacterial strains and plasmids

All *Salmonella enterica* serovar Typhimurium strains were constructed in a 14028s genetic background and grown in 50 mM NaCl Luria Bertani (LB) medium, which corresponds to 100 mOsm, unless otherwise noted. This medium has low osmolarity compared to typical LB (396 mOsm). All bacterial strains, plasmids, and primers are described in Table 2.1. Ampicillin and kanamycin were added to media as required at concentrations of 100 $\mu\text{g ml}^{-1}$ and 50 $\mu\text{g ml}^{-1}$, respectively. Deletions of *csgD*, *rpoS*, *crl*, *ihfA*, *ihfB*, and *mlrA* were generated using the λ -Red recombinase protocol (70), and antibiotic resistance markers were swapped out using pCP20 (71). Phage P22 HT105/1 *int*-201 was used for transduction of *csgD*, *rpoS*, *mlrA*, *crl*, *ihfB*, and *ihfA* mutations into the appropriate strains (72).

Plasmid pSLN15 was constructed by cloning a PCR fragment generated from the primers *csgD*-OE-F and *csgD*-OE-R into the *Bam*HI and *Xho*I sites of pET28b (Qiagen). Plasmid pSLN16 was constructed by cloning a PCR fragment generated from the primers EF154 and EF155 with pKD4 as a template into pHR103 (73) and inserted into the *Pvu*I site. Plasmid pSLN17 (pCsgD) was constructed by cloning the PCR product generated from the primers SP20 and SP21 into the *Xba*I and *Eco*RI sites of pSLN16. Plasmid pQE-80L-RpoS was constructed by cloning the PCR product generated from the primers RpoS-OE-F and RpoS-OE-R into the *Sac*I and *Hind*III sites of pQE-80L (Qiagen). Plasmid pQE-80L-RpoD was constructed by cloning the PCR product generated from the primers RpoD-OE-F and RpoD-OE-R into the *Sac*I and *Hind*III sites of pQE-80L (Qiagen). Plasmid pHN1009 asHNS was constructed by cloning a 128 bp fragment of the HNS promoter region starting 36 bp upstream of the translational start site and spanning 92 bp into

the gene. The fragment was amplified using primers asRNA HNS F and asRNA HNS R and inserted into the *NcoI* and *XhoI* sites of pHN1009 (74). Plasmid pSLN14 was constructed by cloning a PCR fragment generated from the primers *crl-OE-F* and *crl-OE-R* into the *SalI* and *XhoI* sites of pET28b (Qiagen). Plasmid pSLN31 was constructed by cloning a PCR fragment generated from the primers SP100 and SP103 and moved into the *NdeI* and *HindIII* sites of pET28b (Qiagen). Plasmid pSLN24 (pMlrA) was constructed by cloning the PCR product generated from the primers SP64 and SP65 and inserted into the *XbaI* and *EcoRI* sites of pSLN16.

C-terminal HA-tagged H-NS was created using the λ -Red recombinase protocol (70) with insertion of the *tetRA* locus using a PCR product generated from HNS-tetRA F/R primers into strain SL4482. The *tetRA* element was subsequently replaced with a PCR fragment amplified by HA-HNS fill-in F/R primers, generating strain SLN66. Using SLN66 gDNA as a template, Gibson cloning fragment 1 amplified with primers “HNS Gibson Scramble Fragment 1 F/R,” Gibson cloning fragment 2 amplified with primers “HNS Gibson scramble Fragment 2 F/R,” and Gibson cloning fragment 3 amplified with primers “H-NS Gibson Scramble Fragment 3 F and R” were PCR-amplified, gel purified and cloned at equimolar ratios into the *BamHI* site of pRDH10 using Gibson Assembly Master Mix (NEB) and incubated for 90 min at 50°C to construct plasmid pSLN23. pSLN23 was introduced into the *S. Typhimurium* SLN196 recipient strain, containing pSW172, by conjugation using *E. coli* S17-1 λ pir (FLS306) as the donor strain. Strain selection was performed as previously published (75) to create SLN221 and pSW172 was cured by growth at 37°C.

IVT Vectors. Plasmid pSLN7 was generated by cloning a 3.0 kb fragment of the *csgB* region, amplified using primers *csgA* IVT vector R and *csgA* IVT vector F, and ligated into the *HindIII* and *XbaI* sites of pRW20 (Will *et al.*, 2014). Plasmid pSLN25 was generated by cloning a 3kb fragment of the *mlrA* promoter region, amplified using primers *mlrA* IVT vector F and *mlrA* IVT vector R, and ligated into the *XbaI* and *SalI* sites of pRW20. Plasmid pSLN27 was generated by cloning a 2.7kb fragment of the *ihfB* promoter region, amplified using primers *ihfB* IVT vector F and *ihfB* IVT vector R, and ligated into the *XbaI* and *SalI* sites of pRW20. Plasmid pSLN13 was generated by cloning a 2.9kb fragment of the *ugtL* promoter region, amplified using primers *ugtL* IVT vector F and *ugtL* IVT vector R, and ligated into the *BamHI* and *HindIII* sites of pRW20. Plasmid pSLN10 was generated by cloning a 2.9kb fragment of the *purE* promoter region, amplified using primers *purE* IVT vector F and *purE* IVT vector R, and ligated into the *XbaI* and *EcoRI* sites of pRW20. Plasmid pRW20-*spvA* was generated by cloning a 2.5kb fragment of the *spvA* promoter region, amplified using primers *spvA* IVT vector F and *spvA* IVT vector R, and ligated into the *SmaI* and *HindIII* sites of pRW20. Plasmid pRW20-*katE* was generated by cloning a 2.9kb fragment of the *katE* promoter region, amplified using primers *katE* IVT vector F and *katE* IVT vector R, and ligated into the *SmaI* and *HindIII* sites of pRW20. Plasmid pRW20-*gmk* was generated by cloning a 2.0kb fragment of the *gmk* promoter region, amplified using primers *gmk* IVT vector F and *gmk* IVT vector R, and ligated into the *SmaI* and *HindIII* sites of pRW20. Plasmid pSLN19 was generated by cloning a 2.9 kb fragment of the *csgD* promoter region, amplified using primers *csgD* IVT vector F and *csgD* IVT vector R, and ligated into the *PstI* and *XbaI* sites of pRW20. Plasmid DNA for biochemical assays was purified as previously described (10).

RNA isolation and quantitative PCR analysis of *in vivo* gene expression

2×10^7 CFUs of overnight cultures grown in LB broth at 37°C were subcultured into 50 mL 100 mOsm LB broth and grown at 30°C. For exponential phase experiments, cells were split into two flasks, and one was induced with 1mM isopropyl β -D-1-thiogalactoside (IPTG) for approximately four hrs before reaching $OD_{600} \sim 0.6$. For stationary phase experiments, cells were split at $OD_{600} \sim 0.6$ into two flasks, and one was induced with 1 mM IPTG. After induction, cells were grown for another four hrs at 30°C. Cells were then pelleted and re-suspended in TRIzol reagent (Life Technologies) and incubated for a minimum of 30 min. After two chloroform extractions, isolated RNA was suspended in isopropanol and stored at -20°C until further processing. RNA was precipitated and washed per manufacturer's instructions. Five U DNase I (Thermo Fisher Scientific) were added to each sample and incubated for one hr at 37°C to remove residual DNA. RNA was extracted with acid-phenol:chloroform (1:1) and precipitated with 95% ethanol. The final RNA pellet was dissolved in RNase-free water. RNA was converted to cDNA using the QuantiTect RT-PCR kit (Qiagen) according to the manufacturer's instructions. cDNA was diluted appropriately (1:20) to bring samples into linear range of detection and transcripts were quantified via qPCR in a CFX90 (BioRad) using SYBR green master mix (76). Oligonucleotide pairs are described in Table 2.1. The relative expression of genes was determined by normalizing expression levels to *gyrB* transcript.

Phenotypic Analyses

Bacterial strains were grown in 100 mOsm NaCl LB overnight at 37°C. The cells were diluted to OD_{600} 1.0, and 5 μ L were spot inoculated on LB plates without salt and supplemented with the appropriate antibiotic(s), Congo red (40 μ g mL⁻¹), and Coomassie Blue (20 μ g mL⁻¹) (77). For

asHNS knock-down experiments, plates were spread with 40 μ L of 100 mM IPTG before spotting. Plates were incubated at 28°C or 37°C for three days without inversion.

Western Blotting

The asHNS construct and asVector control were transformed into an *S. Typhimurium* 14028s strain carrying an N-terminal HA-tagged H-NS chromosomal construct. Depletion experiments were conducted as above, but instead of harvesting cells for RNA collection, 0.25 OD₆₀₀ cells were collected at each time point by centrifugation. Pellets were boiled for 5 min at 95°C in 30 μ L Laemmli buffer, and total protein was separated using a 4-15% SDS gradient gel. Protein was transferred onto a PVDF membrane and, after blocking with PBS buffer containing 0.05% Tween-20 (PBS-T) and 5% Non-fat dry milk, incubated in blocking solution with 1:2000 anti-HA (Sigma), 1:1000 mouse IgG anti-sigmaS (Biolegend), or 1:80,000 anti-GroEL (Sigma). Membranes were washed in PBS-T and probed with either anti-rabbit IgG or anti-mouse IgG-HRP conjugate secondary antibody (Bio-Rad) diluted 1:10,000 in blocking solution, and visualized with Pierce ECL Western Blotting Substrate (Pierce).

Protein Purification

Sigma Factors. Expression vectors pQE-80L-RpoS and pQE-80L-RpoD were transformed into *E. coli* BL21 (DE3) cells for production and purification of recombinant sigma factors. Cells were grown at 30°C to OD₆₀₀ 0.5 in LB. Expression was induced with 1 mM IPTG for four hrs before cells were pelleted by centrifugation (7,000 \times g, 10 min at 4°C) and stored at -80°C. Cells were re-suspended in 20 mL binding buffer (50 mM NaH₂PO₄, 300 mM NaCl pH 8.0) with 0.5 mg mL⁻¹ lysozyme and protease inhibitors (Sigma). The solution was incubated on ice for twenty min and lysed by sonication, and supernatant was clarified with three rounds of centrifugation

(15,000 × g, 30 minutes each). Lysates were then applied to 5 mL HisTrap HP columns (GE Healthcare Life Sciences) equilibrated with binding buffer. Columns were washed first with 5 column volumes (CV) binding buffer followed by 4 CV binding buffer supplemented with 20 mM imidazole. Proteins were then eluted over a 20 CV gradient from 20 mM to 500 mM imidazole in binding buffer. Fractions containing sigma factors were determined by SDS-PAGE and pooled. Eluate was dialyzed overnight at 4°C at a 1:200 ratio to gel filtration buffer (50 mM Tris pH 7.9, 500 mM NaCl, 0.1 mM EDTA, 10 mM β-mercaptoethanol, 5% glycerol) and concentrated to 2.5 mL. The sample was injected into a 130 mL Superdex 75 gel filtration column (GE Healthcare Life Sciences) equilibrated with gel filtration buffer. Elution occurred over 180 mL. Pure fractions were identified by SDS-PAGE, dialyzed in storage buffer (50 mM Tris pH 7.5, 0.5 M NaCl, 1 mM EDTA, 0.5 mM DTT, 50% glycerol), and stored at -80°C.

H-NS. H-NS purification was performed as previously using pRW13 (10) except that elution from the His-Trap HP column was performed as follows: 10 CV of linear gradient of buffer containing 20 mM to 250 mM imidazole followed by a 5 CV wash with buffer containing 250 mM imidazole followed by a 5 CV linear gradient of buffer containing 250 to 500 mM imidazole. Purified protein was stored in aliquots at -80°C.

CsgD. pSLN15 was transformed into *E. coli* BL21 (DE3) for production and purification of CsgD. Cells were grown at 37°C to OD₆₀₀~0.6 in 100 mOsm LB and then induced with 1 mM IPTG for four hrs at 30°C and harvested and stored as above. Cells were re-suspended in 15 mL binding buffer supplemented with 20 mM imidazole, 1 mM PMSF, and protease inhibitors (Sigma) and lysed by sonication. The lysate was clarified by centrifugation (three times at 20,000

× g, 30 minutes each). Lysates were then loaded onto an equilibrated 5 mL His-Trap HP column (GE Healthcare Life Sciences) and washed with 50 mL binding buffer containing 20 mM imidazole. Protein was eluted over a 120 mL linear gradient of imidazole, from 20 to 250 mM, and CsgD-containing fractions were identified through SDS-PAGE. CsgD was concentrated using an Amicon Ultra centrifugal concentrator (Millipore), and the 6xHis-tag was removed using a Thrombin Cleavage Capture Kit (Novagen) with overnight incubation at 4°C, combining 1 mg protein with 1 U Thrombin. Any remaining precipitate was isolated by centrifugation. Residual thrombin was removed with streptavidin agarose per the manufacturer's protocol. Sample was dialyzed against binding buffer overnight at 4°C and then loaded onto 0.5 mL equilibrated Ni-NTA resin (Qiagen). Purified CsgD was collected from the flow-through and verified by SDS-PAGE. Pure cleaved CsgD was dialyzed into CsgD storage buffer (50 mM Tris pH 8.0, 100 mM NaCl, 0.1 mM EDTA, 0.5 mM TCEP, 50% glycerol) and stored at -80°C.

Crl. pSLN14 was transformed into *E. coli* BL21 (DE3) for production and purification of Crl protein. Cells were grown at 37°C to OD₆₀₀ ~0.6 and then induced with 1 mM IPTG for 3.5 hrs at 30°C before harvesting and storage at -80°C. Cells were resuspended in 15 mL Crl lysis buffer (50 mM Na₂HPO₄ pH 8.0, 300 mM NaCl), 1 mM PMSF, protease inhibitors (Sigma) and 1 mg/mL lysozyme prior to lysis by sonication. The lysate was clarified by centrifugation (2 times at 12,000 rpm, 30 min each) before the supernatant was combined with 2 mL equilibrated Ni-NTA beads (Qiagen) and incubated for 1 hr at 4°C. The beads were loaded onto a column and washed with 20 CV Crl lysis buffer containing 20 mM imidazole. Purified 6xHis-tagged Crl was eluted with 10 CV Crl lysis buffer containing 250 mM imidazole. Crl was concentrated using an Amicon Ultra centrifugal concentrator (Millipore), and the 6xHis-tag was removed using a

Thrombin Cleavage Capture Kit (Novagen) with 2 hr incubation at room temperature combining 1 mg protein with 1 U Thrombin. Remaining precipitate was isolated by centrifugation. Residual thrombin was removed with streptavidin agarose per the manufacturer's protocol. Sample was dialyzed against binding buffer overnight at 4°C and then loaded onto 0.5 mL equilibrated Ni-NTA resin (Qiagen). Purified CsgD was collected from the flow-through and verified by SDS-PAGE. Pure cleaved Crl was dialyzed into Crl storage buffer (50 mM Tris pH 7.6, 200 mM KCl, 10 mM MgCl₂, 1 mM DTT, 0.1 mM EDTA, 50% glycerol) and stored at -80°C.

MlrA. pSLN31 was transformed into *E. coli* BL21 (DE3) for production and purification of MlrA protein. Cells were grown at 37°C to OD₆₀₀ ~0.6 in LB and then induced with 0.1mM IPTG for 3 hrs at 37°C prior to harvesting and storage as above. Cells were resuspended in 20 mL MlrA lysis buffer (50mM Tris pH 8.5, 300mM NaCl, 5mM β-mercaptoethanol) with 1mM PMSF, 1mg/mL lysozyme and protease inhibitors (Sigma) prior to lysis by sonication, and the supernatant was clarified with centrifugation for 30 min at 12,000 rpm. The supernatant was set aside and the resulting pellet resuspended in 20mL Sarcosine Buffer (50mM Tris pH 8.5, 300mM NaCl, 1% Triton X-100, 1.5% N-Lauryl sarcosine, 25mM triethanolamine, 5mM β-mercaptoethanol and 1mM PMSF). The solution was placed over a stir plate in an ice bath and stirred for 30 min before spinning for 10 min at 12,000 rpm, and the resulting supernatant was combined with the supernatant from the lysis procedure and applied to 0.8 mL Ni-NTA beads (Qiagen) equilibrated with MlrA binding buffer (50mM Tris pH 8.5, 300mM NaCl, 20mM imidazole, 10% glycerol, 5mM β-mercaptoethanol and 1 mM PMSF). The supernatant was incubated with the resin for 2 hrs with rotation at 4°C. Beads were loaded onto a column to allow flow-through and then washed with 10 CV MlrA binding buffer followed by 10 CV MlrA wash

buffer (50mM Tris pH 8.5, 1M NaCl, 20mM imidazole, 10% glycerol, 5mM β -mercaptoethanol and 1mM PMSF). Purified protein was eluted with 10 CV MlrA elution buffer (50mM Tris pH 8.5, 150mM NaCl, 500mM imidazole, 10% glycerol and 1mM PMSF). MlrA was concentrated using an Amicon Ultra centrifugal concentrator (Millipore) and the 6xHis-tag removed using a Thrombin Cleavage Capture Kit (Novagen) with 24 hr incubation at 4°C, combining 2 mg protein with 1 U Thrombin. Remaining precipitate was isolated by centrifugation. Residual thrombin was removed with streptavidin agarose per the manufacturer's protocol. Sample was dialyzed against binding buffer overnight at 4°C and then loaded onto 0.8 mL equilibrated Ni-NTA resin (Qiagen). Purified MlrA was collected from the flow-through and verified by SDS-PAGE. Pure cleaved MlrA was dialyzed into MlrA storage buffer (50mM Tris pH 7.6, 200mM KCl, 10mM MgCl₂, 1mM DTT, 0.1mM EDTA and 50% glycerol) and stored at -80°C.

IHF. Purified IHF was received as a gift from Dr. Carlos Catalanos, University of Colorado – Denver and purified using a method described previously (78).

***In vitro* transcription**

All steps of IVT reactions were carried out at 30°C unless otherwise specified. Reactions were assembled in IVT buffer containing 40 mM HEPES, pH 7.3, 1 mM MgCl₂, 120 mM potassium glutamate, 0.5 mM CaCl₂, 1 mM DTT, 0.05% NP-40, 0.1 mg mL⁻¹ BSA and 10% glycerol to a final volume of 20 μ L. This concentration of potassium glutamate was used to promote potential sigma-factor specificity (79). To confirm that the elevated potassium glutamate concentration did not impact counter-silencing, counter-silencing IVT reactions were also performed in IVT buffer containing 50 mM potassium glutamate (Supplementary Figure 4.10a). Purified σ^S was incubated with RNAP core (New England Biolabs) at a 10:1 ratio, whereas purified σ^{70} was

incubated with RNAP core at a 2:1 ratio. RNA polymerase holoenzyme was reconstituted in IVT buffer for 30 min at 30°C immediately before use in IVT reactions. Template at a final concentration of 1 nM was combined with 20 U of RiboLock RNase Inhibitor (Thermo Fisher Scientific) and incubated for 10 min in order to equilibrate. For counter-silencing reactions, CsgD was added at 50 nM for 10 min before H-NS was added to a final concentration of 130 nM and incubated for 10 min, although the order of addition was not found to influence counter-silencing (Supplementary Figure 4.10b). Following the addition of regulatory proteins, reconstituted RNA polymerase holoenzyme was incubated with template for 10 min at a final concentration of 10 nM. rNTPs were added to a final concentration of 1 nM and the reaction incubated for an additional 30 min at 30°C. The reaction was stopped by adding 20 µL DNase I buffer containing 10 mM Tris-HCl (pH 7.5), 2.5 mM MgCl₂, 0.1 mM CaCl₂ and 4 U of DNase I (Thermo Fisher Scientific), and incubated for 30 min at 37°C. EDTA was added to final concentration of 5 mM and the reactions incubated for 10 min at 65°C to inactivate DNase I. cDNA synthesis was performed as previously (10) using the sequence-specific reverse oligonucleotide probes as indicated in Table 2.1.

DNase I Footprinting and Fluorescent Primer Extension

Reactions, fluorescent primer extension, and Differential DNA Footprint Analysis (DDFA) were performed as in Will *et al.* (10) using *csgB* FAM sense or *csgB* FAM anti-sense probes as indicated in Table 2.1.

KMnO₄ Footprinting

Reactions were assembled as described for IVT reactions, except that DTT was omitted from the IVT buffer. Proteins were sequentially added for 10 min each at 30°C as for IVT reactions,

except that RNAP was allowed to incubate for 15 min, at which point KMnO_4 was added to a final concentration of 10 mM. The reactions were allowed to proceed for 2 min and stopped by the addition of 2 μL of 14 M β -mercaptoethanol, followed by 78 μL of quenching buffer containing 1 M β -mercaptoethanol, 20 mM EDTA, and 385 mM sodium acetate (pH 7.0). Reactions were extracted with phenol: CHCl_3 :IAA (25:24:1) followed by chloroform and precipitated with 2 μL glycogen and ethanol. Reactions were washed 3 times with 70% ethanol, dried, and re-dissolved in 10 μL H_2O . Reactions were detected via fluorescent primer extension as above using the *csgB* FAM sense probe as the primer.

Circular Permutation Assay

A 32-bp region of the *csgB* promoter containing the CsgD-binding site was generated by PCR using primers SP136 and SP137 and cloned into the *EcoRI* and *SalI* sites of pTrc99a, making plasmid pSLN32. Using this plasmid as a template, circular permutation fragments were generated using PCR with the corresponding primer pairs for each fragment as indicated in Table 2.1 and diagrammed in Supplementary Figure 4.4a. Mobility of CsgD-bound fragments were analyzed using a gel shift assay. 20 ng of fragments (15.4nM) and 25x-molar concentration of purified CsgD (385 nM) were incubated in EMSA buffer (10 mM Tris pH 7.6, 50 mM KCl, 10% glycerol, 100 ng mL^{-1} BSA, 0.05% NP-40, 1 mM MgCl_2 , and 1 mM DTT) to a total volume of 10 μL . Binding reactions were carried out for 30 min at 30°C. Samples were loaded onto a pre-run 6% 19:1 native acrylamide gel in 0.5x TBE and run at 100V and 4°C. The gel was stained using SybrGold (Thermo Fisher Scientific) in 0.5x TBE at room temperature for 30 min and visualized using a Typhoon 9400 variable mode imager (GE Healthcare, Piscataway, NJ). Bend angle was estimated by determining the ratio of the mobility of the protein-binding site in the

middle of the DNA fragment relative to the mobility of a fragment bound by the DNA at the end (Thompson and Landy, 1988).

***In vitro* Vitamin B₁₂ Transcription Assays**

IVT reactions and E σ^S holoenzyme were assembled as described above. Vitamin B₁₂ (Sigma) dilutions were either covered in foil or pre-treated with 20 min exposure 4 cm from a white light source. One nM supercoiled *csgD* template was incubated with 50 nM or 200 nM MlrA at a 1:1 ratio with vitamin B₁₂ for 10 min before a 10 min incubation with either 130 nM H-NS or 20 nM IHF for 10 min followed by H-NS for 10 min. Reconstituted RNA polymerase holoenzyme was added, and the reactions proceeded as above.

Table 2.1. Strains, Plasmids, and Primers used in this Dissertation

Strain, plasmid, or primer	Genotype, relevant characteristics, or sequence	Reference
<i>Strains</i>		
SLN19	14028s pHN1009 asHNS	This Study
SLN36	14028s pHN1009	This Study
SLN66	SL4482 H-NS HA	This Study
SLN86	14028s <i>rpoS</i> pHN1009	This Study
SLN87	14028s <i>rpoS</i> pHN1009 asHNS	This Study
SLN96	14028s <i>crl</i> ::FRT::kan::FRT	This Study
SLN101	14028s <i>rpoS</i> <i>crl</i> ::FRT::kan::FRT	This Study
SLN102	14028s <i>rpoS</i> <i>hns</i>	This Study
SLN104	14028s <i>rpoS</i> <i>hns</i> <i>crl</i> ::FRT::kan::FRT	This Study
SLN112	14028s <i>csgD</i>	This Study
SLN114	14028s <i>csgDrpoS</i>	This Study
SLN123	14028s <i>csgD</i> pHN1009	This Study
SLN124	14028s <i>csgD</i> pHN1009 asHNS	This Study
SLN125	14028s <i>csgDrpoS</i> pHN1009	This Study
SLN126	14028s <i>csgDrpoS</i> pHN1009 asHNS	This Study
SLN134	SLN19 pSLN16	This Study
SLN135	SLN19 pCsgD	This Study
SLN136	SLN36 pSLN16	This Study
SLN137	SLN36 pCsgD	This Study
SLN138	SLN86 pSLN16	This Study
SLN139	SLN86 pCsgD	This Study
SLN140	SLN87 pSLN16	This Study
SLN141	SLN87 pCsgD	This Study
SLN195	14028s <i>mlrA</i> ::cm	This Study
SLN196	SLN66 pSW172	This Study
SLN198	<i>E. coli</i> S17-1 λ -pir pSLN23	This Study
SLN199	SLN19 pMlrA	This Study
SLN200	SLN36 pMlrA	This Study
SLN201	SLN86 pMlrA	This Study
SLN202	SLN87 pMlrA	This Study
SLN204	14028s <i>rpoS</i> <i>mlrA</i> ::cm	This Study
SLN207	14028s <i>mlrA</i> ::cm pHN1009	This Study
SLN208	14028s <i>mlrA</i> ::cm pHN1009 asHNS	This Study
SLN209	14028s <i>rpoS</i> <i>mlrA</i> ::cm pHN1009	This Study
SLN210	14028s <i>rpoS</i> <i>mlrA</i> ::cm pHN1009 asHNS	This Study

SLN211	14028s <i>rpoS</i> pSLN16	This Study
SLN212	14028s <i>rpoS</i> pMlrA	This Study
SLN221	SLN66 derivative with scrambled H-NS promoter	This Study
SLN222	SLN221 pHN1009	This Study
SLN223	SLN221 pHN1009 asHNS	This Study
SLN225	14028s <i>ihfA</i> ::cm	This Study
SLN242	14028s <i>ihfB</i> ::tetRA	This Study
SLN 272	14028s <i>ihfA</i> ::cm pHN1009	This Study
SLN273	14028s <i>ihfA</i> ::cm pHN1009 asHNS	This Study
SLN274	14028s <i>ihfB</i> ::tetRA pHN1009	This Study
SLN275	14028s <i>ihfB</i> ::tetRA pHN1009 asHNS	This Study
SLN276	14028s <i>ihfA</i> ::cm <i>ihfB</i> ::tetRA	This Study
SLN277	14028s <i>ihfA</i> ::cm <i>ihfB</i> ::tetRA pHN1009	This Study
SLN278	14028s <i>ihfA</i> ::cm <i>ihfB</i> ::tetRA pHN1009 asHNS	This Study
BL21 (DE3)	<i>fhuA2</i> [<i>lon</i>] <i>ompT gal</i> (λ DE3) [<i>dcm</i>] Δ <i>hsdS</i> λ DE3 = λ <i>SbamHI</i> o Δ <i>EcoRI</i> -B int::(<i>lacI</i> :: <i>PlacUV5</i> ::T7 gene1) i21 Δ <i>nin5</i>	New England Biolabs
SL4482	14028s <i>rpoS</i> *	(56)
DH10B	F- <i>mcrA</i> Δ (<i>mrr-hsdRMS-mcrBC</i>) Φ 80 <i>lacZ</i> Δ M15 Δ <i>lacX74 recA1 endA1 araD139 Δ(<i>ara, leu</i>)7697 <i>galU galK</i> λ- <i>rpsL nupG</i></i>	Invitrogen
FLS305	<i>E. coli</i> DH5a sup E44, Δ <i>lacU169</i> (Φ <i>lacZ</i> Δ M15), <i>recA1, endA1, hsdR17, thi-1, gyrA96, relA1, λpir</i> phage lysogen	(80)
FLS306	S17-1 λ <i>pir</i> TpR SmR <i>recA, thi, pro, hsdR</i> -M+RP4: 2-Tc:Mu: Km Tn7 λ <i>pir</i>	(80)
Plasmids		
pHN1009	Paired termini hairpin knock-down vector	(74)
pHN1009 asHNS	H-NS promoter fragment cloned into pHN1009 for induced knock-down	This Study
pHR103	<i>bla</i> Δ <i>lacIQ</i> P _{trc} oricolE1	(73)
pET28b	pBR322 <i>lacI</i>	Qiagen
pQE-80L	pBR322 oricolE1	Qiagen
pRW13	14028s <i>hns</i> cloned into <i>NcoI</i> and <i>XbaI</i> sites of pTrc99a for H-NS overexpression	(10)
pRW20	Transcriptional terminators cloned into pWKS30. Used for <i>in vitro</i> vector construction	(10)
pKD3	<i>bla</i> FRT <i>cm</i> FRT PS1 PS2 ori6K	(70)

pKD4	<i>bla</i> FRT <i>kan</i> FRT PS1 PS2 ori6K	(70)
pKD46	<i>bla</i> <i>araC</i> -P _{araB} $\gamma\beta$ <i>exo</i> oriR101 repA101(Ts)	(70)
pCP20	<i>bla</i> <i>cat</i> cI857 IPr <i>flp</i> PSC101 <i>oriTS</i>	(70)
pCsgD	14028s <i>csgD</i> moved into the <i>XbaI</i> and <i>EcoRI</i> sites of pSLN16 for constitutive expression	This Study
pRW20- <i>gmk</i>	14028s <i>gmk</i> moved into pRW20 for <i>in vitro</i> transcription reactions	This Study
pRW20- <i>katE</i>	14028s <i>katE</i> moved into pRW20 for <i>in vitro</i> transcription reactions	This Study
pRW20- <i>spvA</i>	14028s <i>spvA</i> moved into pRW20 for <i>in vitro</i> transcription reactions	This Study
pQE-80L-RpoD	14028s <i>rpoD</i> cloned into pQE-80L for protein overexpression	This Study
pQE-80L-RpoS	14028s <i>rpoS</i> cloned into pQE-80L for protein overexpression	This Study
pRDH10	<i>SacRB</i> <i>ori6K</i> <i>mobRP4</i> suicide plasmid	(80)
pSW172	OriR101 <i>repA101ts</i> Carb	(81)
pSLN7	14028s <i>csgB</i> region cloned into pRW20 for <i>in vitro</i> transcription reactions	This Study
pSLN10	14028s <i>purE</i> moved into pRW20 for <i>in vitro</i> transcription reactions	This Study
pSLN13	14028s <i>ugtL</i> moved into pRW20 for <i>in vitro</i> transcription reactions	This Study
pSLN14	14028s <i>crl</i> cloned into pET28b for protein overexpression	This Study
pSLN15	14028s <i>csgD</i> moved into the <i>BamHI</i> and <i>XhoI</i> sites of pET28b for overexpression	This Study
pSLN16	Kanamycin cassette moved into pHR103	This Study
pSLN19	14028s <i>csgD</i> moved into pRW20 for <i>in vitro</i> transcription reactions	This Study
pSLN23	Gibson assembly of scrambled H-NS promoter into pRDH10	This Study
pSLN24 (pMlrA)	14028s <i>mlrA</i> cloned into pSLN16 for constitutive expression	This Study
pSLN25	14028s <i>mlrA</i> moved into pRW20 for <i>in vitro</i> transcription reactions	This Study
pSLN27	14028s <i>ihfB</i> moved into pRW20 for <i>in vitro</i> transcription reactions	This Study
pSLN31	14028s <i>mlrA</i> cloned into pET28b for protein overexpression	This Study

pSLN 32	<i>csgB</i> CsgD binding site moved into pTrc99a for circular permutation template	This Study
Primers		
asRNA HNS F	GCCTGCTGCTCTCGAGAACAAACCACCCCA ATATAAGTTTGAG	This Study
asRNA HNS R	AGCAGTTGACACCATGGTTCCAGCATTCT TCAAGCGTTTCCAG	This Study
<i>csgA</i> IVT vector R	GGATCAAGCTTGCCAGCAGGCGTGA	This Study
<i>csgA</i> IVT vector F	CGTGTTCTAGAGCAGTTTTCCGGTTATGG	This Study
CsgD-OE-F	GCAGTGGATCCGTTTAATGAAGTCCATAGT AGTC	This Study
CsgD-OE-R	GAGTCCTCGAGTTACCGCCTGAGATTATCG	This Study
CsgD constitutive Plasmid insertion F	CTG TAG AAT TCA TGT TTA ATG AAG TCC ATA GTA GTC	This Study
CsgD constitutive Plasmid insertion R	CTGTATCTAGATTACCGCCTGAGATTATCG TTTGC	This Study
EF154	CACCGATCGGTCATTTCGAACCCAGAGTC CCGC	(73)
EF155	CACGATCGGATCCCCTCACGCTGCCGCAAG CACTC	(73)
RpoS-OE-F	GAGCTCATGAGTCAGAATACGCTGAAAGTT C	This Study
RpoS-OE-R	AAGCTTTTACTCGCGGAACAGCGCTTC	This Study
RpoD -OE-F	GAGCTCATGCCGCATATCGATCGGGAAG	This Study
RpoD-OE-R	AAGCTTTTAATCGTCGAGGAAGCTGCGCAG	This Study
<i>csgD</i> IVT vector F	CGTGTCTAGAGGCATTGTTTCTGAAACCAT TCTG	This Study
<i>csgD</i> IVT vector R	CGTGCTGCAGCGGTATTAATATTGGTCAAC AAGC	This Study
<i>pagC</i> qPCR F	GGGTCTGTTGAGCCTGAAGG	This Study
<i>pagC</i> qPCR R	GCCATCCTGAGTGGAATGTTC	This Study
<i>csgB</i> qPCR F	CACAAGAAGGAGGAAATAATCG	This Study
<i>csgB</i> qPCR R	TATTGGCCTTATTTCCAGAACC	This Study
<i>csgB</i> FAM anti-sense probe	5'-/56-FAM/CGCACCCAGTATTGTCAACATC	This Study
<i>csgB</i> FAM sense probe	5'-/56-FAM/ATACACTATCTTCTGTGGCC	This Study

<i>katE</i> qPCR F	GTATTCCACGCAGTTATCG	This Study
<i>katE</i> qPCR R	TGTGACTCATCCCATAACC	This Study
<i>purE</i> qPCR F	GTCTTCCC CGCAATAATCC	This Study
<i>purE</i> qPCR R	GGAAACCACTTCTACATGG	This Study
<i>gyrB</i> qPCR F	GATGGGTTTTCCAGCAGGTATTC	This Study
<i>gyrB</i> qPCR R	AGGTCTGATTGCGGTGGTTTC	This Study
<i>csgD</i> qPCR F	ATCTCTGCAAGCTACGG	This Study
<i>csgD</i> qPCR R	TCCGCTTCCATCATATCC	This Study
<i>mlrA</i> qPCR F	AGTAGCGAACAACCTAACG	This Study
<i>mlrA</i> qPCR R	ATGTTTGGGCAGGATAATCC	This Study
<i>ihfA</i> qPCR F	TCTGTTTGATAAGCTTGGGC	This Study
<i>ihfA</i> qPCR R	CAAAACCAGAGAGTTTCACC	This Study
<i>ihfB</i> qPCR F	GGTAAAAGAGATGCTGGAGC	This Study
<i>ihfB</i> qPCR R	TTACCCGGTTTAAAGTGAGG	This Study
<i>gmk</i> qPCR F	TCAGGTTTCCGTTTCACATAACC	This Study
<i>gmk</i> qPCR R	GTAGTAATTGCCAAACACTTCCG	This Study
<i>spvA</i> qPCR F	ACAATGGCACGAACCTGAG	This Study
<i>spvA</i> qPCR R	TGGAAAATGATACGGCAGC	This Study
<i>ugtL</i> qPCR F	TACCGTTTCGTTATCGGATGGGCT	This Study
<i>ugtL</i> qPCR R	AACCCTGCGATGATACCGTAATGC	This Study
<i>hns</i> qPCR F	ATGAGCGTCGTGAAGAAGAAAGCG	This Study
<i>hns</i> qPCR R	GCAGCCATGCTATTCAGCAGTTCA	This Study
<i>ompR</i> qPCR F	CGCCTGCGTAGTCAAAGTAA	This Study
<i>ompR</i> qPCR R	GATTTCCAGCCCGACGATAC	This Study
<i>ssrB</i> qPCR F	CATACGAGCCTGACATACTTATCC	This Study
<i>ssrB</i> qPCR R	CTTGTTGGTATGCTGTGTAAACC	This Study
deltarpoS F	TTGCTAGTTCCGTCAAGGGATCACGGGTAG GAGCCACCTTGTGTAGGCTGGAGCTGCTTC	(82)
deltarpoS R	AAGGCCAGTCGACAGACTGGCCTTTTTTTG ACAAGGGTACATGGGAATTAGCCATGGTCC	(82)
deltacsgD F	CAGCTGTCAGATGTGCGATTAATAAAGTG GAGTTTCATCGTGTAGGCTGGAGCTGCTTC	This Study
deltacsgD R	CTCTGCTGCTACAATCCAGGTCAGATAGCG TTTCATGGCCATATGAATATCCTCCTTAG	This Study
HA-HNS F	CCATACGATGTTCCAGATTACG	This Study
HA-HNS R	GCGTAATCTGGAACATCGTATGG	This Study

HNS Gibson Scramble Fragment 1 F	GCGACCACACCCGTCCTGTGCAAAGTACTG GAATATCTAATTTGTC	This Study
HNS Gibson Scramble Fragment 1 R	GACTGATCAGTTTGTGAGCTAATAATAGA GC	This Study
HNS Gibson Scramble Fragment 2 F	GCTCAACAACTGATCAGTCCGTA CTTTGA GATTGTATCTATGAGTGAGGCTCTTAAGAT CCTGAATAATATCCGCACACTGCCGTGCTC	This Study
HNS Gibson Scramble Fragment 2 R	ACGACGCTCATTAACGACA ACTTCTAATTT TTCAAGCATTTCTTCCAGAGTCTCAAGTGT GCACTCCCTAGCTTGAGCACGCAGTGTGCG	This Study
HNS Gibson Scramble Fragment 3 F	CGCTCTATTATTAGCTCAACAACTGATCA GTCCGTA CTTTGTGAGATTGTATCTATGAGTG AGGCTCTTAAGATCCTGAATAATATCCGCA CACTGCGTGCTCAAGCTAGGGAGTGACAC TTGAGACTCTGGAAGAAATGCTTGAAAAAT TAGAAGTTGTCGTTAATGAGCGTCCG	This Study
HNS Gibson Scramble Fragment 3 R	ACGATGCGTCCGGCGTAGAGCGGTCGCGG GATTGGGAA	This Study
H-NS tetRA F	AGAACAAGGTAAGCAACTGGAAGATTTCC TGATCAAGGAATTAAGACCCACTTTCACAT T	This Study
H-NS tetRA R	CCGCCAGCGGCGGGATTTTAAGCATCCAGG AAGTAAATTACTAAGCACTTGTCTCCTG	This Study
H-NS HA-tag fill-in F	CCGCCAGCGGCGGGATTTTAAGC	This Study
H-NS HA-tag fill-in R	AGAACAAGGTAAGCAACTGGAAGATTTCC TGATCAAGGAAGGAGCCGGAGCCTACCCA TACGATGTTCCAGATTACGCTTAATTTACTT CCTGGATGCTTAAAATCCCGCCGCTGGCGG	This Study
Circ. Perm. F ₁ F	CGCTCAAGGCGCACTCCC	This Study
Circ. Perm. F ₁ R	GACGGAAACATTTTAAAT	This Study
Circ. Perm. F ₂ F	GGATAATGTTTTTTGCGC	This Study
Circ. Perm. F ₂ R	CCAAGCTTGCATGCCTGC	This Study
Circ. Perm. F ₃ F	TCATAACGGTTCTGGCAA	This Study
Circ. Perm. F ₃ R	TCTTCTTCATCCGCCAA	This Study
Circ. Perm. F ₄ F	CTGAAATGAGCTGTTGAC	This Study
Circ. Perm. F ₄ R	TTAATCTGTATCAGGCT	This Study

Circ. Perm. F ₅ F	ATCATCCGGCTCGTATAA	This Study
Circ. Perm. F ₅ R	ATCAGACCGCTTCTGCGT	This Study
Circ. Perm. F ₆ F	GGAATTGTGAGCGGATAA	This Study
Circ. Perm. F ₆ R	TGCCGCCAGGCAAATTCT	This Study
Circ. Perm. F ₇ F	TCACACAGGAAACAGACC	This Study
Circ. Perm. F ₇ R	GTCAGGTGGGACCACCGC	This Study
Circ. Perm. F ₈ F	ATTCCCACGCGTGGGTGA	This Study
Circ. Perm. F ₈ R	TTCACTTCTGAGTTCGGC	This Study
<i>mlrA</i> IVT vector F	CGTGTCTAGACGCCACGCAGCG	This Study
<i>mlrA</i> IVT vector R	CGTGGTCGACGCCACGTTATCCAACAGGGA TCG	This Study
<i>ihfB</i> IVT vector F	CGTGTCTAGAGCGTTGACGGCCTGCTGC	This Study
<i>ihfB</i> IVT vector R	CGTGGTCGACGCCAAAGACTTTGTGATATA ACCG	This Study
<i>katE</i> IVT vector F	CTGCGATGTACCCGGGGCGCACTCTCCATC AGTAACGGC	This Study
<i>katE</i> IVT vector R	CGTGTAGCTTAAGCTTCCTGTCTGAAGGGT TAACGG	This Study
<i>spvA</i> IVT vector F	CTGCGATGTACCCGGGAATCGCTTGTCTGC CGGAC	This Study
<i>spvA</i> IVT vector R	CGTGTAGCTTAAGCTTGAGGTCCACATTGT CACCG	This Study
<i>gmk</i> IVT vector F	CTGCGATGTACCCGGGCGCCTTGTAGTCCG TTACCC	This Study
<i>gmk</i> IVT vector R	CGTGTAGCTTAAGCTTGCTTAATGAGGATG ACGCG	This Study
<i>purE</i> IVT vector F	GGTGTCTAGAAATGGTACTTTCCACACTA ATCACG	This Study
<i>purE</i> IVT vector R	CGTGTGAATTCTTATTTAAGCTTACTTTGCG C	This Study
<i>ugtL</i> IVT vector F	GGTGTGGATCCTACACCTGCCTGGGCGATG CC	This Study
<i>ugtL</i> IVT vector R	CGTGTAAGCTTTCAGGGTCTCTGCTTAACG G	This Study
crl-OE-F	GCAGTGTGACACGTTACCGAGTGGACACC CG	This Study
crl-OE-R	GAGTCCTCGAGTTATGCCGACAGTTTTACC GGC	This Study
SP64	CTGTAGAATTCATGGCGCTTACACAATTG G	This Study

SP65	CTGTATCTAGATTAAACGCCAAGGGGATGA ATGTCCG	This Study
SP100	CGTGAAGCTTTTAAACGCCAAGGGGATGA ATGTCCG	This Study
SP103	GGAATTCCATATGGCGCTTTACACAATTGG TG	This Study
SP136	GCTGGAATTCCCACGCGTGGGTGAGTTATT AA	This Study
SP137	CAGCGTCGACGGAAACATTTTTAATAACTC AC	This Study
delta- <i>mlrA</i> -F	TCTAAAGTTAAACCGGGACCTCGCGAGCAA GGGTGAAACGGTGTAGGCTGGAGCTGCTTC	This Study
delta- <i>mlrA</i> -R	TAAAAGGAGTATACATTAAAGCGAATTTGT TAGCTTCTGTCATATGAATATCCTCCTTAG	This Study
delta- <i>ihfA</i> - F	TTAAAAGAGCGATTCCAGGCATCATTGAGG GATTGAACCTGTGTAGGCTGGAGCTGCTTC	This Study
delta- <i>ihfA</i> -R	TGCCGCAATACACCCTGATGGATGTTATGC CTGGATCTGACATATGAATATCCTCCTTAG	This Study
delta- <i>ihfB</i> -F	ACGGCTGCAGCCAATTTGCCTTTAAGGAAC CGGAGGAATCGTGTAGGCTGGAGCTGCTTC	This Study
delta- <i>ihfB</i> -R	CTGACGGTGCTTTTTTCGGGTTCAAGTTTTG CGTTAAAACCATATGAATATCCTCCTTAG	This Study
delta- <i>crl</i> -F	TTGATTTGGTAAAACAGTTGCTTCATTTAA GGAGATCGCAGTGTAGGCTGGAGCTGCTTC	This Study
delta- <i>crl</i> -R	TGTGCCTGATGGCGCTGCGCCATCAGGCAT GGCAGCAGGGCATATGAATATCCTCCTTAG	This Study

Chapter 3: Role of σ^S as a Transcriptional Regulator and Counter-silencer

Summary

The bacterial sigma factor σ^S is responsible for the selective transcription of a subset of genes involved in adaptation to the stationary phase of growth and stress resistance. However, close relatedness to the housekeeping sigma factor σ^{70} and similar binding site sequences have raised questions regarding the basis of sigma factor selectivity at specific promoters. Some H-NS-silenced genes are transcribed by RNA polymerase (RNAP) associated with σ^S but not with σ^{70} , suggesting that σ^S might serve as a counter-silencer that allows RNAP to overcome H-NS-mediated silencing. If true, this might account for σ^S selectivity at certain promoters co-regulated by H-NS. To determine whether σ^S can directly counter-silence H-NS and whether co-regulation by H-NS accounts for selective σ^S activation of certain promoters, I examined the *spvAB* and *csgBA* promoters, which are known to be regulated by both σ^S and H-NS. Using genetic and *in vitro* transcription assays, I found that σ^S alone is unable to counter H-NS-mediated silencing at these genes. Rather, additional regulatory proteins are required to disrupt H-NS silencing of these promoters.

Introduction

Bacterial transcription in *Salmonella* is initiated by core RNAP (RNA polymerase) coupled with one of five sigma factors: RpoD (σ^{70}), RpoN (σ^{54} , σ^N), RpoH (σ^{32} , σ^H), RpoS (σ^{38} , σ^S) and RpoE (σ^{24} , σ^E). Each sigma factor directs RNAP to a different subset of promoters to alter patterns of gene expression. Formation of holoenzymes with different sigma factors is triggered by environmental cues or facilitated by expression of other cellular factors. Two of the

most prominent sigma factors are RpoD and RpoS. RpoD (σ^{70}) is the housekeeping sigma factor, responsible for transcribing the majority of *Salmonella* genes. RpoS (σ^S) is most important during times of environmental stress. This alternative sigma factor allows cellular adaptation to environmental factors such as pH, temperature, oxidative stress and nutrient deprivation (83,84). The latter response is commonly associated with activation of the RpoS regulon, because RpoS levels rise during stationary phase as cells experience starvation conditions. At that time, RpoS directly or indirectly promotes the expression of more than 500 genes in stationary phase, comprising just over 10% of the *Salmonella* genome (85). An RpoS response triggered by any of these stressors provides broad resistance to multiple stress conditions (86).

The mechanism of promoter selectivity for specific sigma factors has been intensively studied. RpoS itself is regulated at multiple levels, including transcription, translation, degradation and activity (for review see (85)). RpoS protein is essentially undetectable during exponential phase but levels increase during stationary phase and peak at about 1,600 copies per cell. This is still lower than stationary-phase levels of RpoD (7,000 copies per cell) or RNAP core (typically 2,500 copies per cell) (87). Moreover the affinity of RpoS for core RNAP is five-fold less than that of RpoD (88), raising the question of how $E\sigma^S$ effectively competes with $E\sigma^{70}$ at RpoS-regulated promoters.

Currently, there are three general theories for the basis of sigma factor selectivity at regulated promoters: (a) differences in promoter elements (89), (b) changes in promoter topology (90), and (c) participation by other inputs or global regulators to facilitate the formation or promoter interactions of specific RNAP holoenzymes (91) and thereby confer selectivity (92,93). Because RpoD and RpoS share considerable structural homology, promoter recognition sequences for these two sigma factors are very similar. Transcription from the promoters for

many genes are able to be initiated by either sigma factor *in vitro* (90), and *de novo* promoter sequences optimized for *in vitro* expression by $E\sigma^S$ retain the same core promoter elements as those for $E\sigma^{70}$ (94). Subtle structural changes in promoter elements, such as a conserved cytosine at -13 (94) or a more degenerate -35 site (95) can sometimes, but not always, drive a shift toward σ^S selectivity. Topologically, σ^S may have more flexibility regarding the geometric alignments of the -10 and -35 sites (96), creating more tolerance for supercoiling and non-optimal spacer lengths. However, exceptions to this observation occur as well (97).

Nucleoid-associated proteins can promote σ^S -selectivity through a variety of mechanisms. In some instances, activators, such as cAMP-CRP at the *csiD* promoter, are essential and only able to interact with $E\sigma^S$ rather than $E\sigma^{70}$ (98). In other instances, $E\sigma^S$ appears to be more efficient at disrupting transcriptional inhibitors, such as Crp, Lrp and IHF at the *osmY* promoter (92). Many σ^S -dependent genes have been shown to be transcribed independently of σ^S in an *hns* mutant strain, and by either sigma factor *in vitro*. These include many virulence genes such as *csgBA* (99) and *hdeAB* in *E.coli*, (66) and *spv* (68) and *csiD* (98) in *S. Typhimurium*. Based on these observations, it has been suggested that H-NS is a determinant of sigma factor selectivity, owing to a unique ability of σ^S to overcome H-NS mediated silencing (100).

Studies looking to examine the relationship between H-NS and RNAP have suggested multiple possible mechanisms by which H-NS represses transcription. Some observations have indicated that H-NS multimers occlude the promoter and prevent RNAP access (10,101), while others have correlated RNAP occupancy with H-NS binding at more than 65% of H-NS bound promoters (102), suggesting a model in which RNAP may be trapped by H-NS (52,66,103). However, such interactions implicate H-NS binding in a "bridging" mode (104), which occurs under conditions of high magnesium concentrations (51,52). Increasing evidence, however,

suggests that the linear filament or "stiffening" mode of H-NS binding is correlated with transcriptional silencing (53,54).

As the RpoS response is activated under conditions of environmental stress, as during *Salmonella* infection of a host, it seems plausible that RpoS could serve as a counter-silencer to promote the expression of virulence genes silenced by H-NS. Some have even suggested that RpoS promoter selectivity is a specific function of H-NS (85). However, while a number of studies have investigated a possible counter-silencing role for RpoS (66,67,92,98), other researchers have posited that RpoS indirectly stimulates the expression of H-NS-repressed genes by acting upstream in complex regulatory cascades (105).

In this chapter, I describe genetic and biochemical approaches to definitively characterize the role of σ^S -associated RNAP in alleviating H-NS mediated silencing at the *Salmonella spvAB* and *csgBA* genetic loci. Although my observations are inconsistent with the original hypothesis that RpoS directly counters H-NS silencing, I provide experimental support for the concept that RpoS antagonizes H-NS silencing of specific promoters by acting upstream to stimulate the expression of additional regulatory proteins that are responsible for H-NS counter-silencing.

Results

H-NS depletion restores *spvB* expression in *rpoS* mutant *S. Typhimurium*

My initial studies to investigate the potential role of RpoS as a counter-silencer utilized the *spv* operon. The *spv* genes are found in specific non-typhoidal *Salmonella* strains and are arranged in two operons, with the gene encoding a positive transcriptional regulator (*spvR*) transcribed upstream of the *spvABCD* structural genes. The *spv* genes are typically carried on the pSLT virulence plasmid (106), but in some cases, integration into the chromosome has been

noted (107). Expression is required for maximal virulence of *Salmonella* in mice and is induced upon intracellular localization. Both the transcriptional regulator SpvR and RpoS are required for expression (108), and H-NS has been shown to *silence spv* expression (68).

To better understand the co-regulatory relationship between H-NS and σ^S , we performed an *in vivo* genetic analysis of the *spvABCD* operon. Previous studies have found that *S. Typhimurium hns* mutants exhibit profound growth defects and rapidly acquire compensatory mutations in *rpoS*, resulting in reduced σ^S activity (56,109). To avoid adventitious compensatory mutations in *rpoS*, we used an IPTG-inducible antisense RNA construct to conditionally deplete *hns* mRNA *in vivo* (74). The paired-termini anti-sense *hns* (asHNS) transcript hybridizes to sequences flanking the ribosome-binding site and start codon of the *hns* promoter, occluding these regions and inhibiting translation (Figure 3.1), allowing inducible control of H-NS protein levels. Although σ^S protein levels also decrease during H-NS depletion, this is likely a result of H-NS acting indirectly as a positive regulator of *rpoS*, a phenomenon that has been observed previously (110,111). To confirm that the asHNS construct was not also directly inhibiting *rpoS* translation, the upstream portion of the *hns* transcript recognized by asHNS was mutated to disrupt asRNA binding but maintain a functional *hns* coding sequence (Supplementary Figure 3.1). H-NS and σ^S protein levels, as determined by immunoblot, were unchanged in strains encoding the mutant *hns* transcript, indicating that the decrease in σ^S levels observed in the wild-type strain is due to indirect regulation via H-NS and not due to a non-specific interaction between the *rpoS* transcript and asHNS.

Levels of the *spvA* transcript were measured during stationary phase in strains containing either the asHNS construct or an asRNA vector control. Expression of *spvA* is maximal during stationary phase (112). However, depletion of H-NS with asHNS resulted in an additional log-

fold increase in expression (Figure 3.2a), suggesting that under these conditions, H-NS is still able to silence *spv* expression to some extent despite the presence of RpoS. In an *rpoS* mutant, *spvA* expression was decreased by over one-log (Figure 3.2a), confirming that RpoS is required for *spv* transcription. Depletion of H-NS increased transcript levels by 2-fold, but levels of *spvA* transcription remained significantly lower than in wild-type (Figure 3.2a), indicating that σ^S and H-NS have independent roles in the regulation of *spvA* expression. Quantitation of control genes specifically dependent on either RpoS (*katE*) (Figure 3.2b) or H-NS (*pagC*) (Figure 3.2c) by qRT-PCR yielded the expected results.

$E\sigma^S$ is unable to counter-silence *spvAB* *in vitro*

To understand the direct roles of σ^S and H-NS in the regulation of *spvAB*, the *spvAB* transcriptional circuit was reconstituted *in vitro* from individual purified components on large supercoiled targets, which are likely to be more physiologically and structurally indicative of *spvAB* regulation *in vivo* than the small linear targets typically used in such studies. *In vitro* transcription assays using purified proteins show some target specificity, as H-NS exhibits increased repression for target genes with lower GC content (Figure 3.3a). $E\sigma^{70}$ stimulated higher levels of *gmk* transcription than $E\sigma^S$, whereas the reverse was observed for *katE* transcription (Figure 3.3b), indicating that these assays could detect σ factor promoter selectivity. However, the *spv* promoter did not exhibit a preference for either sigma factor, as levels of *spvA* transcription were similar for $E\sigma^{70}$ and $E\sigma^S$ (Figure 3.3b). To determine whether either RNAP holoenzyme was able to overcome H-NS-mediated silencing at the *spvAB* promoter, IVT assays were performed with either $E\sigma^{70}$ or $E\sigma^S$ on *spvAB* template incubated with increasing concentrations of H-NS. The two σ -factors exhibited nearly identical susceptibility to H-NS

silencing at this promoter (Figure 3.4a), suggesting that σ^S alone does not function as a counter-silencer of H-NS at the *spvAB* promoter.

Based on these observations, we investigated whether σ^S might promote counter-silencing in concert with additional regulatory proteins. As a precedent, the regulatory proteins SlyA and PhoP act in combination to relieve H-NS-mediated repression of the *Salmonella pagC* promoter (10). cAMP-CRP (98) and YncC (113) are also believed to be required for σ^S -mediated counter-silencing at their respective promoters, either by initiating sigma-specific recruitment or by altering the structure of the nucleoprotein complex at the promoter. In the case of *spvAB*, the LysR-family regulator SpvR is a good candidate as it has previously been shown to directly bind the *spvA* promoter region to up-regulate transcription (114) and has also been implicated in σ^S -mediated counter-silencing (68). However, numerous efforts to purify SpvR were unsuccessful, as the native protein was found to be insoluble, so I was unable to confirm this hypothesis *in vitro*. Nevertheless, the *in vitro* analysis of *spvAB* suggested that σ^S by itself is unable to counter-silence the actions of H-NS at this locus.

σ^S is unable to counter-silence *csgB* *in vitro*

I next focused my attention on the *csgBA* promoter. *In vitro* assays again confirmed that σ^S alone was not sufficient to promote counter-silencing (Figure 3.4b). However, at the *csgBA* locus, there are two other regulators in addition to RpoS and H-NS that have a possible regulatory influence, one being Crl (115). Crl was an attractive candidate for participation in sigma-mediated counter-silencing because of its ability to specifically interact with σ^S (116) and promote σ^S -dependent transcription initiation (115). Crl was first identified as a regulator of the *csg* genes that is important for curli fiber production (117) and the rdar morphotype (115). Crl

production is highest at lower temperatures (28°C), suggesting a potential role as a thermosensor (118) that links expression of the *csgBA* operon to temperature. Although *crl* mutations may decrease the expression of many RpoS-regulated genes (91), the strength of the direct interaction between the two proteins is considered to be relatively low (119), and the impact of Crl on gene expression is variable for different promoters (120,121).

In contrast to *Salmonella* and *E. coli*, many bacterial species that contain *rpoS* do not possess the *crl* gene (122), suggesting that it may have been horizontally acquired and supporting the idea that it may play a particularly important role in the regulation of horizontally-acquired genes such as the *csg* locus. Proposed mechanisms of Crl action include the modification of E σ^S positioning to alter DNA-RNAP complex architecture or enhancement of DNA melting by E σ^S (116). Either of these activities could effectively serve to disrupt H-NS silencing to allow transcription.

To test this hypothesis, a *crl* mutation was created to determine whether *crl* is necessary for *csgB* gene expression in the presence or absence of H-NS. Expression of *csgB* in wild-type cells occurs during stationary phase (123), but a *crl* mutation was not found to affect *csgB* expression (Figure 3.5a), suggesting that Crl is not required for *csgB* transcription in stationary phase. As *rpoS* mutants are defective for *csgB* transcription in stationary phase, expression was unaffected by a *crl* mutation in this background as expected. An increase in *csgB* transcript levels in stationary phase compared to exponential phase in an *rpoS* mutant, even with H-NS present, suggested that additional factors such as DNA supercoiling may affect H-NS silencing during stationary phase. However, the introduction of an *hns* mutation made *csgB* expression independent of both σ^S and Crl, enhancing transcription in exponential phase close to 10,000-fold, to a level comparable to that of stationary phase wild-type cells (Figure 3.5a). This suggests

that σ^S and CrI are not required for *csgB* transcription in the absence of H-NS. Furthermore, CrI does not appear to be responsible for counter-silencing of H-NS at the *csgB* promoter.

To further confirm this hypothesis, I incubated purified CrI for *in vitro* reactions with the $E\sigma^{70}$ and $E\sigma^S$ holoenzymes. This experiment verified that CrI does not enhance sigma factor activity or selectivity *in vitro* (Figure 3.5b).

Discussion

During the past two decades, several investigators have suggested that the ability of RpoS to overcome H-NS silencing may represent a mechanism of sigma factor selectivity. However, little direct *in vitro* evidence to support this hypothesis has been presented. My analysis of two different *Salmonella* genetic loci that exhibit regulation by both H-NS and σ^S suggests that RpoS is not in fact a direct counter-silencer of H-NS. My observations have shown that neither sigma factor is capable of disrupting H-NS under silencing conditions (Figure 3.4), and although RpoS is required for *spv* and *csg* gene expression in intact cells (Figures 3.2a and 3.5a), some relief of H-NS-mediated silencing can be observed during stationary phase that is independent of RpoS (Figure 3.5a), and that over 90% of H-NS-regulated genes are independent of σ^S (Supplementary Figure 3.2). This suggests that the involvement of σ^S is most likely independent of H-NS.

Some reports have suggested that only $E\sigma^S$ alone is able to form an open-complex in the presence of H-NS (98), using linear templates that are exclusively σ^S -regulated. Despite evidence that these same promoters in supercoiled templates exhibited equal levels of activation by either sigma factor, the effect of H-NS under these conditions was not studied. Other studies that have utilized supercoiled templates to conclude σ^S -specific counter-silencing have been based on the idea that H-NS can form bridges that can trap $E\sigma^{70}$ but not $E\sigma^S$ (66). However, the

bridging model relies on magnesium concentrations (10 mM) that are well above physiological concentrations (124). Since bridging in this model is the basis for selectivity, it would be curious to see if the same results occur under low magnesium concentrations when H-NS is in a stiffening mode. My study using supercoiled templates at biologically relevant magnesium concentrations (1 mM) has revealed that transcription levels are equivalent with $E\sigma^{70}$ and $E\sigma^S$ holoenzymes under these conditions and that H-NS is equally able to silence expression driven by either form of RNAP (Figure 3.4a).

To investigate the possibility of σ^S serving as a counter-silencer at other H-NS regulated promoters, and whether this activity could account for the apparent σ^S -selectivity of some promoters, i.e., whether $E\sigma^S$ is better able than $E\sigma^{70}$ to overcome H-NS-mediated silencing, we looked to the literature to identify genes within the σ^S -H-NS co-regulon. Although no studies have specifically compared H-NS, σ^S , and σ^{70} binding profiles in log and stationary phase, an analysis of previously published datasets suggests that significant overlap between the H-NS and RNAP- σ^S regulons is unlikely. Previous ChIP experiments revealed that H-NS binds approximately 35% of all σ^S -dependent genes during exponential phase (125), including the *csg* operon (101). However, many datasets describing the σ^S regulon rely on transcriptomic data, which is a poor indicator of actual σ^S binding, as they fail to account for cascading downstream effects that reflect indirect actions of σ^S (126). ChIP datasets from *E. coli* further reveal that as many as 90% of σ^S -regulated genes, including *csgD*, are also bound by σ^{70} to some extent, even during stationary phase (127). With these caveats in mind, we performed a comparative analysis of existing ChIP-chip (56) and transcriptomic datasets (128) from *S. Typhimurium*. Our analysis found that only 1% of all genes exhibit regulation by both H-NS and σ^S (Supplementary Figure 3.2). In view of this limited overlap, it appears unlikely that H-NS counter-silencing is a general

characteristic of the σ^S -regulatory network. Further investigation of these genes revealed that nearly all relied on additional transcription factors for transcriptional activation and possible disruption of H-NS (Supplementary Table 3.1). This observation by itself suggests that it is unlikely that H-NS is a major determinant of sigma factor selectivity at most σ^S -regulated promoters. Additional regulatory factors are likely to preferentially promote σ^S -binding (89,92) and to mediate counter-silencing.

Returning to the literature that served as the basis for this investigation, there are also indications that other proteins are involved in H-NS counter-silencing of RpoS-regulated genes. For example, regulatory proteins that bind to the *hdeAB* promoter region, such as GadW/X, are able to overcome H-NS silencing (129,130) of this RpoS-dependent gene (131), suggesting that RpoS acts at an upstream level. Another well-studied LysR regulator, LeuO, has been demonstrated to relieve H-NS repression (132,133), setting a precedent for SpvR-mediated counter-silencing.

The organizations of the *spv* and *csg* operons are similar in terms of having an auto-regulated transcription factor that is responsible for the downstream activation of structural genes. As will be discussed in Chapter 4, the transcriptional regulator of the *csg* structural genes, CsgD, is in fact a counter-silencer of H-NS. It is attractive to speculate that SpvR operates in a similar manner, disrupting H-NS silencing of the structural *spv* genes. In this scenario, RpoS would act upstream at the level of *spvR* transcription, which could account for my observation that H-NS can silence gene expression promoted by either sigma factor in the absence of SpvR. Further *in vitro* studies with purified SpvR protein would elucidate its potential role as a counter-silencer, but this will await technical advances that allow the purification of soluble protein. The basis for σ^S -regulation of the *spvR* promoter will also need to be explored. Although NAPs can

enhance σ^S binding (92), the interactions between RpoS and NAPs are likely to be much more complex, involving upstream actions and additional regulatory factors. Although a more comprehensive analysis of additional promoters will need to be done before H-NS is definitively excluded as a mechanism of σ^S -selectivity, the *in vitro* and transcriptomic analyses presented in this study suggest that this is improbable.




Figure 3.1. Depletion of H-NS using an inducible asHNS construct. H-NS was quantified from exponential and stationary phase cultures of SLN90 containing pHN1009 (asVector) and pHN1009 asHNS, which encodes an asRNA complimentary to the region flanking the ribosome binding site of *hns*. asRNA expression was induced with IPTG for 4 hrs, cells were harvested, and H-NS levels visualized via immunoblot analysis using an anti-HA antibody. σ^S is absent in log phase but increases in abundance during stationary phase. GroEL was detected as a loading control.





Figure 3.2. H-NS and σ^S play distinct and independent regulatory roles in *spvA* expression *in vivo*. Transcript levels of *spvA* (a), *katE* (b) and *pagC* (c) were quantified using qRT-PCR in wild-type and *rpoS* *S. Typhimurium* strains containing asVector or asHNS with IPTG added to deplete H-NS. Data are presented as the mean +/-SD of three replicates normalized to *gmk*. ** indicates $p < 0.01$ by ratio-paired t-test.



Gene Name	GC-content of Gene	%GC 500bp Upstream	%GC 200bp Upstream
<i>purE</i>	60.2	62.4	62
<i>katE</i>	49.6	53.9	57
<i>ugtL</i>	40.4	35.6	34
<i>csgB</i>	44.3	37.4	41.5

Figure 3.3. *In vitro* transcription assays with different target promoters exhibit regulatory factor specificity. a) Four supercoiled-template targets with various GC-contents were incubated with commercial holoenzyme and tested for H-NS silencing by adding increasing concentrations of H-NS. Genes with known high AT-content that are regulated by H-NS (*ugtL* and *csgB*) exhibit more silencing by H-NS than genes with higher GC-content (*purE* and *katE*). Data are presented as the mean +/-SD of three replicates and normalized to an RNAP-only control.

b) Reconstituted holoenzymes $E\sigma^S$ and $E\sigma^{70}$ both show transcriptional activity *in vitro*. $E\sigma^{70}$ showed higher levels of transcription of the housekeeping gene *gmK*, but $E\sigma^S$ had 2-fold higher transcription of the RpoS-regulated *katE* gene. The RpoS-regulated *spvA* gene exhibited no sigma factor selectivity *in vitro*. Data are presented as the mean +/-SD of six replicates and normalized to RNAP core without a sigma factor. ** indicates $p < 0.01$ by ratio-paired t-test.




Figure 3.4. Neither $E\sigma^S$ nor $E\sigma^{70}$ show resistance to H-NS silencing *in vitro*. *In vitro* transcription analysis of *spvA* (a) or *csgB* (b) shows that promoters transcribed by $E\sigma^{70}$ or $E\sigma^S$ exhibit concentration-dependent inhibition by H-NS at similar levels. Data are presented as the mean +/-SD of three replicates and normalized to an RNAP-only control.






Figure 3.5. Crl does not mediate sigma-specific counter-silencing nor promoter selectivity at *csgB*. a) The *csgB* gene exhibits stationary phase regulation *in vivo* that is reduced in the absence of *rpoS* but unaffected by a *crl* mutation. Introduction of an *hns* mutation results in a 4-log increase in expression during exponential phase that is also independent of *rpoS* and *crl*. b) The addition of purified Crl with either E σ^S or E σ^{70} *in vitro* does not stimulate *csgB* transcription. Data are presented as the mean +/-SD of three replicates normalized to *gyrB* expression (a) or expressed as relative copy number (b).



Supplementary Figure 3.1. The asHNS transcript does not directly deplete σ^S . To establish that pHN1009 asHNS does not directly target σ^S , the *hns* transcript sequence targeted by asHNS was mutated to disrupt recognition while maintaining *hns* expression. pHN1009 asHNS was induced for 4 hrs and σ^S and H-NS levels visualized via immunoblot. GroEL was used as a loading control.



	# of Regulated Genes
H-NS	691
σ^S	641
H-NS and σ^S	54
Other	4148

Supplementary Figure 3.2. H-NS and σ^S exhibit little regulatory overlap in *Salmonella Typhimurium*. Previous transcriptomic studies of the σ^S (Lévi-Meyrueis, Monteil *et al.* 2014) and H-NS (Navarre *et al.*, 2006) regulons were compared to identify co-regulated genes. σ^S and H-NS each regulate approximately 12% of the genome, whereas only approximately 1% of the genome is co-regulated by both σ^S and H-NS.

Supplementary Table 3.1. The H-NS- σ^S co-regulon in *S. Typhimurium*. Accessory proteins are those found to bind or have binding sites near the promoter based on data from *Salmonella* spp. or *Escherichia coli*. Blank entries indicate genes for which no accessory proteins have been identified or no data exists.

	Accessory Proteins	Function	Supplemental Reference
<i>bcfA</i>	GcvA; Hfq	fimbrial subunit	1, 2
STM14_0341		putative RHS-like protein	
STM14_0421		putative cytoplasmic protein	
<i>yahO</i>		putative periplasmic protein	
<i>ybaJ</i>	CpxR; PdhR (in <i>E. coli</i>); BasR	modulates Hha toxicity in <i>E. coli</i>	3,4,5
<i>ybeF</i>	AgrA	Lys-R family transcriptional regulator	1
<i>kdpE</i>		DNA binding transcriptional activator	
STM14_0886, <i>fumC?</i>	SoxS, MarA, Crp (<i>E. coli</i>), ArcA, Fnr	fumarate hydratase	6,7,8,9,10
<i>ycaM</i>		putative APC transporter	
<i>focA</i>	Crp, IHF, Fnr, NarL, ArcA, <i>wrcA</i> (<i>E. coli</i>)	formate transporter	11,12,13,14
<i>yccD</i>	Fis	chaperone-modulator protein CbpM	15
STM14_1454	Zur	periplasmic lysozyme inhibitor; possible phage protein	
STM14_1486		putative cytoplasmic protein	
<i>pagC</i>	SlyA, PhoP	virulence membrane protein	20
STM14_1523		putative protein	
STM14_1526		putative response regulator	
STM14_1529		putative cytoplasmic protein	
<i>spy</i>	CpxR, BaeR	Periplasmic stress response chaperone	42
<i>celD</i>	Crp, NagC, ChbR, Cap	DNA-binding transcriptional regulator ChbR	14,43
<i>ydiV</i>	TyrR, SdiA, FliZ	anti-FlhDC factor	1,44,45
STM14_1829		putative cytoplasmic protein	
<i>ydeJ</i>	Fnr (<i>E. coli</i>)	competence damage-inducible protein A	16
<i>ydeI</i>	Fnr, RcdA (<i>E. coli</i>), Rcs, PhoPQ, PmrAB	important for systemic infection	16,17,18,19
<i>yddX</i>	RcsB (<i>E. coli</i>), Fnr	biofilm dependent modulation protein	1,20,21
<i>yncC</i>	YgiV (<i>E. coli</i>)	DNA binding transcriptional regulator	22
<i>tyrR</i>	TyrR (<i>E. coli</i>)	DNA binding transcriptional regulator	23
<i>osmB</i>	RcsB (<i>E. coli</i>), FabR?	osmotically and stress inducible	24,25

		lipoprotein	
<i>yciG</i>	YncC	hypothetical protein	26
<i>yciF</i>	YncC	hypothetical protein	26
<i>yciE</i>	YncC	hypothetical protein	26
STM14_2094	TyrR, CyaR small rna (<i>E. coli</i>)	putative catalase	1,27
<i>ftnB</i>	CpxR (<i>E. coli</i>)	ferritin B	3
STM14_3108	TyrR, Crp	putative cytoplasmic protein	1
STM14_3193		hypothetical protein	
<i>hin</i>		DNA invertase	
<i>ygaU</i>	CpxR (<i>E. coli</i>)	uncharacterized protein containing LysM domain	28
<i>yqaE</i>	CpxR, CyaR (<i>E. coli</i>)	Membrane transporter	27,29
<i>nrdF</i>	Fur, NrdR, IscR (<i>E. coli</i>)	ribonucleoside-diphosphate reductase 2, beta subunit,	30,31
<i>luxS</i>	GcvA (<i>Salmonella</i>), CyaR small RNA (<i>E. coli</i>)	S-ribosylhomocysteine lyase/auto-inducer production	1,27
<i>mscL</i>		large conductance mechanosensitive channel protein	
<i>yhjY</i>		lipase	
<i>viaG</i>	Crp	Transcriptional regulator	1
<i>yibL</i>		conserved cytoplasmic protein	
<i>fidL</i>		Putative Inner Membrane Protein	
<i>marT</i>		Transcriptional Regulator of the ToxR family	
<i>lsrR</i>	LsrR, Crp	Transcriptional Regulator of the SorC family	32
<i>lsrD</i>	LsrR, Crp	Autoinducer-2 ABC transporter - membrane subunit	32
<i>lsrA</i>	LsrR, Crp	AI-2 ABC transporter - ATP binding subunit	32
<i>lsrB</i>	LsrR, Crp	Autoinducer-2 ABC transporter - periplasmic binding protein	32
<i>metJ</i>	Fur, MetJ	Transcriptional Repressor	33,34
STM14_5188		AraC-type DNA binding protein	
<i>spvA</i>	SpvR	Plasmid Virulence Gene	35
<i>slrP</i>	RstA, PhoP, SsrB, HilD	E3 ubiquitin-protein ligase	36,37,38
<i>dps</i>	MntR, Fis, OxyR, IHF, LysR	DNA starvation/stationary phase protection protein	1,39,40,41

Chapter 4: CsgD Serves as a Transcriptional Regulator and Counter-Silencer at the *csgB* locus

Summary

The *csg* locus required for curli fimbrial production in *Salmonella* and *E. coli* is stringently regulated under conditions of bacterial stress. With a primary role in environmental survival and host colonization, the transcriptional activation of this locus depends on σ^S and CsgD, whereas repression is mediated by the nucleoid-associated protein H-NS. In the previous chapter, I have shown that σ^S is not responsible for direct H-NS antagonism. In this chapter, I describe my investigations of the role of the LuxR-family transcriptional activator CsgD in disrupting H-NS. Using genetic and *in vitro* biochemical analyses, I have found that σ^S promotes *csgBA* expression via an indirect mechanism upstream of CsgD regulation. I further show that CsgD directly counter-silences the *csgBA* promoter by altering the structure of the nucleoprotein complex to disrupt H-NS-mediated silencing, in addition to directing the binding and stabilization of the RNAP open complex.

Introduction

The *csg* locus in *Salmonella* is a horizontally-acquired region (80) that encodes the production of curli fimbriae, which are important for both virulence in mice and bacterial survival in the environment (134). Curli are produced by many enteric pathogens, including many *Escherichia* and *Salmonella* spp., and promote community behavior and host colonization. In the environment, curli are important for adhesion to surfaces, cell aggregation, and biofilm formation, and are induced under conditions of low temperature and osmolarity, as well as in stationary phase (67). Organized as two divergently transcribed operons, the *csg* region consists

of *csgBA*, which encodes the major structural subunits of the fibrous polymers, and *csgDEFG*, which encodes the major biofilm transcriptional regulator (CsgD) and the protein components important for secretion and assembly of the curli structures (CsgEFG). While regulation of this operon has been studied extensively in *E. coli*, the binding pattern of CsgD has been noted to be very different between *E. coli* and *Salmonella* (135), despite high conservation of the immediate upstream regulatory sequences. An intergenic alignment between *E. coli* and *S. Typhimurium* shows that only 70% of the residues are conserved, with much of the divergence located further upstream into possible H-NS nucleation sites (Supplementary Figure 4.1), warranting additional study to compare genetic regulatory mechanisms between the two bacterial species.

The *csg* genes are regulated by the alternative sigma factor σ^S (Olsen *et al.*, 1993) but are also regulated by the LuxR-family transcriptional regulator CsgD and the nucleoid-associated silencing protein H-NS. Given that neither σ^S nor Crl has been implicated in H-NS counter-silencing at *csgB* (Chapter 3), it seems possible that CsgD plays a role in regulating *csgB* expression in the presence of H-NS. Disruptive counter-silencing by transcriptional regulators involves the remodeling of the H-NS-DNA complex to allow RNAP binding or transcript initiation and elongation (136). While H-NS binds non-specifically to many promoters, sequence-specific DNA-binding proteins such as CsgD have in some cases been shown to competitively antagonize H-NS. Such regulators typically exhibit consensus recognition sites that are relatively AT-rich (137,138) to coincide with AT-rich H-NS nucleation sites.

Mechanisms of counter-silencing by transcriptional activators can be grouped into three categories. The first involves competitive binding to recognition motifs by more specific regulatory proteins, leading to H-NS displacement from the DNA. This is observed with the H-NS homolog Ler. The binding affinity of Ler for the Lee5p promoter is 40-fold greater than that

of H-NS, so Ler is able to displace H-NS directly (139). Other proteins, such as ToxT, may indirectly displace H-NS by binding to high-affinity upstream sites and oligomerizing to lower affinity downstream sites to disrupt H-NS-DNA complexes (140). A second mechanism involves the structural alteration of a promoter to disrupt H-NS filament formation. For instance, VirB in *Shigella flexneri* binds and bends DNA around itself, disrupting H-NS nucleoprotein filaments (141). LeuO binding creates a physical barrier to H-NS oligomerization, indirectly inhibiting the ability of H-NS to silence transcription of the *ompS1* gene (142,143). A third mechanism by which transcriptional regulators can mediate counter-silencing is through stabilization of the RNAP complex. PhoP and SlyA, for instance, work cooperatively to distort the DNA in a way that stabilizes the RNAP open complex (10). Transcriptional elongation by RNAP may also be required to disrupt downstream H-NS filaments or bridging interactions (104,144). Transcriptional regulators may exhibit dual activities, as is observed with ToxT, which both counters H-NS silencing by competing for binding and stimulates RNAP recruitment to activate gene expression (140).

In this study, we used genetic and biochemical approaches to characterize the mechanism of H-NS-mediated silencing at the *csgBA* promoter and investigate the role of CsgD and σ^S -associated RNAP in alleviating this silencing. Contrary to some previous studies, we found that counter-silencing at this promoter is σ^S -independent, as the formation of an H-NS filament occludes RNAP binding, regardless of the associated sigma factor. The requirement for σ^S in curli expression is more likely to be at a level upstream of the *csgBA* operon, as previously suggested (105). Rather, it is the curli transcriptional regulator CsgD that disrupts H-NS-mediated silencing through the formation of a sharp bend in the promoter DNA, altering the structure of the H-NS-DNA filament and allowing directed binding of RNAP. This finding

highlights a novel counter-silencing protein, supports DNA bending as a fundamental mechanism of counter-silencing, and adds to a growing body of evidence suggesting that counter-silencing is a predominant mechanism of transcriptional regulation in bacteria.

Results

H-NS depletion restores *csgB* expression in *rpoS* and *csgD* mutant *S. Typhimurium*

The *csgBA* operon encoding curli fimbrial production is regulated by both H-NS and σ^S . To better understand the co-regulatory relationship between H-NS and σ^S , we performed an *in vivo* genetic analysis of the *csgBA* operon using an IPTG-inducible antisense RNA construct to deplete H-NS as above. The *csgB* transcript levels were then measured in strains containing either the asHNS construct or an asRNA vector control to examine the relationship between H-NS, σ^S , and CsgD. During exponential growth, *csgB* expression is low and unaffected by the mutation of either *rpoS* or *csgD* (Figure 4.1a), neither of which are normally expressed under these conditions (Figure 3.1) (145). However, in stationary phase, both *rpoS* and *csgD* are up-regulated (145), resulting in over a 350-fold increase in *csgB* expression relative to exponentially growing cells. Both σ^S and CsgD appear to be required for this growth phase-dependent expression, as mutation of either *rpoS* or *csgD* resulted in decreased *csgB* transcript levels similar to those observed in exponential phase (Figure 4.1b). However, the depletion of H-NS with asHNS resulted in a 4- to 6-fold increase of *csgB* transcript levels during exponential phase and a 10- to 21-fold increase during stationary phase in *rpoS* and *csgD* mutant strains, respectively, suggesting that these proteins oppose H-NS-mediated regulation of *csgB*. In wild-type cells during stationary phase, depletion of H-NS had no effect because both σ^S and CsgD were present and silencing was disrupted. Although a moderate decrease in *csgB* expression was

observed under these conditions, this is likely due to decreased concentrations of σ^S resulting from H-NS depletion (Figure 3.1). The regulatory phenotypes of the *hns*, *rpoS*, and *csgD* mutant strains were confirmed by quantifying the expression of genes regulated by either H-NS alone (*pagC*) or σ^S alone (*katE*) by quantitative RT-PCR (Supplementary Figure 4.2).

The comparable levels of *csgB* expression in *rpoS* and *csgD* mutants and the restoration of *csgB* transcription to similar levels by σ^S and CsgD suggests epistatic regulation of *csgB* by σ^S and CsgD. Although σ^S regulates *csgD* (Figure 4.2a)(145), it is unknown whether σ^S -mediated regulation of *csgB* occurs directly at the *csgB* promoter or indirectly via *csgD*. To experimentally uncouple *csgD* and *rpoS*, and to determine the regulatory role of CsgD independent of *rpoS*, the plasmid pCsgD, expressing *csgD* from a constitutive promoter was transformed into wild-type and *rpoS* mutant strains. Wild-type cultures containing pCsgD exhibited a 30-fold increase in *csgB* transcription during stationary phase (Figure 4.2b) as a result of increased *csgD* expression from the multicopy plasmid (Figure 4.2a)(146). In an *rpoS* mutant, *csgB* transcription decreased but was restored to wild-type levels in strains containing pCsgD, suggesting that σ^S is required for CsgD synthesis but not directly required for *csgB* transcription. H-NS depletion in an *rpoS* mutant did not result in any further increase in *csgB* expression in strains containing pCsgD (Figure 4.2b), suggesting that CsgD is able to completely alleviate H-NS-mediated silencing.

H-NS depletion restores RDAR phenotypes in an *rpoS* mutant

Expression of curli, along with cellulose and other polysaccharides, results in the formation of RDAR (red, dry, and rough) colonies in many *Salmonella* strains under conditions of low temperature (30°C) and osmolarity, as part of a multicellular stress response (147). The RDAR phenotype is dependent on the expression of a functional *csg* region. Wild-type cultures

are typically unable to form RDAR colonies at 37°C, but cultures expressing the asHNS construct at 37°C exhibit a partial RDAR phenotype (Figure 4.3a), suggesting that the temperature-sensitivity is a product of H-NS-mediated regulation. Although the colony structure of the asHNS strain is distinct, this may reflect a decrease in overall fitness due to the prolonged absence of H-NS, altering multicellular behavior, rather than a specific function of H-NS (56). *rpoS* mutant cells are unable to form RDAR colonies (Figure 4.3a). However, depletion of H-NS resulted in a rough phenotype in an *rpoS* mutant after three days at 30°C, and a partial restoration of the RDAR phenotype at 37°C.

Cultures expressing *csgD* constitutively from pCsgD were not temperature-sensitive, forming RDAR colonies at both 30°C and 37°C, as previously described (Kader *et al.*, 2006), and pCsgD partially rescued the RDAR phenotype in *rpoS* strains, even in the presence of H-NS (Figure 4.3b), suggesting that CsgD is a critical determinant of RDAR colony formation. However, none of the strains tested were capable of fully complementing an *rpoS* mutation and forming wild-type RDAR colonies, indicating that additional σ^S -dependent factors contribute to RDAR morphology.

CsgD alone can counter-silence *csgB* *in vitro*

To understand the direct roles of σ^S , H-NS, and CsgD in the regulation of *csgB*, the *csgB* transcriptional circuit was reconstituted *in vitro* from individual purified components on large supercoiled targets, which are likely to be more physiologically and structurally indicative of *csgB* regulation *in vivo* than the small linear targets typically used in such studies. *In vitro* transcription assays with both $E\sigma^{70}$ and $E\sigma^S$ indicated that the *csgB* promoter does not exhibit any basal σ -factor selectivity, as both holoenzymes transcribed *csgB* at similar levels (Figure

4.4), an observation that has been reported for other σ^S -dependent promoters (148,149). They both exhibit nearly identical susceptibility to H-NS silencing (Figures 4.4 and 3.4b). However, when purified CsgD was incubated with the H-NS silenced template, transcription increased 4-fold with $E\sigma^S$ and 8-fold with $E\sigma^{70}$ (Figure 4.4), suggesting that counter-silencing at *csgB* is dependent on CsgD rather than σ^S .

Biochemical analysis of CsgD-mediated counter-silencing

To understand the structure of the nucleoprotein complexes involved in silencing and counter-silencing of *csgB*, Differential DNA Footprint Analysis (DDFA), a highly sensitive quantitative method for analyzing DNA-protein interactions and DNA structure in footprinting experiments, was performed (10). This approach utilizes large targets and signal normalization to facilitate the analysis of DNA interactions with proteins such as H-NS that bind DNA in a relatively non-specific manner, which is not possible with conventional footprinting methods. Supercoiled *csgB* target was incubated with H-NS, as in the IVT studies described above, and the resulting complexes were analysed by DNase I footprinting. Analysis of the anti-sense strand revealed that although H-NS binds extensively along the *csgB* promoter region, two regions of concentrated binding are evident. The first is located upstream of the promoter, ranging from position -93 to -76 relative to the transcriptional start site (TSS), while a second region is detectable near the RNAP binding site from -37 to -5 (Figure 4.5a, Supplementary Figure 4.3b). These locations may represent sites of H-NS nucleation, and indeed, exhibit AT-rich sequences with some similarity to a previously defined high-affinity binding site (150). The absence of hypersensitive sites on either strand (Figure 4.5a, Supplementary Figure 4.5a), indicated by large upward peaks on DDFA plots and representative of DNA bends or distortions, suggests that H-

NS binds the *csgB* promoter in a “stiffening” mode to form a nucleoprotein filament, corroborating evidence that H-NS forms filaments at low magnesium concentrations (54).

Observed protected sites at -20 to -25 and -86 on the anti-sense strand (Figure 4.5b) and at -40 and -60 on the sense strand (Supplementary Figure 4.5b) suggest the locations of the CsgD footprint, which align more closely to previous findings in *E. coli* (135) than had been predicted in *Salmonella* (151). Binding closer to the promoter region introduced a hypersensitive site at position -33 (Figure 4.5b, Supplementary Figure 4.3c), suggesting that CsgD bends the DNA upon binding upstream of the *csgB* promoter. This is significant, as recent studies of SlyA-PhoP-mediated counter-silencing suggested that DNA-bending disrupts the H-NS-DNA filament to alleviate silencing (Will, *et al.*, 2014). The induction of a bend was confirmed by electrophoretic mobility shift assays (EMSAs) with circularly permuted DNA fragments (152). The differential gel mobility of identically sized CsgD-bound fragments with a binding site situated in the middle or at the ends demonstrated a bend, as a central bend results in increased distortion and slower migration compared to fragments with a peripheral bend. The ratio of the mobility shift exhibited by the fragment with a central site ($F_4=\mu_M$) compared to the fragment with a peripheral site ($F_8=\mu_E$) was 0.58 (Supplementary Figure 4.4), corresponding to a bend angle of approximately 108° (153).

CsgD and H-NS are able to concomitantly bind the *csgB* promoter, which can be discerned from the fact that the combined footprint of an H-NS + CsgD complex is distinct from that of each individual protein (Figure 4.5). Binding of CsgD to H-NS-bound DNA produces the same hypersensitive site as is observed with CsgD alone (Figure 4.5e). CsgD binding between -20 and -25, and near -86 (Figure 4.5b), overlaps both potential H-NS nucleation sites, suggesting that CsgD may disrupt filament formation through direct competition

for binding at H-NS nucleation sites. Although H-NS binding was also perturbed at other positions, such as -75 and -7, these positions exhibited significant variability, suggesting that the H-NS-CsgD-DNA complexes at these locations are unstable, perhaps as a result of a disrupted nucleation site. As we have observed at other promoters (10), most H-NS was not displaced despite profound changes in the architectural structure of the promoter introduced by CsgD, particularly upstream of the transcriptional start site at -5 and adjacent to the RNA polymerase binding site, at -25 (Figure 4.5e), indicating that the structure of the H-NS-DNA complex, rather than simple binding, is a critical determinant of H-NS activity. This is not entirely unexpected, as other studies have recognized that H-NS may remain bound to DNA during counter-silencing conditions, and the force imparted by RNAP elongation is sufficient to overcome bridging interactions (104,144,154).

Differential DNA Footprinting Analysis of the sense strand demonstrated CsgD binding at previously described recognition motifs near -60 (Supplementary Figures 4.5b and 4.6c), again in a pattern more similar to that observed in *E. coli* (135) than what had been predicted in *Salmonella* (151). H-NS is able to protect this strand at the -10 and -35 regions (Supplementary Figures 4.5a and 4.6d) but is displaced in the presence of CsgD, as reflected by the positive change at these sites when CsgD and H-NS are both present as compared to H-NS alone (Supplementary Figure 4.5c). However, the most striking distortion still appears to take place on the anti-sense strand, as noted above.

To investigate the mechanism of counter-silencing, KMnO₄ footprinting was performed, which identifies sites of open-complex formation through reaction with single-stranded DNA exposed by RNAP binding (155). H-NS silencing of the *csgB* promoter via an occlusion mechanism would be expected to result in the disappearance of an open complex upon H-NS

addition. However, silencing by a trapping mechanism would be expected to still show an open complex following the addition of H-NS, and silencing would result from abortive transcription (104). The addition of RNAP holoenzyme alone to the *csgB* promoter produced a stable open complex (Figure 4.6a, Supplementary Figure 4.7b), indicating that this promoter is transcriptionally competent. However, in the absence of other proteins, the open complex formed approximately 50 bp upstream of the usual transcription start site (99). This open complex was abrogated by the addition of H-NS (Figure 4.6b, Supplementary Figure 4.7e), suggesting that H-NS silences the *csgB* promoter by occlusion rather than by bridging and trapping (52). DNase I footprinting showed that RNAP is unable to bind in the presence of H-NS, particularly in the -20 region (Supplementary Figure 4.8b), eliminating the possibility that H-NS is able to bind but unable to form an open complex. The addition of CsgD restored the ability of RNAP to form an open complex in the presence of H-NS (Figure 4.6b, Supplementary Figure 4.7f) at a location corresponding to the usual transcription start site. RNAP also forms an open complex at this location with CsgD in the absence of H-NS (Figure 4.6a, Supplementary Figure 4.7d), suggesting that CsgD recruits RNAP to this site. These observations support the hypothesis that CsgD alters the H-NS nucleoprotein complex to allow RNAP binding and generate a transcriptionally competent promoter.

Discussion

Previous studies have shown that regulation of the *E. coli csgBA* curli fimbrial operon involves the interplay of several transcription factors, including H-NS, CsgD, and σ^S , with σ^S required for expression *in vivo* (67). In this study, we demonstrate that CsgD acts as a counter-silencer of H-NS in *S. Typhimurium*, remodeling the H-NS-DNA complex at the *csgB* promoter

to restore RNAP binding, whether associated with σ^S or σ^{70} , and that the specific requirement for σ^S is indirect and upstream of *csgD* expression. In addition, as is typical for a classical activator, CsgD directs RNAP binding to facilitate open complex formation at the *csgBA* promoter. These findings provide further evidence that counter-silencing is a major mechanism of transcriptional regulation in bacteria.

In agreement with previous studies (99), we found that *csgBA* expression is dependent on σ^S *in vivo*, but becomes σ^S -independent following depletion of H-NS by asHNS (Figure 4.1). Similarly, *csgBA* transcription is reduced in a *csgD* mutant but is restored by depletion of H-NS. Furthermore, transcription from the *csgBA* promoter becomes σ^S -independent in the absence of H-NS, as well as when *csgD* is constitutively expressed (Figure 4.2). Although previous studies suggested that H-NS is unable to silence transcription in the presence of σ^S (66), our data indicate that H-NS is able to repress σ^S -bound promoters both *in vivo* and *in vitro*. This suggests a direct requirement for CsgD, rather than σ^S , to mediate counter-silencing and drive transcription of the *csgBA* promoter. σ^S activates a feed-forward regulatory loop at the *csg* operon, in which σ^S either directly or indirectly stimulates expression of *csgD* at the onset of stationary phase (145), and in turn CsgD enhances expression of σ^S indirectly through transcriptional activation of *iraP*, which stabilizes σ^S (Gualdi *et al.* 2007). The apparent σ^S -dependence of *csgB* may be attributable to the σ^S -CsgD feed-forward loop. Correspondingly, the lack of σ^S is analogous to the absence of CsgD, abolishing transcription of *csgBA*.

Our DNase I footprinting DDFA studies (Figure 4.5) are consistent with H-NS nucleation at high affinity “TpA” steps and oligomerization along lower affinity regions flanking the *csgBA* promoter (54,156), beginning upstream of the RNAP binding site and extending into the coding region, likely resulting in the occlusion of RNAP binding (95). DDFA plots of CsgD binding at

csgBA revealed that CsgD binds immediately upstream of the TSS, competing with H-NS nucleation sites and inducing a sharp bend in the H-NS-bound DNA at the promoter, a structural change that is likely to disrupt H-NS-DNA filament formation (10,136). Previous studies have suggested that CsgD functions as a classical activator due to its binding site overlapping the -35 box of the RNAP binding site (157), and our observation of directed open complex formation in the presence of CsgD supports that hypothesis. However our observations also suggest that CsgD-mediated counter-silencing is essential for *csgB* expression.

There appear to be additional uncharacterized requirements for CsgD-mediated regulation at some promoters, as CsgD is reported to regulate other genes, including its own promoter (145), but is unable to counter-silence or activate its own promoter *in vitro* (Supplementary Figure 4.9). A likely explanation is that an additional factor acts as a co-counter-silencer with CsgD. However, the identity of potential co-counter-silencers at *csgD* is presently unknown.

CsgD is a member of the LuxR-family of transcriptional regulators, which have been shown to be involved in biological processes including quorum sensing, virulence, motility, plasmid transfer, and biofilm formation in a variety of bacterial species (158). Previous studies have suggested that LuxR-family members can serve as either direct activators or repressors of transcription (159,160), but there is also a precedent for LuxR and its homologs to serve as counter-silencers. In *Vibrio* species, LuxR acts in conjunction with σ^S at the *lux* bioluminescence genes to relieve H-NS silencing, as neither LuxR nor σ^S are necessary for *lux* expression in an *hns* mutant (161,162). In *Pseudomonas aeruginosa*, the LuxR regulators RhIR and LasR promote stationary-phase expression of *lecA*, which is silenced by the H-NS functional homologue, MvaT (163), and in other enteric bacteria, LuxR regulators such as BglJ (found in *Salmonella*, *E. coli*,

and *Shigella*) (164) and EcpR (found in both enteropathogenic and enterohemorrhagic *Escherichia coli*) (165) have also been found to disrupt H-NS silencing. The recognition sequences of LuxR-family proteins tend to be degenerate in nature, allowing them to recognize a variety of foreign promoters (166,167). Additional studies have suggested that, like CsgD, LuxR bends DNA upon binding (Stevens, Dolan *et al.*, 1994), which might allow it to disrupt the H-NS-DNA filament and function as a counter-silencer. In view of these observations, the LuxR-family transcriptional regulators may function primarily as counter-silencers rather than classical activators. As this family of transcriptional regulators can be found in many bacterial species, counter-silencing by these proteins may be a conserved mechanism to incorporate horizontally acquired genes into host genomes.

In summary, we have demonstrated for the first time that CsgD induces distinct structural changes at the *csgBA* promoter and promotes transcription by disrupting H-NS silencing and directing RNAP binding and open complex formation. As σ^S does not act as a counter-silencer of *csgBA* expression, the basis for the σ^S -dependence of the curli operon is presently unclear. A role of σ^S in *csgD* regulation has not been excluded. However, given the number of additional regulators at the *csgD* promoter (145), the explanation is likely to be more complex and awaits further investigation, as will be discussed in Chapter 5.




Figure 4.1. CsgD and σ^S up-regulate *csgB* in stationary phase. *csgB* transcript levels were quantified by qRT-PCR during a) exponential or b) stationary phase in wild-type, *rpoS*, *csgD*, and *rpoS csgD* *S. Typhimurium* strains containing pHN1009 or pHN1009asHNS, with IPTG added to deplete H-NS. Data are presented as the mean +/- SD of three replicates normalized to *gyrB*; * indicates $p < 0.05$, ** indicates $p < 0.01$, *** indicates $p < 0.001$, and **** indicates $p < 0.0001$ by ratio-paired t-test.




Figure 4.2. Constitutive *csgD* expression *in trans* stimulates σ^S -independent *csgB* transcription.

a) *csgD* transcript levels were quantified using qRT-PCR in wild-type and *rpoS* *S. Typhimurium* containing pCsgD, which contains *csgD* downstream of a constitutive promoter. b) *csgB* transcript levels were quantified in response to *csgD* constitutive expression in strains containing both pCsgD and pHN1009asHNS. Data are presented as the mean +/- SD of three replicates normalized to *gyrB* expression; ** indicates $p < 0.01$, and *** indicates $p < 0.001$ by ratio-paired t-test.




Figure 4.3. Depletion of H-NS restores biofilm formation in σ^S -deficient *S. Typhimurium*.

a) Wild-type and *rpoS* strains of *S. Typhimurium* were spotted on Congo Red plates and incubated at 30 or 37° C to determine their RDAR phenotypes. b) *rpoS* strains containing pCsgD exhibited enhanced RDAR morphology in an *rpoS* mutant when compared to an *rpoS* strain containing the control vector.




Figure 4.4. CsgD counter-silences the *csgB* promoter *in vitro*. The *csgB* transcriptional circuit was reconstituted *in vitro* using purified, supercoiled DNA template containing a 3kb-region of DNA surrounding the *csgB* promoter and purified protein components. Either E σ^S or E σ^{70} can initiate transcription of the *csgB* promoter *in vitro*. CsgD-mediated counter-silencing was assayed by incubating the *csgB* template in the presence of 50 nM CsgD before adding 130 nM H-NS. Transcript levels are expressed as relative copy number. Data are presented as the mean +/- SD of three replicates; * indicates p<0.05 by ratio-paired t-test.




Figure 4.5. Anti-sense strand DNaseI Differential DNA Footprint Analysis (DDFA) of the *csgB* promoter region. *In vitro* DNase I footprinting at the *csgB* promoter was performed with 130 nM H-NS and 50 nM CsgD, as indicated. Peaks are regions of hypersensitivity, which are suggestive of distorted or bent DNA, whereas valleys indicate sites of protection. Base positions are indicated relative to the TSS. a) H-NS, b) CsgD, or e) CsgD and H-NS were added to the *csgB* promoter and the fluorescent peak height following DNase I cleavage determined relative to the protein-free control in relative fluorescent units (RFU). The differences compared to the H-NS control (c) and the CsgD control (d) were also analyzed. Data are presented as the mean \pm SD of three replicates.






Figure 4.6. KMnO₄ Differential DNA Footprint Analysis (DDFA) at the *csgB* promoter region.

KMnO₄ footprinting reactions, which detect regions of single-stranded DNA generated during open-complex formation, were performed on the *csgB* promoter region with RNAP, CsgD, and H-NS, as indicated. Peaks, in relative fluorescent units (RFUs), indicate regions of single stranded DNA present in the experimental samples that are not present in control (no RNAP) reactions. Base positions are indicated relative to the TSS. a) KMnO₄ footprinting analysis indicates that the location of RNAP open complex formation on the naked DNA promoter is dependent on the presence or absence of CsgD. RNAP alone is capable of forming a weak open complex at an upstream site, but the addition of CsgD directs RNAP to the previously identified transcriptional start site. b) RNAP is unable to form an open complex in the presence of H-NS, but the addition of CsgD restores open complex formation at the *csgB* promoter. Data are presented as the mean +/- SD of three replicates.




Supplementary Figure 4.2. H-NS depletion and mutation of *rpoS* or *csgD* have distinctive regulatory effects. To confirm the specific regulatory effects of H-NS depletion, or the inactivation of the *rpoS* and *csgD* genes, transcript levels of well-characterised σ^S - and H-NS- regulated genes (*katE* and *pagC*, respectively), along with an unregulated control gene (*purE*), were quantified by qRT-PCR during a) exponential phase, b) stationary phase, and c) in strains containing pCsgD. Data are normalized to *gyrB* and presented as the mean +/- SD of three replicates.




Supplementary Figure 4.3. Anti-sense strand DNase I footprinting at the *csgB* promoter.

Representative chromatograms are shown for DNase I footprinting reactions presented in Figure 4.5. Purified *csgB* template was incubated with 130 nM H-NS (b), 50 nM CsgD (c) or both (d) as indicated adjacent to each reaction. The fluorescence of each reaction is normalized to the total signal for all analyzed samples. Base positions are indicated relative to the TSS. The red trace denotes the GeneScan 500 LIZ size standard.




Supplementary Figure 4.4. Circular Permutation Analysis of the DNA bending induced by CsgD binding. a) Structure of the DNA fragment used to generate circularly permuted sequences. The filled box indicates the site of the CsgD binding site within the sequence. PCR primers were used to amplify 200-bp fragments containing the CsgD binding site at various positions, as indicated by the filled box. The resulting fragments are denoted as F₁ – F₈. b) Electrophoretic mobility shift assay of CsgD binding to circularly permuted fragments. 20ng of DNA were loaded along with a 25x molar concentration of CsgD and run on a native 6% polyacrylamide gel. The position of unbound DNA is indicated as free, and the origin of the gel is also noted. μ_M indicates the position of mobility of the slowest fragment, wherein the CsgD binding site is in the middle of the fragment, while μ_E points to the position of the fastest fragment, in which CsgD binds near the end. The relative migration ratio of CsgD-bound complexes to μ_M is noted above each fragment.




Supplementary Figure 4.5. Sense-strand DNase I Differential DNA Footprint Analysis (DDFA)

of the *csgB* promoter region. *In vitro* DNase I footprinting at the *csgB* promoter was performed with 130 nM H-NS and 50 nM CsgD, as indicated and as in Figure 4.5, except an alternative probe was used to detect sensitivity on the sense-strand of the DNA. Peaks are regions of hypersensitivity, which are suggestive of distorted or bent DNA, whereas valleys indicate sites of protection. Base positions are indicated relative to the TSS. a) H-NS, b) CsgD, or e) CsgD and H-NS were added to the *csgB* promoter and the fluorescent peak height following DNase I cleavage determined relative to the protein-free control in relative fluorescent units (RFU). The differences compared to the H-NS control (c) and the CsgD control (d) were also analyzed. Data are presented as the mean +/- SD of three replicates.




Supplementary Figure 4.6. Sense-strand DNase I footprinting at the *csgB* promoter.

Representative chromatograms are shown for sense-strand DNase I footprinting reactions presented in Supplementary Figure 4.5. Purified *csgB* template used in IVT reactions was incubated with 10 nM commercial holoenzyme (a), 130 nM H-NS (d), RNAP + H-NS (c), 50 nM CsgD (e), or CsgD + H-NS (f). The fluorescence of each reaction is normalized to the total signal for all analyzed samples. Base positions are indicated relative to the TSS. The red trace denotes the GeneScan 500 LIZ size standard.




Supplementary Figure 4.7. KMnO_4 footprinting analysis of the *csgB* promoter region.

Representative chromatograms are shown for KMnO_4 footprinting reactions performed with 50 nM CsgD, 130 nM H-NS, and 10 nM commercial RNAP as indicated next to each reaction. Base positions are indicated relative to the TSS, while relative fluorescence is indicated on the vertical axis.




Supplementary Figure 4.8. Sense-strand DNase I DDFA of RNAP at the *csgB* promoter. *In vitro* DNase I footprinting at the *csgB* promoter was performed with 130 nM H-NS and 10 nM commercial RNAP, as indicated. Base positions are indicated relative to the TSS. In a) RNAP was added to the *csgB* promoter and the fluorescent peak height following DNase I cleavage determined relative to a protein-free control in relative fluorescent units (RFU). Addition of H-NS to RNAP bound DNA (b) and normalized to RNAP-only bound sample reveals changes in RNAP-binding as a result of H-NS. Data are presented as the mean +/- SD of three replicates.



Supplementary Figure 4.9. CsgD does not counter-silence its own promoter *in vitro*.

Purified, supercoiled *csgD* template was incubated in the presence of 50 nM CsgD and 130 nM H-NS as indicated, along with $E\sigma^S$ or $E\sigma^{70}$, and transcriptional output assayed. Data are presented as the mean +/- SD of three replicates.



Supplementary Figure 4.10. CsgD counter-silences the *csgB* promoter *in vitro* under varying conditions. *In vitro* transcription assays were carried out as in Figure 4.4, except that potassium glutamate levels were reduced to 50 mM (a) or 130 nM H-NS was added prior to 50 nM CsgD (b). Transcript levels are expressed as relative copy number. Data are presented as the mean +/- SD of three replicates.

Chapter 5: MlrA Antagonizes H-NS Silencing at the *csgD* promoter

Summary

Transcriptional regulation of the *csgD* promoter is complex, involving many transcription factors that mediate activation or repression. These factors confer responsiveness to different environmental conditions and regulate biofilm formation in response to stress. The mechanisms of several of these proteins have been well-characterized, but the role of the MerR-family regulatory protein, MlrA, has been largely undefined. In this study, I have demonstrated the role of MlrA as an H-NS counter-silencer at the *csgD* promoter *in vitro* and further suggest that DNA binding by IHF (integration host factor) can facilitate MlrA-mediated counter-silencing. *In vivo* analyses indicate that both of these proteins are highly σ^S -dependent, pointing toward an explanation for sigma factor selectivity in biofilm expression. In addition, I have sought to identify environmental modulators of *csg* gene expression and suggest a possible novel role of vitamin B₁₂ as an allosteric regulator of MlrA.

Introduction

CsgD is widely viewed as the master regulator of curli expression and biofilm formation in *Salmonella* and *E. coli*, serving as both a transcriptional activator and counter-silencer (Chapter 4). Biofilms are resistant to a variety of stress conditions (168) and antibiotics (169,170), thus regulatory networks that respond to these factors are critically important to ensure the expression of curli genes under appropriate conditions. Curli genes are selectively expressed during stationary phase, but the mechanisms responsible for the stationary phase expression of *csg* genes are incompletely defined. The stationary phase sigma factor σ^S is known to be required for curli gene expression during stationary phase, but in Chapter 4, I showed that

σ^S does not directly regulate the *csgBA* promoter. Here I examine the regulation of *csgD*, which encodes the transcriptional activator and counter-silencer of the *csgBA* promoter. Regulation of the *csgD* promoter is complex, with binding demonstrated by ten different transcriptional regulators and five small RNAs. However, expression of *csgD* under particular conditions involves only a subset of these regulators, as each factor responds to different environmental conditions. For instance, RstA and OmpR serve as activators in response to acid stress (145,171), while CpxR monitors membrane stress (172). Small RNAs regulate mRNA levels in response to osmolarity, carbon-limitation, and cell envelope stress (see (173) for review). While studies have implicated roles for OmpR (174) and SsrB (175) in countering CpxR or H-NS activity, respectively, at *csgD*, neither of these regulators provides an explanation for σ^S selectivity (Supplementary Figure 5.1), so I examined the potential role of other candidate regulatory proteins.

MlrA is a member of the MerR-family of transcriptional regulators. MerR family members are thought to function as allosteric regulators, with an N-terminus containing a helix-turn-helix DNA-binding domain and a C-terminus, which varies between family members, interacting with a sensor molecule (176). Interaction with an inducer can lead to positive regulation resulting from transcriptional activation (177) or promotion of oligomerization (178), but in other cases binding can cause the regulator to release DNA, resulting in derepression (178). Binding sites of MerR-family members are typically situated between the -10 and -35 regions of a promoter, with preferential binding in regions with spacer lengths of 17 \pm 1 bp, non-optimal for σ^{70} recognition. Allosteric changes cause these proteins to underwind the DNA, changing the superhelicity and modulating the distance between the -10 and -35 to make it more accessible to RNAP.

Given the properties of the MerR-family members, I hypothesized that MlrA might account for sigma-factor selectivity at the *csgD* promoter. As mentioned previously (Chapter 3), σ^S -associated RNAP is better able to recognize promoters with non-optimal spacer regions, and previous studies have suggested a strong correlation between sigma-factor selectivity and DNA supercoiling (90), with σ^S -coupled RNAP better able to transcribe DNA in a relaxed state than RNAP containing σ^{70} (179). Additional studies have suggested that MerR is able to directly interact with the sigma-domain of RNAP (180), raising the question as to whether this property imparts sigma-factor selectivity to MlrA. Earlier studies have suggested that MlrA binds close to the -35 region of *csgD*, as single base pair mutations at -44 result in MlrA-independent regulation (181). However, more recently, the MlrA-binding region in *E. coli* has been identified to occur from -113 to -146, far upstream of the RNAP-binding site (182). In view of these discrepant observations, I also considered how MlrA might be able to facilitate H-NS counter-silencing by binding far upstream of the promoter.

Another possible contributor to stationary phase *csgD* regulation is integration host factor (IHF). IHF is a nucleoid-associated protein that has been demonstrated to play an important role in gene regulation (183). It is composed of two subunits, IHF α and IHF β , that interact to form a functionally active heterodimer that binds to the minor groove of DNA (184). Most notably, IHF is capable of bending DNA up to 160° (185), which creates a promoter architecture critical for regulation of some genes. Previous studies have shown that IHF mutants exhibit reduced expression of *csgD*, (171) and that IHF levels increase up to 3-fold upon entry into stationary phase (145). IHF has a higher binding affinity for DNA than H-NS, so in some cases, it may outcompete H-NS (145), suggesting a potential role of IHF as a counter-silencer (111,165,186).

However, when multiple IHF binding sites are present, IHF may simultaneously bind with H-NS as well (145).

In a recent study in *Vibrio harveyi*, IHF was found to act synergistically with the LuxR transcriptional activator, serving as a co-activator of gene expression. Sites critical for LuxR regulation are positioned far upstream of the transcriptional start site of *luxC*, preventing productive interactions with RNAP (187). IHF bends the DNA to reorganize the promoter architecture, bringing the LuxR binding site into closer proximity to the -35 promoter region (188,189). In view of its established binding site at the *csgD* promoter between the transcriptional start and MlrA-binding sites (171), I posited that IHF might facilitate MlrA-directed activation of *csgD* transcription by remodeling promoter architecture as well as counter-silencing H-NS.

The studies described in this chapter were performed to characterize the role of MlrA at the *Salmonella csgD* promoter. In view of the conflicting previous reports regarding the location of MlrA binding, *in vitro* DNaseI footprinting was performed to establish the site of MlrA binding. In addition, I investigated potential cooperative interactions between IHF and MlrA in counter-silencing of H-NS at the *csgD* promoter. Lastly, I sought to identify a small molecular ligand that could interact with MlrA to mediate allosteric regulation, and speculate regarding its possible role in facilitating counter-silencing and biofilm formation.

Results

H-NS depletion restores *csgD* expression in *rpoS* and *mlrA* mutant *S. Typhimurium*

In vivo genetic analyses with inducible antisense RNA to deplete H-NS demonstrated that, as seen previously with *csgB*, expression of *csgD* is regulated by H-NS during stationary

phase (Figure 5.1). Analysis of *mlrA* and *rpoS* mutants revealed that MlrA and σ^S are required for expression in intact cells, as mutations in either locus resulted in a 6- to 7-fold decrease in *csgD* expression. However, depletion of H-NS under these conditions resulted in a 2.3-to-3.3-fold increase in *csgD* expression in *rpoS* and *mlrA* mutant strains, respectively, suggesting that these proteins are required to oppose H-NS silencing of *csgD*. In contrast to *csgB* expression, wherein a *rpoS csgD* double-mutant phenocopies the single mutants (Chapter 4, Figure 4.1), there appears to be an additive effect of *mlrA* and *rpoS* mutations compared to either individually (Figure 5.1), suggesting that the contributions of these proteins are at least in part independent. The *mlrA* gene itself does exhibit σ^S regulation (Figure 5.2a), so the plasmid pMlrA expressing *mlrA* from a constitutive σ^S -independent promoter was used to determine if σ^S plays a direct role in counter-silencing at *csgD*. Wild-type cultures containing pMlrA exhibited a 56-fold increase in *csgD* transcription during stationary phase (Figure 5.2b) as a result of increased *csgD* expression from the multicopy plasmid (146). In an *rpoS* mutant containing pMlrA, *csgD* expression could be restored to wild-type levels, suggesting that σ^S is not directly required for H-NS counter-silencing. H-NS depletion did not result in increased *csgD* expression in *rpoS*-null strains containing pMlrA, suggesting that MlrA is sufficient to alleviate silencing (Figure 5.2b).

Investigation of the σ^S dependence of other loci implicated in the regulation of the *csgD* promoter revealed that *ihfB* is also highly σ^S -dependent (Figure 5.3a). While not regulated by MlrA or H-NS, expression of *ihfB* drops more than three-logs in an *rpoS* mutant during stationary phase, corresponding to previous observations that IHF levels increase during stationary phase (190). This may account for the additive effect of *mlrA* and *rpoS* mutations. Current studies are underway to examine levels of *csgD*, *rpoS*, and *mlrA* transcripts in *ihfB* mutants during stationary phase. Preliminary experiments indicate that H-NS is effectively able

to silence *csgD* in stationary phase in an *ihf* mutant and that depletion of H-NS through antisense induction restores *csgD* expression to wild-type levels, suggesting that IHF is only required in the presence of H-NS (Figure 5.3b).

Given the previously established MlrA-binding site, it is possible that IHF function is necessary for MlrA activity. If that is the case, then we would expect the *ihfB* and *mlrA* mutants to exhibit a similar phenotype. It is important to note that in the absence of *rpoS*, constitutive expression of MlrA leads to levels similar to WT (Figure 5.2b), suggesting that *ihfB* is not necessary for MlrA activity in the presence of H-NS. However, *ihfA* levels are unaffected by an *rpoS* mutation (Figure 5.3a). In theory, since IHF α and IHF β function as a heterodimer, IHF protein levels should also be reduced, but the possibility of the formation of a functional homodimeric protein cannot be excluded (191) and requires further investigation. The regulatory phenotypes of the various mutants were confirmed by individual quantification of the expression of genes regulated by MlrA and H-NS (Supplementary Figure 5.2).

MlrA is able to serve as a counter-silencer to H-NS independently of IHF *in vitro*

To better understand the interplay of H-NS, IHF, MlrA and σ^S in the regulation of *csgD*, the *csgD* transcriptional circuit was reconstituted *in vitro* using purified proteins and large supercoiled templates. *In vitro* transcription assays with both $E\sigma^{70}$ and $E\sigma^S$ revealed that neither *csgD*, *mlrA*, nor *ihfB* exhibit basal σ -factor selectivity, as both holoenzymes transcribed these promoters at similar levels (Figures S4.9 and 5.4a). At *csgD*, purified MlrA did not demonstrate any properties as an activator when paired with $E\sigma^S$, but when incubated with H-NS-silenced template, transcription increased 5.3-fold (Figure 5.4b), suggesting that MlrA is able to drive counter-silencing at *csgD* independent of other factors. Current studies are underway to examine

if a similar level of counter-silencing occurs when MlrA is coupled with $E\sigma^{70}$ at the *csgD* promoter and whether the addition of purified IHF enhances MlrA-counter-silencing activity *in vitro*.

MlrA shows sequence similarity to other MerR-family members sensitive to vitamin B₁₂

As previously noted, MerR-family members typically regulate transcription through allosteric changes driven by the interactions between the C-terminus and a specific ligand (176). To date, no ligand has specifically been identified for MlrA. Since interaction with a binding molecule is important for protein function of these family members, identifying the compound(s) with which MlrA interacts is of considerable interest. Using the on-line COACH server (192) complemented with Phyre2 (193), structural predictions and comparisons to binding-specific substructure were made to identify homologous proteins and predict ligand-binding sites. The two analyses revealed several proteins with structural and sequence similarity to MlrA (Supplementary Tables 5.1 and 5.2). Notably, half of these proteins showed high sequence and structural similarity at the C-terminus and frequently had been shown to bind vitamin B₁₂.

Vitamin B₁₂ is recognized as an essential vitamin in humans and has been shown to be an important cofactor for enzymes involved in many cellular processes in both eukaryotes and bacteria. The making and breaking of carbon and cobalt bonds drives B₁₂-dependent enzymatic reactions important in methylation, DNA synthesis, fatty acid production and amino acid metabolism (194,195). Vitamin B₁₂ has also played a critical role as a ligand in different riboswitches (196) and as a cofactor for light-sensing regulatory proteins (178). Also known as cobalamin, vitamin B₁₂, exists in two forms *in vivo*: adenosylcobalamin (AdoB₁₂) and methylcobalamin (MeB₁₂). Upon photo- or thermo-excitation, both AdoB₁₂ and MeB₁₂ undergo

homolytic cleavage of the carbon-cobalt bond, creating the photoproduct hydroxocobalamin (OHB₁₂).

In many organisms, vitamin B₁₂ plays a vital role in facilitating protein function, typically leading to a conformational change upon binding. For instance, in *Bacillus* and *Salmonella*, the transcriptional regulators LitR (197) and MetR (198) cause transcriptional repression upon interaction with cobalamin. MlrA shows the highest degree of homology with the protein CarH in *Thermus thermophilus* (Figure 5.5). B₁₂ binding to CarH in the dark causes protein oligomerization and repression of carotenoid genes, but photolysis of AdoB₁₂ to OHB₁₂ destabilizes this complex, leading to gene activation (178).

Although not designated as a homologous hit by COACH, AerR in *Rhodobacter capsulatus* binds B₁₂ in an alternative regulatory mechanism. While AerR does not have an identifiable DNA-binding domain, it is thought to control expression of genes by modulating the activity of the transcriptional repressor CrtJ (199,200). Only AerR bound with B₁₂ can interact with CrtJ, which inhibits CrtJ's ability to bind DNA, thereby causing derepression (201). In view of the roles of B₁₂-modulated proteins in the direct and indirect activation of gene transcription, we have considered whether this ligand might modulate the transcriptional regulatory activity of MlrA at *csgD* *in vitro*.

Light Exposure of the vitamin B₁₂-MlrA complex leads to high levels of transcriptional activation and counter-silencing *in vitro*

Studies are presently underway with our collaborators to determine whether direct binding of MlrA by cobalamin can occur (202). In parallel, we are investigating whether the incubation of MlrA, with B₁₂, alters its regulatory properties. Preliminary studies suggest that B₁₂

can stimulate MlrA activity by nearly four-fold, and this activity is exclusively light-dependent (Figure 5.6a). In addition, *in vitro* experiments suggest that intact B₁₂ in the absence of photolysis may inhibit the ability of MlrA to counter H-NS activity (Figure 5.6b), although confirmation of these findings is pending.

Discussion

Regulation of the *Salmonella csgD* promoter is complex, with input from more than ten different regulatory proteins and five small RNAs acting under various environmental conditions. In this study, we explored the role of the MerR-family regulator MlrA as both an activator and a counter-silencer at the *csgD* promoter, examined conditions under which *csgD* is induced, and investigated whether IHF is required for MlrA regulation. Some studies are still ongoing, but it appears that MlrA may serve as a novel vitamin B₁₂-sensor, and B₁₂ may modulate MlrA counter-silencing of H-NS and biofilm formation.

My *in vivo* studies have confirmed the role of σ^S , MlrA, and IHF as important regulatory inputs into *csgD* expression and demonstrated that they are no longer required if H-NS is depleted (Figures 5.1-5.3). However, the mechanisms by which these transcription factors interact to relieve H-NS silencing is unclear. The importance of σ^S may stem from direct transcriptional dependency of both *mlrA* and *ihfB* (Figures 5.2 and 5.3), but whether or not IHF is required for the counter-silencing actions of MlrA *in vivo* still needs to be investigated. My *in vitro* experiments have suggested that this is not the case, as MlrA is able to relieve H-NS-mediated silencing at *csgD* independent of IHF (Figure 5.4). However, studies are underway to better characterize the relationship of these factors in the presence or absence of different forms of B₁₂ and to determine whether the counter-silencing by MlrA is sigma-factor specific.

Nearly all *Salmonella* isolates are able to synthesize cobalamin *de novo* (203), with close to 1% of the *S. Typhimurium* genome devoted to the synthesis and uptake of cobalamin, and another 1% involved in metabolic pathways that require it (204). However, vitamin B₁₂ has not been previously implicated in *Salmonella* biofilm formation. In *Pseudomonas*, as in *Salmonella*, vitamin B₁₂ production is closely linked to the availability of oxygen. During anaerobic conditions, B₁₂ production is impaired and exogenous exposure to B₁₂ helps to alleviate stress and enhance growth (205). While some groups have suggested that cobalamin production in *Salmonella* occurs only under conditions of anaerobic growth (206), others suggest that oxygen is needed at some level to facilitate B₁₂ synthesis (207). Previous studies have suggested that CsgD expression is maximal under aerobic or microaerophilic conditions (208), correlating with observations that biofilm formation is greatest under microaerophilic and CO₂-rich conditions (209) and inhibited under anaerobic conditions (210,211). In this context, it is possible that the environmental cues that influence curli gene expression are conditions of low oxygen or exposure to exogenous B₁₂, a scenario thought to exist during infection, as members of the intestinal microbiota are prominent producers of the molecule (212). In our *in vivo* genetic experiments, the cultures are heavily aerated, suggesting that the bacteria are not primed to produce their own vitamin B₁₂. Nevertheless, we still observe MlrA-dependent *csgD* expression (Figure 5.1). Luria Bertani medium, as used in this study, contains yeast extract, an important source of vitamin B₁₂ in microbial growth media, and likely provides an exogenous source that cues this transcriptional response. Studies under minimal media conditions would need to be carried out to verify that MlrA-dependent counter-silencing *in vivo* is mediated by environmental cues from interaction with vitamin B₁₂.

An additional signal worth considering is light. As previously mentioned, vitamin B₁₂ in itself is extremely light sensitive and often requires exposure to light for cleavage into an active form. Preliminary *in vitro* data suggest that photolysis of B₁₂ may be necessary for MlrA activity (Figure 5.6). As biofilms are a known defense mechanism against UV exposure (213), one possibility is that B₁₂ confers light-responsiveness to biofilm formation by inhibiting MlrA counter-silencing in the dark and promoting curli formation following cleavage by UV light. Previous studies in *E. coli* have examined the influence of blue light on the MlrA paralogue, BluR, suggesting that exposure to blue light leads to derepression of genes important for biofilm formation (214). These authors suggested that light-regulation in this case was inadvertent and likely a result of evolutionary descent from an ancestral light-responsive protein.

I hypothesize a model in which MlrA promotes a conformational change in DNA that disrupts H-NS silencing, leading to *csgD* expression and biofilm formation (Figure 5.7). Vitamin B₁₂, either produced endogenously under microaerobic conditions or provided exogenously by the gut microbiota, modulates this response. Dark-state cyanocobalamin may sequester and modify MlrA to inhibit DNA binding, while photo-activated cobalamin restores MlrA DNA-binding activity. Understanding the mechanisms by which MlrA, IHF, and σ^S act coordinately to relieve H-NS-mediated silencing remains a work in progress. It is possible that MlrA and IHF act together to relieve counter-silencing, but *in vivo* and *in vitro* transcriptional assays suggest that MlrA is independently capable of this activity as well. Planned DNase I footprinting studies will confirm the binding site of MlrA, as it is possible that another binding site more proximal to the -35 region also exists (181), which may obviate the need for IHF. These studies, coupled with KMnO₄ and UV laser footprinting assays, will provide insight into the mechanism by which MlrA mediates counter-silencing. Further exploration of the possible role of vitamin B₁₂ as an

allosteric regulator modulating MlrA counter-silencing may identify a novel environmental context in which curli gene expression and biofilm formation is initiated.




Figure 5.1. MlrA and σ^S up-regulate *csgD* in stationary phase. *csgD* transcript levels during stationary phase were quantified by qRT-PCR in wild-type, *rpoS*, *mlrA*, and *rpoS mlrA* *S.* Typhimurium strains containing pHN1009 asVector or pHN1009 asHNS with IPTG added to deplete H-NS. Data are presented as the mean +/- SD of 3 replicates normalized to *gyrB*; * indicates $p < 0.05$, and ** indicates $p < 0.01$ by ratio-paired t-test.




Figure 5.2. Constitutive *mlrA* expression *in trans* stimulates σ^S -independent *csgD* transcription. a) *mlrA* transcript levels were quantified using qRT-PCR in wild-type and *rpoS* mutant *S. Typhimurium* containing pMlrA, which contains *mlrA* downstream of a constitutive promoter. b) *csgD* transcript levels were quantified in response to *mlrA* constitutive expression in strains containing both pMlrA and asHNS. Data are presented as a mean +/- SD of 3 replicates normalized to *gyrB* expression; * indicates $p < 0.05$, and ** indicates $p < 0.01$ by ratio-paired t-test.




Figure 5.3. *ihfB* expression is dependent on σ^S and required for *csgD* transcription in the presence of H-NS. a) *ihfB* or *ihfA* transcript levels during stationary phase were quantified using qRT-PCR in wild-type, *mlrA*, and *rpoS* *S. Typhimurium* strains containing pHN1009 asVector or pHN1009 asHNS, with IPTG added to deplete H-NS. Data are presented as the mean +/- standard deviation of 3 replicates normalized to *gyrB* expression. b) *csgD* expression during stationary phase was measured using qRT-PCR in *ihf* mutants of *S. Typhimurium* containing asVector or asHNS. Results shown are from one experiment.




Figure 5.4. MlrA counter-silences the *csgD* promoter *in vitro*. a) Reconstituted holoenzymes $E\sigma^S$ and $E\sigma^{70}$ showed equal transcriptional activity *in vitro* on supercoiled templates containing the *ihfB* or *mlrA* promoter regions, suggesting no sigma-factor selectivity. Data are presented as the mean +/- SD of 3 replicates and are normalized to RNAP core without a sigma-factor. b) $E\sigma^S$ alone can initiate transcription of the *csgD* promoter *in vitro*. MlrA-mediated counter-silencing was assayed by incubating *csgD* template in the presence of 100nM MlrA for 20 min before adding 130nM H-NS. Transcript levels are expressed as relative copy number. Data are presented as the mean +/- SD of 4 replicates; * indicates $p < 0.05$ by ratio-paired t-test.




Figure 5.5. MlrA protein structure is similar to CarH. a) Utilization of the PHYRE server suggested similar protein structures based on amino acid sequence for *T. thermophilus* CarH and *S. Typhimurium* MlrA. b) Cartoon diagrams of the conformation of CarH (blue) and MlrA (red) proteins in complex with vitamin B₁₂ (yellow spheres). The N-terminal DNA binding domain is located at the top and the C-terminal sensor domain is at the bottom.





Figure 5.6. Modulation of MlrA activity by vitamin B₁₂ is light-dependent. a) Vitamin B₁₂ was incubated with varying concentrations of MlrA at a 1:1 ratio, added to *csgD* supercoiled template along with E σ^S , and incubated at 30°C under white light or covered with foil. Data shown are the results of two experiments. b) 100nM MlrA was incubated with vitamin B₁₂ at a 1:1 molar ratio for 10 min at the *csgD* supercoiled template, followed by 20nM IHF, 130nM H-NS, and 10nM E σ^S each for 10 min at 30°C. Reactions were placed either under white light or covered with foil. Transcript levels are normalized to levels of promoter silenced by H-NS alone under light or dark conditions. Data shown are from one experiment.

Dark



Light






Figure 5.7. Model of B₁₂-modulated regulation of *csgD* expression by MlrA and IHF. Under dark conditions, vitamin B₁₂ binds to MlrA, inhibiting its ability to interact with DNA and allowing H-NS to bind and silence expression. Following photolysis, B₁₂ is no longer able to bind and sequester MlrA. IHF expression in stationary phase bends DNA to facilitate localization of upstream-bound MlrA more proximally to the promoter, thereby disrupting the H-NS complex and allowing transcription.



Supplementary Figure 5.1. σ^S -dependent curli expression does not result from SsrAB or OmpR regulation. qRT-PCR expression measured transcriptional activity of the *ssrA* or *ompR* promoters in stationary phase wild-type or isogenic *rpoS* mutant *S. Typhimurium*. Data are presented as the mean +/- SD of 3 replicates and normalized to *gyrB*.



Supplementary Figure 5.2. MlrA and H-NS do not influence the expression of other *csgD* regulators. Quantitative RT-PCR was used to measure gene expression during stationary phase in wild-type or *mlrA* mutant *S. Typhimurium* (a), after H-NS depletion by anti-sense expression (b), or during constitutive MlrA expression (c). Data are presented as the mean +/- SD of 3 replicates and normalized to *gyrB*.

Supplementary Table 5.1. Molecules most structurally-related to MlrA retrieved by the PHYRE server.

PDB identity	Confidence	Identity %	Protein/Function	Species	MerR-Type Regulator	Binds B₁₂
5c8e	100	18	CarH: Light-Dependent Transcriptional Regulator	<i>Thermus thermophilus</i>	Yes	Yes
1r8d	99.8	23	MtaN: Transcriptional Regulator	<i>Bacillus subtilis</i>	Yes	No
3hh0	99.8	18	Transcriptional Regulator	<i>Bacillus cereus</i>	Yes	No
3gpv	99.8	17	Transcriptional Regulator	<i>Bacillus thuringiensis</i>	Yes	No
3qao	99.8	16	Transcriptional Regulator	<i>Listeria monocytogenes</i>	Yes	No
2zhh	99.8	19	SoxR: oxidative-stress transcriptional regulator	<i>Escherichia coli</i>	Yes	No

Supplementary Table 5.2. Molecules most structurally-related to MlrA retrieved by

COACH. COACH is a meta-server approach to protein-ligand binding site prediction that combines the results of methods such as COFACTOR, FINDSITE, and ConCavity to increase the strength of a prediction. Confidence scores range from 0-1, where a higher score indicates a more reliable prediction.

PDB identity	Confidence Score	Protein/Function	Species	MerR-Type Regulator	Binds B₁₂
5c8eG	.19	CarH Nucleic acid binding domain	<i>T. thermophilus</i>	Yes	Yes
5c8aB	.12	CarH B ₁₂ binding domain	<i>T. thermophilus</i>	Yes	Yes
3IV9A	.06	B ₁₂ -dependent methionine synthase (MethH)	<i>E. coli</i>	Yes	Yes
4REQA	.04	Methylmalonyl-coA mutase	<i>Propionibacterium shermanii</i>	No	Yes
1R8EA	0.02	BmrR	<i>Bacillus subtilis</i>	Yes	No

Chapter 6: Significance and Future Directions

Curli gene expression has been extensively studied in both *E. coli* and *Salmonella* during the past two decades. My studies have identified new insights into the mechanisms by which curli expression is regulated at the level of *csgB* and *csgD* transcription. I have found that counter-silencing plays a central role in the regulation at both genes, and that modulation of the expression of counter-silencing proteins by the stationary phase sigma factor σ^S may be responsible for growth phase-dependent curli expression.

Data presented in Chapter 3 explored direct actions of σ^S at the *csgBA* and *spvAB* promoters during stationary phase. These genes, also regulated by H-NS, could not be transcribed by σ^S alone *in vitro* when H-NS was present (Figure 3.4), indicating that σ^S is unable to overcome H-NS silencing of these promoters and rather influences *csgBA* expression indirectly. Many of the genes co-regulated by H-NS and σ^S (Supplementary Table 3.1) are controlled by additional regulators, suggesting that the counter-silencing of these genes is complex. Future studies including comparative ChIP-seq analyses of H-NS and σ^S under different growth conditions would provide a more detailed picture of the degree of overlap between the H-NS and σ^S regulons. Although I cannot generalize from the data presented herein regarding two promoters to all σ^S -H-NS regulated promoters, my observations suggest that σ^S may not serve as a direct counter-silencer but may nevertheless modulate counter-silencing by indirect actions.

While previous studies have suggested that CsgD serves as a transcriptional activator (157), the experiments described in Chapter 4 show that CsgD is also responsible for relieving H-NS silencing at the *csgB* promoter. *In vitro* analyses have revealed that H-NS inhibits transcription by occluding RNAP (Figure 4.6), but CsgD distorts the DNA to disrupt the H-NS

filament and restore RNAP-DNA contacts (Figure 4.5). As discussed in this chapter, CsgD is a member of the LuxR-family of transcriptional regulators. Therefore, it would be interesting to conduct future studies to identify if this mechanism of counter-silencing is common to other LuxR-family members. Studies by other groups have suggested this is a possibility (161-165), and our *in vitro* system could provide a more detailed view of how these proteins function in the presence of H-NS. This would lend additional insight into the regulation of genes involved in virulence and quorum sensing across bacterial species.

Chapter 5 describes my efforts to identify the source of stationary phase regulation of the curli genes. The *csgD* promoter itself is not σ^S -specific *in vitro* (Supplementary Figure 4.9), but two upstream regulators of *csgD*, MlrA and IHF β , are σ^S -dependent *in vivo* (Figures 5.2 and 5.3). While I have been able to show that MlrA alone is able to relieve H-NS silencing, future studies will be required to determine whether IHF also plays an integral role *in vivo* and *in vitro* in *csgD* counter-silencing. DNaseI footprinting could either confirm the predicted MlrA-binding site (182) or suggest that it might bind further downstream (181), which would help to explain how MlrA is able to serve as a counter-silencer independent of other factors. That neither *mlrA* nor *ihfB* show sigma-factor selectivity *in vitro* (Figure 5.4), underscores that more work will be needed to understand the direct basis of σ^S -mediated curli regulation. Further characterization of the environmental cues responsible for MlrA-mediated counter-silencing is also of considerable interest. *In silico* modeling has suggested that MlrA is able to interact with vitamin B₁₂. Other studies have suggested that vitamin B₁₂ can serve as an allosteric regulator (178,197,198), so it will be of interest to determine whether vitamin B₁₂ can modulate MlrA-activity. *In vivo* studies using the H-NS knock-down system in minimal medium lacking or supplemented with vitamin

B₁₂ could suggest whether vitamin B₁₂ modulates curli gene expression and suggest the environmental conditions in which expression is triggered.

In conclusion, the analysis of counter-silencing mechanisms in *Salmonella enterica* can provide important insights into mechanisms of horizontal gene transfer and the accommodation of new genetic sequences into pre-existing regulatory networks. Many of the proteins described in this dissertation are conserved across different bacterial species, so it is likely that the mechanisms by which they act are similar in diverse bacteria. The molecular mechanisms by which bacterial virulence genes are regulated is also critical for an understanding of bacterial pathogenesis. As multi-drug resistant strains become more prevalent, understanding these processes could aid in targeting future drug development. Finally, an understanding of how horizontally acquired genes become integrated into host regulatory networks can provide insight into how transcriptional mechanisms have facilitated the evolution of *Salmonella* over time.

References

1. Goldenfeld, N., and Woese, C. (2007) Biology's next revolution. *Nature* **445**, 369
2. Andersson, J. O. (2005) Lateral gene transfer in eukaryotes. *Cell Mol Life Sci* **62**, 1182-1197
3. Gao, C., Ren, X., Mason, A. S., Liu, H., Xiao, M., Li, J., and Fu, D. (2014) Horizontal gene transfer in plants. *Funct Integr Genomics* **14**, 23-29
4. Ochman, H., Lawrence, J. G., and Groisman, E. A. (2000) Lateral gene transfer and the nature of bacterial innovation. *Nature* **405**, 299-304
5. Guljamow, A., Jenke-Kodama, H., Saumweber, H., Quillardet, P., Frangeul, L., Castets, A. M., Bouchier, C., Tandeau de Marsac, N., and Dittmann, E. (2007) Horizontal gene transfer of two cytoskeletal elements from a eukaryote to a cyanobacterium. *Curr Biol* **17**, R757-759
6. Watkins, R. F., and Gray, M. W. (2006) The frequency of eubacterium-to-eukaryote lateral gene transfers shows significant cross-taxa variation within amoebzoa. *J Mol Evol* **63**, 801-814
7. Boto, L. (2010) Horizontal gene transfer in evolution: facts and challenges. *Proc Biol Sci* **277**, 819-827
8. Davies, J., and Davies, D. (2010) Origins and evolution of antibiotic resistance. *Microbiol Mol Biol Rev* **74**, 417-433
9. Furuya, E. Y., and Lowy, F. D. (2006) Antimicrobial-resistant bacteria in the community setting. *Nat Rev Microbiol* **4**, 36-45
10. Will, W. R., Bale, D. H., Reid, P. J., Libby, S. J., and Fang, F. C. (2014) Evolutionary expansion of a regulatory network by counter-silencing. *Nat Commun* **5**, 5270
11. Kuo, C. H., and Ochman, H. (2009) The fate of new bacterial genes. *FEMS Microbiol Rev* **33**, 38-43
12. Marcus, S. L., Brumell, J. H., Pfeifer, C. G., and Finlay, B. B. (2000) *Salmonella* pathogenicity islands: big virulence in small packages. *Microbes Infect* **2**, 145-156
13. Lawrence, J. G., and Ochman, H. (1997) Amelioration of bacterial genomes: rates of change and exchange. *J Mol Evol* **44**, 383-397
14. Coburn, B., Grassl, G. A., and Finlay, B. B. (2007) *Salmonella*, the host and disease: a brief review. *Immunol Cell Biol* **85**, 112-118
15. Ochman, H., and Lawrence, J. G. (1996) *Escherichia coli and Salmonella: Cellular and Molecular Biology*, ASM Press
16. Elsinghorst, E. A., Baron, L. S., and Kopecko, D. J. (1989) Penetration of human intestinal epithelial cells by *Salmonella*: molecular cloning and expression of *Salmonella* Typhi invasion determinants in *Escherichia coli*. *Proc Natl Acad Sci U S A* **86**, 5173-5177

17. Hohmann, A. W., Schmidt, G., and Rowley, D. (1978) Intestinal colonization and virulence of *Salmonella* in mice. *Infect Immun* **22**, 763-770
18. Li, J., Ochman, H., Groisman, E. A., Boyd, E. F., Solomon, F., Nelson, K., and Selander, R. K. (1995) Relationship between evolutionary rate and cellular location among the Inv/Spa invasion proteins of *Salmonella enterica*. *Proc Natl Acad Sci U S A* **92**, 7252-7256
19. Hensel, M., Shea, J. E., Gleeson, C., Jones, M. D., Dalton, E., and Holden, D. W. (1995) Simultaneous identification of bacterial virulence genes by negative selection. *Science* **269**, 400-403
20. Behlau, I., and Miller, S. I. (1993) A PhoP-repressed gene promotes *Salmonella typhimurium* invasion of epithelial cells. *J Bacteriol* **175**, 4475-4484
21. Guiney, D. G., Libby, S., Fang, F. C., Krause, M., and Fierer, J. (1995) Growth-phase regulation of plasmid virulence genes in *Salmonella*. *Trends Microbiol* **3**, 275-279
22. Gries, T. J., Kontur, W. S., Capp, M. W., Saecker, R. M., and Record, M. T. (2010) One-step DNA melting in the RNA polymerase cleft opens the initiation bubble to form an unstable open complex. *Proc Natl Acad Sci U S A* **107**, 10418-10423
23. Dorman, C. J., Barr, G. C., Ni Bhriain, N., and Higgins, C. F. (1988) DNA supercoiling and the anaerobic and growth phase regulation of *tonB* gene expression. *J Bacteriol* **170**, 2816-2826
24. Wu, Y., and Datta, P. (1995) Influence of DNA topology on expression of the *tdc* operon in *Escherichia coli* K-12. *Mol Gen Genet* **247**, 764-767
25. Jovanovich, S. B., and Lebowitz, J. (1987) Estimation of the effect of coumermycin A1 on *Salmonella typhimurium* promoters by using random operon fusions. *J Bacteriol* **169**, 4431-4435
26. Gellert, M., Mizuuchi, K., O'Dea, M. H., and Nash, H. A. (1976) DNA gyrase: an enzyme that introduces superhelical turns into DNA. *Proc Natl Acad Sci U S A* **73**, 3872-3876
27. Wang, J. C. (1971) Interaction between DNA and an *Escherichia coli* protein omega. *J Mol Biol* **55**, 523-533
28. Brahms, S., Nakasu, S., Kikuchi, A., and Brahms, J. G. (1989) Structural changes in positively and negatively supercoiled DNA. *Eur J Biochem* **184**, 297-303
29. Boles, T. C., White, J. H., and Cozzarelli, N. R. (1990) Structure of plectonemically supercoiled DNA. *J Mol Biol* **213**, 931-951
30. Dorman, C. J. (2013) Co-operative roles for DNA supercoiling and nucleoid-associated proteins in the regulation of bacterial transcription. *Biochem Soc Trans* **41**, 542-547
31. Lim, H. M., Lewis, D. E., Lee, H. J., Liu, M., and Adhya, S. (2003) Effect of varying the supercoiling of DNA on transcription and its regulation. *Biochemistry* **42**, 10718-10725
32. Owen-Hughes, T. A., Pavitt, G. D., Santos, D. S., Sidebotham, J. M., Hulton, C. S., Hinton, J. C., and Higgins, C. F. (1992) The chromatin-associated protein H-NS interacts with curved DNA to influence DNA topology and gene expression. *Cell* **71**, 255-265

33. Viollier, P. H., Thanbichler, M., McGrath, P. T., West, L., Meewan, M., McAdams, H. H., and Shapiro, L. (2004) Rapid and sequential movement of individual chromosomal loci to specific subcellular locations during bacterial DNA replication. *Proc Natl Acad Sci U S A* **101**, 9257-9262
34. Wiggins, P. A., Cheveralls, K. C., Martin, J. S., Lintner, R., and Kondev, J. (2010) Strong intranucleoid interactions organize the *Escherichia coli* chromosome into a nucleoid filament. *Proc Natl Acad Sci U S A* **107**, 4991-4995
35. Fisher, J. K., Bourniquel, A., Witz, G., Weiner, B., Prentiss, M., and Kleckner, N. (2013) Four-dimensional imaging of *E. coli* nucleoid organization and dynamics in living cells. *Cell* **153**, 882-895
36. Bloomfield, V. A. (1997) DNA condensation by multivalent cations. *Biopolymers* **44**, 269-282
37. Miyoshi, D., and Sugimoto, N. (2008) Molecular crowding effects on structure and stability of DNA. *Biochimie* **90**, 1040-1051
38. Cunha, S., Woldringh, C. L., and Odijk, T. (2001) Polymer-mediated compaction and internal dynamics of isolated *Escherichia coli* nucleoids. *J Struct Biol* **136**, 53-66
39. Luijsterburg, M. S., White, M. F., van Driel, R., and Dame, R. T. (2008) The major architects of chromatin: architectural proteins in bacteria, archaea and eukaryotes. *Crit Rev Biochem Mol Biol* **43**, 393-418
40. Dame, R. T., Kalmykova, O. J., and Grainger, D. C. (2011) Chromosomal macrodomains and associated proteins: implications for DNA organization and replication in gram negative bacteria. *PLoS Genet* **7**, e1002123
41. Sugimura, S., and Crothers, D. M. (2006) Stepwise binding and bending of DNA by *Escherichia coli* integration host factor. *Proc Natl Acad Sci U S A* **103**, 18510-18514
42. Swinger, K. K., Lemberg, K. M., Zhang, Y., and Rice, P. A. (2003) Flexible DNA bending in HU-DNA cocrystal structures. *EMBO J* **22**, 3749-3760
43. Schneider, R., Travers, A., Kutateladze, T., and Muskhelishvili, G. (1999) A DNA architectural protein couples cellular physiology and DNA topology in *Escherichia coli*. *Mol Microbiol* **34**, 953-964
44. Weinstein-Fischer, D., Elgrably-Weiss, M., and Altuvia, S. (2000) *Escherichia coli* response to hydrogen peroxide: a role for DNA supercoiling, topoisomerase I and Fis. *Mol Microbiol* **35**, 1413-1420
45. Schechter, L. M., Jain, S., Akbar, S., and Lee, C. A. (2003) The small nucleoid-binding proteins H-NS, HU, and Fis affect *hila* expression in *Salmonella enterica* serovar Typhimurium. *Infect Immun* **71**, 5432-5435
46. Altuvia, S., Almirón, M., Huisman, G., Kolter, R., and Storz, G. (1994) The *dps* promoter is activated by OxyR during growth and by IHF and sigma S in stationary phase. *Mol Microbiol* **13**, 265-272

47. Spassky, A., Rimsky, S., Garreau, H., and Buc, H. (1984) H1a, an *E. coli* DNA-binding protein which accumulates in stationary phase, strongly compacts DNA *in vitro*. *Nucleic Acids Res* **12**, 5321-5340
48. Arold, S. T., Leonard, P. G., Parkinson, G. N., and Ladbury, J. E. (2010) H-NS forms a superhelical protein scaffold for DNA condensation. *Proc Natl Acad Sci U S A* **107**, 15728-15732
49. Amit, R., Oppenheim, A. B., and Stavans, J. (2003) Increased bending rigidity of single DNA molecules by H-NS, a temperature and osmolarity sensor. *Biophys J* **84**, 2467-2473
50. Gordon, B. R., Li, Y., Cote, A., Weirauch, M. T., Ding, P., Hughes, T. R., Navarre, W. W., Xia, B., and Liu, J. (2011) Structural basis for recognition of AT-rich DNA by unrelated xenogeneic silencing proteins. *Proc Natl Acad Sci U S A* **108**, 10690-10695
51. Liu, Y., Chen, H., Kenney, L. J., and Yan, J. (2010) A divalent switch drives H-NS/DNA-binding conformations between stiffening and bridging modes. *Genes Dev* **24**, 339-344
52. Dame, R. T., Wyman, C., Wurm, R., Wagner, R., and Goosen, N. (2002) Structural basis for H-NS-mediated trapping of RNA polymerase in the open initiation complex at the *rrnB* P1. *J Biol Chem* **277**, 2146-2150
53. Walthers, D., Li, Y., Liu, Y., Anand, G., Yan, J., and Kenney, L. J. (2011) *Salmonella enterica* response regulator SsrB relieves H-NS silencing by displacing H-NS bound in polymerization mode and directly activates transcription. *J Biol Chem* **286**, 1895-1902
54. Lim, C. J., Lee, S. Y., Kenney, L. J., and Yan, J. (2012) Nucleoprotein filament formation is the structural basis for bacterial protein H-NS gene silencing. *Sci Rep* **2**, 509
55. Navarre, W. W., McClelland, M., Libby, S. J., and Fang, F. C. (2007) Silencing of xenogeneic DNA by H-NS-facilitation of lateral gene transfer in bacteria by a defense system that recognizes foreign DNA. *Genes Dev* **21**, 1456-1471
56. Navarre, W. W., Porwollik, S., Wang, Y., McClelland, M., Rosen, H., Libby, S. J., and Fang, F. C. (2006) Selective silencing of foreign DNA with low GC content by the H-NS protein in *Salmonella*. *Science* **313**, 236-238
57. Falconi, M., Brandi, A., La Teana, A., Gualerzi, C. O., and Pon, C. L. (1996) Antagonistic involvement of FIS and H-NS proteins in the transcriptional control of *hns* expression. *Mol Microbiol* **19**, 965-975
58. Falconi, M., Higgins, N. P., Spurio, R., Pon, C. L., and Gualerzi, C. O. (1993) Expression of the gene encoding the major bacterial nucleotide protein H-NS is subject to transcriptional auto-repression. *Mol Microbiol* **10**, 273-282
59. Tupper, A. E., Owen-Hughes, T. A., Ussery, D. W., Santos, D. S., Ferguson, D. J., Sidebotham, J. M., Hinton, J. C., and Higgins, C. F. (1994) The chromatin-associated protein H-NS alters DNA topology *in vitro*. *EMBO J* **13**, 258-268
60. Dole, S., Nagarajavel, V., and Schnetz, K. (2004) The histone-like nucleoid structuring protein H-NS represses the *Escherichia coli* *bgl* operon downstream of the promoter. *Mol Microbiol* **52**, 589-600

61. Nagarajavel, V., Madhusudan, S., Dole, S., Rahmouni, A. R., and Schnetz, K. (2007) Repression by binding of H-NS within the transcription unit. *J Biol Chem* **282**, 23622-23630
62. Dame, R. T., Wyman, C., and Goosen, N. (2000) H-NS mediated compaction of DNA visualised by atomic force microscopy. *Nucleic Acids Res* **28**, 3504-3510
63. Falconi, M., Colonna, B., Prosseda, G., Micheli, G., and Gualerzi, C. O. (1998) Thermoregulation of *Shigella* and *Escherichia coli* EIEC pathogenicity. A temperature-dependent structural transition of DNA modulates accessibility of *virF* promoter to transcriptional repressor H-NS. *EMBO J* **17**, 7033-7043
64. Falconi, M., Prosseda, G., Giangrossi, M., Beghetto, E., and Colonna, B. (2001) Involvement of FIS in the H-NS-mediated regulation of *virF* gene of *Shigella* and enteroinvasive *Escherichia coli*. *Mol Microbiol* **42**, 439-452
65. Williamson, H. S., and Free, A. (2005) A truncated H-NS-like protein from enteropathogenic *Escherichia coli* acts as an H-NS antagonist. *Mol Microbiol* **55**, 808-827
66. Shin, M., Song, M., Rhee, J. H., Hong, Y., Kim, Y. J., Seok, Y. J., Ha, K. S., Jung, S. H., and Choy, H. E. (2005) DNA looping-mediated repression by histone-like protein H-NS: specific requirement of Esigma70 as a cofactor for looping. *Genes Dev* **19**, 2388-2398
67. Olsén, A., Arnqvist, A., Hammar, M., Sukupolvi, S., and Normark, S. (1993) The RpoS sigma factor relieves H-NS-mediated transcriptional repression of *csgA*, the subunit gene of fibronectin-binding curli in *Escherichia coli*. *Mol Microbiol* **7**, 523-536
68. Robbe-Saule, V., Schaeffer, F., Kowarz, L., and Norel, F. (1997) Relationships between H-NS, sigma S, SpvR and growth phase in the control of *spvR*, the regulatory gene of the *Salmonella* plasmid virulence operon. *Mol Gen Genet* **256**, 333-347
69. Bäumler, A. J. (1997) The record of horizontal gene transfer in *Salmonella*. *Trends Microbiol* **5**, 318-322
70. Datsenko, K. A., and Wanner, B. L. (2000) One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc Natl Acad Sci U S A* **97**, 6640-6645
71. Cherepanov, P. P., and Wackernagel, W. (1995) Gene disruption in *Escherichia coli*: TcR and KmR cassettes with the option of FIp-catalyzed excision of the antibiotic-resistance determinant. *Gene* **158**, 9-14
72. Schmieger, H. (1972) Phage P22-mutants with increased or decreased transduction abilities. *Mol Gen Genet* **119**, 75-88
73. Frawley, E. R., Crouch, M. L., Bingham-Ramos, L. K., Robbins, H. F., Wang, W., Wright, G. D., and Fang, F. C. (2013) Iron and citrate export by a major facilitator superfamily pump regulates metabolism and stress resistance in *Salmonella* Typhimurium. *Proc Natl Acad Sci U S A* **110**, 12054-12059
74. Nakashima, N., and Tamura, T. (2009) Conditional gene silencing of multiple genes with antisense RNAs and generation of a mutator strain of *Escherichia coli*. *Nucleic Acids Res* **37**, e103

75. Faber, F., Tran, L., Byndloss, M. X., Lopez, C. A., Velazquez, E. M., Kerrinnes, T., Nuccio, S. P., Wangdi, T., Fiehn, O., Tsohis, R. M., and Bäumlner, A. J. (2016) Host-mediated sugar oxidation promotes post-antibiotic pathogen expansion. *Nature* **534**, 697-699
76. Aparicio, O., Geisberg, J. V., Sekinger, E., Yang, A., Moqtaderi, Z., and Struhl, K. (2005) Chromatin immunoprecipitation for determining the association of proteins with specific genomic sequences *in vivo*. *Curr Protoc Mol Biol* **Chapter 21**, Unit 21.23
77. Anwar, N., Rouf, S. F., Römling, U., and Rhen, M. (2014) Modulation of biofilm-formation in *Salmonella enterica* serovar Typhimurium by the periplasmic DsbA/DsbB oxidoreductase system requires the GGDEF-EAL domain protein STM3615. *PLoS One* **9**, e106095
78. Nash, H. A., Robertson, C. A., Flamm, E., Weisberg, R. A., and Miller, H. I. (1987) Overproduction of *Escherichia coli* integration host factor, a protein with nonidentical subunits. *J Bacteriol* **169**, 4124-4127
79. Rajkumari, K., Kusano, S., Ishihama, A., Mizuno, T., and Gowrishankar, J. (1996) Effects of H-NS and potassium glutamate on sigmaS- and sigma70-directed transcription *in vitro* from osmotically regulated P1 and P2 promoters of *proU* in *Escherichia coli*. *J Bacteriol* **178**, 4176-4181
80. Bäumlner, A. J., Gilde, A. J., Tsohis, R. M., van der Velden, A. W., Ahmer, B. M., and Heffron, F. (1997) Contribution of horizontal gene transfer and deletion events to development of distinctive patterns of fimbrial operons during evolution of *Salmonella* serotypes. *J Bacteriol* **179**, 317-322
81. Winter, S. E., Winter, M. G., Xavier, M. N., Thiennimitr, P., Poon, V., Keestra, A. M., Laughlin, R. C., Gomez, G., Wu, J., Lawhon, S. D., Popova, I. E., Parikh, S. J., Adams, L. G., Tsohis, R. M., Stewart, V. J., and Bäumlner, A. J. (2013) Host-derived nitrate boosts growth of *E. coli* in the inflamed gut. *Science* **339**, 708-711
82. Singletary, L. A., Karlinsey, J. E., Libby, S. J., Mooney, J. P., Lokken, K. L., Tsohis, R. M., Byndloss, M. X., Hirao, L. A., Gaulke, C. A., Crawford, R. W., Dandekar, S., Kingsley, R. A., Msefula, C. L., Heyderman, R. S., and Fang, F. C. (2016) Loss of Multicellular Behavior in Epidemic African Nontyphoidal *Salmonella enterica* Serovar Typhimurium ST313 Strain D23580. *MBio* **7**, e02265
83. Fang, F. C., Libby, S. J., Buchmeier, N. A., Loewen, P. C., Switala, J., Harwood, J., and Guiney, D. G. (1992) The alternative sigma factor *katF* (*rpoS*) regulates *Salmonella* virulence. *Proc Natl Acad Sci U S A* **89**, 11978-11982
84. Lange, R., and Hengge-Aronis, R. (1991) Identification of a central regulator of stationary-phase gene expression in *Escherichia coli*. *Mol Microbiol* **5**, 49-59
85. Battesti, A., Majdalani, N., and Gottesman, S. (2011) The RpoS-mediated general stress response in *Escherichia coli*. *Annu Rev Microbiol* **65**, 189-213
86. Lee, I. S., Lin, J., Hall, H. K., Bearson, B., and Foster, J. W. (1995) The stationary-phase sigma factor sigma S (RpoS) is required for a sustained acid tolerance response in virulent *Salmonella typhimurium*. *Mol Microbiol* **17**, 155-167

87. Piper, S. E., Mitchell, J. E., Lee, D. J., and Busby, S. J. (2009) A global view of *Escherichia coli* Rsd protein and its interactions. *Mol Biosyst* **5**, 1943-1947
88. Colland, F., Fujita, N., Ishihama, A., and Kolb, A. (2002) The interaction between sigmaS, the stationary phase sigma factor, and the core enzyme of *Escherichia coli* RNA polymerase. *Genes Cells* **7**, 233-247
89. Hengge-Aronis, R. (2002) Stationary phase gene regulation: what makes an *Escherichia coli* promoter sigmaS-selective? *Curr Opin Microbiol* **5**, 591-595
90. Kusano, S., Ding, Q., Fujita, N., and Ishihama, A. (1996) Promoter selectivity of *Escherichia coli* RNA polymerase E sigma 70 and E sigma 38 holoenzymes. Effect of DNA supercoiling. *J Biol Chem* **271**, 1998-2004
91. Pratt, L. A., and Silhavy, T. J. (1998) Crl stimulates RpoS activity during stationary phase. *Mol Microbiol* **29**, 1225-1236
92. Colland, F., Barth, M., Hengge-Aronis, R., and Kolb, A. (2000) sigma factor selectivity of *Escherichia coli* RNA polymerase: role for CRP, IHF and Lrp transcription factors. *EMBO J* **19**, 3028-3037
93. Barth, M., Marschall, C., Muffler, A., Fischer, D., and Hengge-Aronis, R. (1995) Role for the histone-like protein H-NS in growth phase-dependent and osmotic regulation of sigma S and many sigma S-dependent genes in *Escherichia coli*. *J Bacteriol* **177**, 3455-3464
94. Gaal, T., Ross, W., Estrem, S. T., Nguyen, L. H., Burgess, R. R., and Gourse, R. L. (2001) Promoter recognition and discrimination by EsigmaS RNA polymerase. *Mol Microbiol* **42**, 939-954
95. Becker, G., and Hengge-Aronis, R. (2001) What makes an *Escherichia coli* promoter sigma(S) dependent? Role of the -13/-14 nucleotide promoter positions and region 2.5 of sigma(S). *Mol Microbiol* **39**, 1153-1165
96. Typas, A., and Hengge, R. (2006) Role of the spacer between the -35 and -10 regions in sigmaS promoter selectivity in *Escherichia coli*. *Mol Microbiol* **59**, 1037-1051
97. Typas, A., and Hengge, R. (2005) Differential ability of sigma(s) and sigma70 of *Escherichia coli* to utilize promoters containing half or full UP-element sites. *Mol Microbiol* **55**, 250-260
98. Marschall, C., Labrousse, V., Kreimer, M., Weichart, D., Kolb, A., and Hengge-Aronis, R. (1998) Molecular analysis of the regulation of *csiD*, a carbon starvation-inducible gene in *Escherichia coli* that is exclusively dependent on sigma s and requires activation by cAMP-CRP. *J Mol Biol* **276**, 339-353
99. Arnqvist, A., Olsén, A., and Normark, S. (1994) Sigma S-dependent growth-phase induction of the *csdB* promoter in *Escherichia coli* can be achieved *in vivo* by sigma 70 in the absence of the nucleoid-associated protein H-NS. *Mol Microbiol* **13**, 1021-1032
100. Typas, A., Becker, G., and Hengge, R. (2007) The molecular basis of selective promoter activation by the sigmaS subunit of RNA polymerase. *Mol Microbiol* **63**, 1296-1306

101. Lucchini, S., Rowley, G., Goldberg, M. D., Hurd, D., Harrison, M., and Hinton, J. C. (2006) H-NS mediates the silencing of laterally acquired genes in bacteria. *PLoS Pathog* **2**, e81
102. Oshima, T., Ishikawa, S., Kurokawa, K., Aiba, H., and Ogasawara, N. (2006) *Escherichia coli* histone-like protein H-NS preferentially binds to horizontally acquired DNA in association with RNA polymerase. *DNA Res* **13**, 141-153
103. Singh, S. S., and Grainger, D. C. (2013) H-NS can facilitate specific DNA-binding by RNA polymerase in AT-rich gene regulatory regions. *PLoS Genet* **9**, e1003589
104. Kotlajich, M. V., Hron, D. R., Boudreau, B. A., Sun, Z., Lyubchenko, Y. L., and Landick, R. (2015) Bridged filaments of histone-like nucleoid structuring protein pause RNA polymerase and aid termination in bacteria. *Elife* **4**
105. Weber, H., Pesavento, C., Possling, A., Tischendorf, G., and Hengge, R. (2006) Cyclic-di-GMP-mediated signalling within the sigma network of *Escherichia coli*. *Mol Microbiol* **62**, 1014-1034
106. Rotger, R., and Casadesús, J. (1999) The virulence plasmids of *Salmonella*. *Int Microbiol* **2**, 177-184
107. Libby, S. J., Lesnick, M., Hasegawa, P., Kurth, M., Belcher, C., Fierer, J., and Guiney, D. G. (2002) Characterization of the *spv* locus in *Salmonella enterica* serovar Arizona. *Infect Immun* **70**, 3290-3294
108. Kowarz, L., Coynault, C., Robbe-Saule, V., and Norel, F. (1994) The *Salmonella typhimurium katF (rpoS)* gene: cloning, nucleotide sequence, and regulation of *spvR* and *spvABCD* virulence plasmid genes. *J Bacteriol* **176**, 6852-6860
109. Visick, J. E., and Clarke, S. (1997) RpoS- and OxyR-independent induction of HPI catalase at stationary phase in *Escherichia coli* and identification of *rpoS* mutations in common laboratory strains. *J Bacteriol* **179**, 4158-4163
110. Silva, A. J., Sultan, S. Z., Liang, W., and Benitez, J. A. (2008) Role of the histone-like nucleoid structuring protein in the regulation of *rpoS* and RpoS-dependent genes in *Vibrio cholerae*. *J Bacteriol* **190**, 7335-7345
111. Wang, H., Ayala, J. C., Benitez, J. A., and Silva, A. J. (2012) Interaction of the histone-like nucleoid structuring protein and the general stress response regulator RpoS at *Vibrio cholerae* promoters that regulate motility and hemagglutinin/protease expression. *J Bacteriol* **194**, 1205-1215
112. Fang, F. C., Krause, M., Roudier, C., Fierer, J., and Guiney, D. G. (1991) Growth regulation of a *Salmonella* plasmid gene essential for virulence. *J Bacteriol* **173**, 6783-6789
113. Beraud, M., Kolb, A., Monteil, V., D'Alayer, J., and Norel, F. (2010) A proteomic analysis reveals differential regulation of the $\sigma(S)$ -dependent *yciGFE(katN)* locus by YncC and H-NS in *Salmonella* and *Escherichia coli* K-12. *Mol Cell Proteomics* **9**, 2601-2616
114. Grob, P., and Guiney, D. G. (1996) *In vitro* binding of the *Salmonella dublin* virulence plasmid regulatory protein SpvR to the promoter regions of *spvA* and *spvR*. *J Bacteriol* **178**, 1813-1820

115. Robbe-Saule, V., Jaumouillé, V., Prévost, M. C., Guadagnini, S., Talhouarne, C., Mathout, H., Kolb, A., and Norel, F. (2006) Crl activates transcription initiation of RpoS-regulated genes involved in the multicellular behavior of *Salmonella enterica* serovar Typhimurium. *J Bacteriol* **188**, 3983-3994
116. Bougdour, A., Lelong, C., and Geiselmann, J. (2004) Crl, a low temperature-induced protein in *Escherichia coli* that binds directly to the stationary phase sigma subunit of RNA polymerase. *J Biol Chem* **279**, 19540-19550
117. Arnqvist, A., Olsén, A., Pfeifer, J., Russell, D. G., and Normark, S. (1992) The Crl protein activates cryptic genes for curli formation and fibronectin binding in *Escherichia coli* HB101. *Mol Microbiol* **6**, 2443-2452
118. Robbe-Saule, V., Carreira, I., Kolb, A., and Norel, F. (2008) Effect of growth temperature on Crl-dependent regulation of sigmaS activity in *Salmonella enterica* serovar Typhimurium. *J Bacteriol* **190**, 4453-4459
119. England, P., Westblade, L. F., Karimova, G., Robbe-Saule, V., Norel, F., and Kolb, A. (2008) Binding of the unorthodox transcription activator, Crl, to the components of the transcription machinery. *J Biol Chem* **283**, 33455-33464
120. Gaal, T., Mandel, M. J., Silhavy, T. J., and Gourse, R. L. (2006) Crl facilitates RNA polymerase holoenzyme formation. *J Bacteriol* **188**, 7966-7970
121. Robbe-Saule, V., Lopes, M. D., Kolb, A., and Norel, F. (2007) Physiological effects of Crl in *Salmonella* are modulated by sigmaS level and promoter specificity. *J Bacteriol* **189**, 2976-2987
122. Monteil, V., Kolb, A., D'Alayer, J., Beguin, P., and Norel, F. (2010) Identification of conserved amino acid residues of the *Salmonella* sigmaS chaperone Crl involved in Crl-sigmaS interactions. *J Bacteriol* **192**, 1075-1087
123. Hammar, M., Arnqvist, A., Bian, Z., Olsén, A., and Normark, S. (1995) Expression of two *csg* operons is required for production of fibronectin- and congo red-binding curli polymers in *Escherichia coli* K-12. *Mol Microbiol* **18**, 661-670
124. Martin-Orozco, N., Touret, N., Zaharik, M. L., Park, E., Kopelman, R., Miller, S., Finlay, B. B., Gros, P., and Grinstein, S. (2006) Visualization of vacuolar acidification-induced transcription of genes of pathogens inside macrophages. *Mol Biol Cell* **17**, 498-510
125. Lucchini, S., McDermott, P., Thompson, A., and Hinton, J. C. (2009) The H-NS-like protein StpA represses the RpoS (sigma 38) regulon during exponential growth of *Salmonella* Typhimurium. *Mol Microbiol* **74**, 1169-1186
126. Makinoshima, H., Nishimura, A., and Ishihama, A. (2002) Fractionation of *Escherichia coli* cell populations at different stages during growth transition to stationary phase. *Mol Microbiol* **43**, 269-279
127. Cho, B. K., Kim, D., Knight, E. M., Zengler, K., and Palsson, B. O. (2014) Genome-scale reconstruction of the sigma factor network in *Escherichia coli*: topology and functional states. *BMC Biol* **12**, 4

128. Lévi-Meyrueis, C., Monteil, V., Sismeiro, O., Dillies, M. A., Monot, M., Jagla, B., Coppée, J. Y., Dupuy, B., and Norel, F. (2014) Expanding the RpoS/ σ S-network by RNA sequencing and identification of σ S-controlled small RNAs in *Salmonella*. *PLoS One* **9**, e96918
129. Giangrossi, M., Zattoni, S., Tramonti, A., De Biase, D., and Falconi, M. (2005) Antagonistic role of H-NS and GadX in the regulation of the glutamate decarboxylase-dependent acid resistance system in *Escherichia coli*. *J Biol Chem* **280**, 21498-21505
130. Tramonti, A., De Canio, M., Delany, I., Scarlato, V., and De Biase, D. (2006) Mechanisms of transcription activation exerted by GadX and GadW at the *gadA* and *gadBC* gene promoters of the glutamate-based acid resistance system in *Escherichia coli*. *J Bacteriol* **188**, 8118-8127
131. Ma, Z., Richard, H., Tucker, D. L., Conway, T., and Foster, J. W. (2002) Collaborative regulation of *Escherichia coli* glutamate-dependent acid resistance by two AraC-like regulators, GadX and GadW (YhiW). *J Bacteriol* **184**, 7001-7012
132. Venkatesh, G. R., Kembou Koungni, F. C., Paukner, A., Stratmann, T., Blissenbach, B., and Schnetz, K. (2010) BglJ-RcsB heterodimers relieve repression of the *Escherichia coli* *bgl* operon by H-NS. *J Bacteriol* **192**, 6456-6464
133. Ueguchi, C., Ohta, T., Seto, C., Suzuki, T., and Mizuno, T. (1998) The *leuO* gene product has a latent ability to relieve *bgl* silencing in *Escherichia coli*. *J Bacteriol* **180**, 190-193
134. Tükel, C., Raffatellu, M., Humphries, A. D., Wilson, R. P., Andrews-Polymenis, H. L., Gull, T., Figueiredo, J. F., Wong, M. H., Michelsen, K. S., Akçelik, M., Adams, L. G., and Bäumlner, A. J. (2005) CsgA is a pathogen-associated molecular pattern of *Salmonella enterica* serotype Typhimurium that is recognized by Toll-like receptor 2. *Mol Microbiol* **58**, 289-304
135. Ogasawara, H., Yamamoto, K., and Ishihama, A. (2011) Role of the biofilm master regulator CsgD in cross-regulation between biofilm formation and flagellar synthesis. *J Bacteriol* **193**, 2587-2597
136. Will, W. R., Navarre, W. W., and Fang, F. C. (2015) Integrated circuits: how transcriptional silencing and counter-silencing facilitate bacterial evolution. *Curr Opin Microbiol* **23**, 8-13
137. Stapleton, M. R., Norte, V. A., Read, R. C., and Green, J. (2002) Interaction of the *Salmonella* typhimurium transcription and virulence factor SlyA with target DNA and identification of members of the SlyA regulon. *J Biol Chem* **277**, 17630-17637
138. Hulbert, R. R., and Taylor, R. K. (2002) Mechanism of ToxT-dependent transcriptional activation at the *Vibrio cholerae* *tcpA* promoter. *J Bacteriol* **184**, 5533-5544
139. Shin, M. (2017) The mechanism underlying Ler-mediated alleviation of gene repression by H-NS. *Biochem Biophys Res Commun* **483**, 392-396
140. Yu, R. R., and DiRita, V. J. (2002) Regulation of gene expression in *Vibrio cholerae* by ToxT involves both antirepression and RNA polymerase stimulation. *Mol Microbiol* **43**, 119-134
141. Gao, X., Zou, T., Mu, Z., Qin, B., Yang, J., Waltersperger, S., Wang, M., Cui, S., and Jin, Q. (2013) Structural insights into VirB-DNA complexes reveal mechanism of transcriptional activation of virulence genes. *Nucleic Acids Res* **41**, 10529-10541

142. Chen, C. C., Ghole, M., Majumder, A., Wang, Z., Chandana, S., and Wu, H. Y. (2003) LeuO-mediated transcriptional derepression. *J Biol Chem* **278**, 38094-38103
143. De la Cruz, M.A., Fernández-Mora, M., Guadarrama, C., Flores-Valdez, M. A., Bustamante, V. H., Vázquez, A., and Calva, E. (2007) LeuO antagonizes H-NS and StpA-dependent repression in *Salmonella enterica ompS1*. *Mol Microbiol* **66**, 727-743
144. Chandraprakash, D., and Seshasayee, A. S. (2014) Inhibition of factor-dependent transcription termination in *Escherichia coli* might relieve xenogene silencing by abrogating H-NS-DNA interactions *in vivo*. *J Biosci* **39**, 53-61
145. Ogasawara, H., Yamada, K., Kori, A., Yamamoto, K., and Ishihama, A. (2010) Regulation of the *Escherichia coli* *csgD* promoter: interplay between five transcription factors. *Microbiology* **156**, 2470-2483
146. Berggren, R. E., Wunderlich, A., Ziegler, E., Schleicher, M., Duke, R. C., Looney, D., and Fang, F. C. (1995) HIV gp120-specific cell-mediated immune responses in mice after oral immunization with recombinant *Salmonella*. *J Acquir Immune Defic Syndr Hum Retrovirol* **10**, 489-495
147. Römling, U. (2005) Characterization of the *rdar* morphotype, a multicellular behaviour in *Enterobacteriaceae*. *Cell Mol Life Sci* **62**, 1234-1246
148. Olvera, L., Mendoza-Vargas, A., Flores, N., Olvera, M., Sigala, J. C., Gosset, G., Morett, E., and Bolívar, F. (2009) Transcription analysis of central metabolism genes in *Escherichia coli*. Possible roles of sigma38 in their expression, as a response to carbon limitation. *PLoS One* **4**, e7466
149. Šilar, R., Holátko, J., Rucká, L., Rapoport, A., Dostálová, H., Kadeřábková, P., Nešvera, J., and Pátek, M. (2016) Use of *In Vitro* Transcription System for Analysis of *Corynebacterium glutamicum* Promoters Recognized by Two Sigma Factors. *Curr Microbiol*
150. Bouffartigues, E., Buckle, M., Badaut, C., Travers, A., and Rimsky, S. (2007) H-NS cooperative binding to high-affinity sites in a regulatory element results in transcriptional silencing. *Nat Struct Mol Biol* **14**, 441-448
151. Zakikhany, K., Harrington, C. R., Nimtz, M., Hinton, J. C., and Römling, U. (2010) Unphosphorylated CsgD controls biofilm formation in *Salmonella enterica* serovar Typhimurium. *Mol Microbiol* **77**, 771-786
152. Wu, H. M., and Crothers, D. M. (1984) The locus of sequence-directed and protein-induced DNA bending. *Nature* **308**, 509-513
153. Thompson, J. F., and Landy, A. (1988) Empirical estimation of protein-induced DNA bending angles: applications to lambda site-specific recombination complexes. *Nucleic Acids Res* **16**, 9687-9705
154. Dame, R. T., Noom, M. C., and Wuite, G. J. (2006) Bacterial chromatin organization by H-NS protein unravelled using dual DNA manipulation. *Nature* **444**, 387-390

155. Sasse-Dwight, S., and Gralla, J. D. (1989) KMnO_4 as a probe for *lac* promoter DNA melting and mechanism *in vivo*. *J Biol Chem* **264**, 8074-8081
156. Winardhi, R. S., Fu, W., Castang, S., Li, Y., Dove, S. L., and Yan, J. (2012) Higher order oligomerization is required for H-NS family member MvaT to form gene-silencing nucleoprotein filament. *Nucleic Acids Res* **40**, 8942-8952
157. Brombacher, E., Dorel, C., Zehnder, A. J., and Landini, P. (2003) The curli biosynthesis regulator CsgD co-ordinates the expression of both positive and negative determinants for biofilm formation in *Escherichia coli*. *Microbiology* **149**, 2847-2857
158. Chen, J., and Xie, J. (2011) Role and regulation of bacterial LuxR-like regulators. *J Cell Biochem* **112**, 2694-2702
159. Miyamoto, C. M., Smith, E. E., Swartzman, E., Cao, J. G., Graham, A. F., and Meighen, E. A. (1994) Proximal and distal sites bind LuxR independently and activate expression of the *Vibrio harveyi lux* operon. *Mol Microbiol* **14**, 255-262
160. van Kessel, J. C., Rutherford, S. T., Shao, Y., Utria, A. F., and Bassler, B. L. (2013) Individual and combined roles of the master regulators AphA and LuxR in control of the *Vibrio harveyi* quorum-sensing regulon. *J Bacteriol* **195**, 436-443
161. Ulitzur, S., Matin, A., Fraley, C., and Meighen, E. (1997) H-NS protein represses transcription of the *lux* systems of *Vibrio fischeri* and other luminous bacteria cloned into *Escherichia coli*. *Curr Microbiol* **35**, 336-342
162. Ulitzur, S. (1998) H-NS controls the transcription of three promoters of *Vibrio fischeri lux* cloned in *Escherichia coli*. *J Biolumin Chemilumin* **13**, 185-188
163. Diggle, S. P., Winzer, K., Lazdunski, A., Williams, P., and Cámara, M. (2002) Advancing the quorum in *Pseudomonas aeruginosa*: MvaT and the regulation of N-acylhomoserine lactone production and virulence gene expression. *J Bacteriol* **184**, 2576-2586
164. Giel, M., Desnoyer, M., and Lopilato, J. (1996) A mutation in a new gene, *bglJ*, activates the *bgl* operon in *Escherichia coli* K-12. *Genetics* **143**, 627-635
165. Martínez-Santos, V. I., Medrano-López, A., Saldaña, Z., Girón, J. A., and Puente, J. L. (2012) Transcriptional regulation of the *ecp* operon by EcpR, IHF, and H-NS in attaching and effacing *Escherichia coli*. *J Bacteriol* **194**, 5020-5033
166. Tsou, A. M., Cai, T., Liu, Z., Zhu, J., and Kulkarni, R. V. (2009) Regulatory targets of quorum sensing in *Vibrio cholerae*: evidence for two distinct HapR-binding motifs. *Nucleic Acids Res* **37**, 2747-2756
167. Lee, D. H., Jeong, H. S., Jeong, H. G., Kim, K. M., Kim, H., and Choi, S. H. (2008) A consensus sequence for binding of SmcR, a *Vibrio vulnificus* LuxR homologue, and genome-wide identification of the SmcR regulon. *J Biol Chem* **283**, 23610-23618
168. Møretrø, T., Vestby, L. K., Nesse, L. L., Storheim, S. E., Kotlarz, K., and Langsrud, S. (2009) Evaluation of efficacy of disinfectants against *Salmonella* from the feed industry. *J Appl Microbiol* **106**, 1005-1012

169. Papavasileiou, K., Papavasileiou, E., Tseleni-Kotsovili, A., Bersimis, S., Nicolaou, C., Ioannidis, A., and Chatzipanagiotou, S. (2010) Comparative antimicrobial susceptibility of biofilm versus planktonic forms of *Salmonella enterica* strains isolated from children with gastroenteritis. *Eur J Clin Microbiol Infect Dis* **29**, 1401-1405
170. Tabak, M., Scher, K., Chikindas, M. L., and Yaron, S. (2009) The synergistic activity of triclosan and ciprofloxacin on biofilms of *Salmonella* Typhimurium. *FEMS Microbiol Lett* **301**, 69-76
171. Gerstel, U., Park, C., and Römling, U. (2003) Complex regulation of *csgD* promoter activity by global regulatory proteins. *Mol Microbiol* **49**, 639-654
172. Pogliano, J., Lynch, A. S., Belin, D., Lin, E. C., and Beckwith, J. (1997) Regulation of *Escherichia coli* cell envelope proteins involved in protein folding and degradation by the Cpx two-component system. *Genes Dev* **11**, 1169-1182
173. Mika, F., and Hengge, R. (2014) Small RNAs in the control of RpoS, CsgD, and biofilm architecture of *Escherichia coli*. *RNA Biol* **11**, 494-507
174. Jubelin, G., Vianney, A., Beloin, C., Ghigo, J. M., Lazzaroni, J. C., Lejeune, P., and Dorel, C. (2005) CpxR/OmpR interplay regulates curli gene expression in response to osmolarity in *Escherichia coli*. *J Bacteriol* **187**, 2038-2049
175. Desai, S. K., Winardhi, R. S., Periasamy, S., Dykas, M. M., Jie, Y., and Kenney, L. J. (2016) The horizontally-acquired response regulator SsrB drives a *Salmonella* lifestyle switch by relieving biofilm silencing. *Elife* **5**
176. Brown, N. L., Stoyanov, J. V., Kidd, S. P., and Hobman, J. L. (2003) The MerR family of transcriptional regulators. *FEMS Microbiol Rev* **27**, 145-163
177. Ansari, A. Z., Bradner, J. E., and O'Halloran, T. V. (1995) DNA-bend modulation in a repressor-to-activator switching mechanism. *Nature* **374**, 371-375
178. Ortiz-Guerrero, J. M., Polanco, M. C., Murillo, F. J., Padmanabhan, S., and Elías-Arnanz, M. (2011) Light-dependent gene regulation by a coenzyme B₁₂-based photoreceptor. *Proc Natl Acad Sci U S A* **108**, 7565-7570
179. Bordes, P., Conter, A., Morales, V., Bouvier, J., Kolb, A., and Gutierrez, C. (2003) DNA supercoiling contributes to disconnect sigmaS accumulation from sigmaS-dependent transcription in *Escherichia coli*. *Mol Microbiol* **48**, 561-571
180. Kulkarni, R. D., and Summers, A. O. (1999) MerR cross-links to the alpha, beta, and sigma 70 subunits of RNA polymerase in the preinitiation complex at the *merTPCAD* promoter. *Biochemistry* **38**, 3362-3368
181. Brown, P. K., Dozois, C. M., Nickerson, C. A., Zuppardo, A., Terlonge, J., and Curtiss, R. (2001) MlrA, a novel regulator of curli (AgF) and extracellular matrix synthesis by *Escherichia coli* and *Salmonella enterica* serovar Typhimurium. *Mol Microbiol* **41**, 349-363
182. Ogasawara, H., Yamamoto, K., and Ishihama, A. (2010) Regulatory role of MlrA in transcription activation of *csgD*, the master regulator of biofilm formation in *Escherichia coli*. *FEMS Microbiol Lett* **312**, 160-168

183. Friedman, D. I. (1988) Integration host factor: a protein for all reasons. *Cell* **55**, 545-554
184. Yang, C. C., and Nash, H. A. (1989) The interaction of *E. coli* IHF protein with its specific binding sites. *Cell* **57**, 869-880
185. Le, S., Chen, H., Cong, P., Lin, J., Dröge, P., and Yan, J. (2013) Mechanosensing of DNA bending in a single specific protein-DNA complex. *Sci Rep* **3**, 3508
186. Queiroz, M. H., Madrid, C., Paytubi, S., Balsalobre, C., and Juárez, A. (2011) Integration host factor alleviates H-NS silencing of the *Salmonella enterica* serovar Typhimurium master regulator of SPI1, *hilA*. *Microbiology* **157**, 2504-2514
187. van Kessel, J. C., Ulrich, L. E., Zhulin, I. B., and Bassler, B. L. (2013) Analysis of activator and repressor functions reveals the requirements for transcriptional control by LuxR, the master regulator of quorum sensing in *Vibrio harveyi*. *MBio* **4**
188. Chaparian, R. R., Olney, S. G., Hustmyer, C. M., Rowe-Magnus, D. A., and van Kessel, J. C. (2016) Integration host factor and LuxR synergistically bind DNA to coactivate quorum-sensing genes in *Vibrio harveyi*. *Mol Microbiol* **101**, 823-840
189. Shultzaberger, R. K., Chen, Z., Lewis, K. A., and Schneider, T. D. (2007) Anatomy of *Escherichia coli* σ 70 promoters. *Nucleic Acids Res* **35**, 771-788
190. Aviv, M., Giladi, H., Schreiber, G., Oppenheim, A. B., and Glaser, G. (1994) Expression of the genes coding for the *Escherichia coli* integration host factor are controlled by growth phase, *rpoS*, ppGpp and by autoregulation. *Mol Microbiol* **14**, 1021-1031
191. Zulianello, L., de la Gorgue de Rosny, E., van Ulsen, P., van de Putte, P., and Goosen, N. (1994) The HimA and HimD subunits of integration host factor can specifically bind to DNA as homodimers. *EMBO J* **13**, 1534-1540
192. Yang, J., Roy, A., and Zhang, Y. (2013) Protein-ligand binding site recognition using complementary binding-specific substructure comparison and sequence profile alignment. *Bioinformatics* **29**, 2588-2595
193. Kelley, L. A., Mezulis, S., Yates, C. M., Wass, M. N., and Sternberg, M. J. (2015) The Phyre2 web portal for protein modeling, prediction and analysis. *Nat Protoc* **10**, 845-858
194. Schneider, Z., and A., S. (1987) Adenosylcobamide-dependent Reactions in *Comprehensive B₁₂* (Schneider, Z., and A., S. eds.), Walter de Gruyter, Berlin. pp 226-259
195. Schneider, Z., and Stroinski, A. (1987) Methylcobamide-dependent Reactions in *Comprehensive B₁₂* (Schneider, Z. S., A. ed.), Walter de Gruyter, Berlin. pp 259-266
196. Nahvi, A., Barrick, J. E., and Breaker, R. R. (2004) Coenzyme B₁₂ riboswitches are widespread genetic control elements in prokaryotes. *Nucleic Acids Res* **32**, 143-150
197. Takano, H., Mise, K., Hagiwara, K., Hirata, N., Watanabe, S., Toriyabe, M., Shiratori-Takano, H., and Ueda, K. (2015) Role and Function of LitR, an Adenosyl B₁₂-Bound Light-Sensitive Regulator of *Bacillus megaterium* QM B1551, in Regulation of Carotenoid Production. *J Bacteriol* **197**, 2301-2315

198. Wu, W. F., Urbanowski, M. L., and Stauffer, G. V. (1992) Role of the MetR regulatory system in vitamin B₁₂-mediated repression of the *Salmonella typhimurium metE* gene. *J Bacteriol* **174**, 4833-4837
199. Gomelsky, L., Sram, J., Moskvina, O. V., Horne, I. M., Dodd, H. N., Pemberton, J. M., McEwan, A. G., Kaplan, S., and Gomelsky, M. (2003) Identification and *in vivo* characterization of PpaA, a regulator of photosystem formation in *Rhodobacter sphaeroides*. *Microbiology* **149**, 377-388
200. Masuda, S., Berleman, J., Hasselbring, B. M., and Bauer, C. E. (2008) Regulation of aerobic photosystem synthesis in the purple bacterium *Rhodospirillum rubrum* by CrtJ and AerR. *Photochem Photobiol Sci* **7**, 1267-1272
201. Cheng, Z., Li, K., Hammad, L. A., Karty, J. A., and Bauer, C. E. (2014) Vitamin B₁₂ regulates photosystem gene expression via the CrtJ antirepressor AerR in *Rhodobacter capsulatus*. *Mol Microbiol* **91**, 649-664
202. Romine, M. F., Rodionov, D. A., Maezato, Y., Anderson, L. N., Nandhikonda, P., Rodionova, I. A., Carre, A., Li, X., Xu, C., Clauss, T. R., Kim, Y. M., Metz, T. O., and Wright, A. T. (2017) Elucidation of roles for vitamin B₁₂ in regulation of folate, ubiquinone, and methionine metabolism. *Proc Natl Acad Sci U S A* **114**, E1205-E1214
203. Price-Carter, M., Tingey, J., Bobik, T. A., and Roth, J. R. (2001) The alternative electron acceptor tetrathionate supports B₁₂-dependent anaerobic growth of *Salmonella enterica* serovar typhimurium on ethanolamine or 1,2-propanediol. *J Bacteriol* **183**, 2463-2475
204. Roth, J. R., Lawrence, J. G., and Bobik, T. A. (1996) Cobalamin (coenzyme B₁₂): synthesis and biological significance. *Annu Rev Microbiol* **50**, 137-181
205. Lee, K. M., Go, J., Yoon, M. Y., Park, Y., Kim, S. C., Yong, D. E., and Yoon, S. S. (2012) Vitamin B₁₂-mediated restoration of defective anaerobic growth leads to reduced biofilm formation in *Pseudomonas aeruginosa*. *Infect Immun* **80**, 1639-1649
206. Jeter, R. M., Olivera, B. M., and Roth, J. R. (1984) *Salmonella typhimurium* synthesizes cobalamin (vitamin B₁₂) *de novo* under anaerobic growth conditions. *J Bacteriol* **159**, 206-213
207. Keck, B., and Renz, P. (2000) *Salmonella typhimurium* forms adenylobamamide and 2-methyladenylobamamide, but no detectable cobalamin during strictly anaerobic growth. *Arch Microbiol* **173**, 76-77
208. Gerstel, U., and Römling, U. (2001) Oxygen tension and nutrient starvation are major signals that regulate *agfD* promoter activity and expression of the multicellular morphotype in *Salmonella typhimurium*. *Environ Microbiol* **3**, 638-648
209. Stepanović, S., Ćirković, I., Mijač, V., and Švabić-Vlahović, M. (2003) Influence of the incubation temperature, atmosphere and dynamic conditions on biofilm formation by *Salmonella* spp. *Food Microbiology* **20**, 5
210. Roth, J. R., Lawrence, J. G., Rubenfield, M., Kieffer-Higgins, S., and Church, G. M. (1993) Characterization of the cobalamin (vitamin B₁₂) biosynthetic genes of *Salmonella typhimurium*. *J Bacteriol* **175**, 3303-3316

211. Lamas, A., Miranda, J. M., Vázquez, B., Cepeda, A., and Franco, C. M. (2016) Biofilm formation, phenotypic production of cellulose and gene expression in *Salmonella enterica* decrease under anaerobic conditions. *Int J Food Microbiol* **238**, 63-67
212. Albert, M. J., Mathan, V. I., and Baker, S. J. (1980) Vitamin B₁₂ synthesis by human small intestinal bacteria. *Nature* **283**, 781-782
213. Elasri, M. O., and Miller, R. V. (1999) Study of the response of a biofilm bacterial community to UV radiation. *Appl Environ Microbiol* **65**, 2025-2031
214. Tschowri, N., Lindenberg, S., and Hengge, R. (2012) Molecular function and potential evolution of the biofilm-modulating blue light-signalling pathway of *Escherichia coli*. *Mol Microbiol* **85**, 893-906

Supplementary References

1. Pérez, A. G., Angarica, V. E., Vasconcelos, A. T., and Collado-Vides, J. (2007) Tractor_DB (version 2.0): a database of regulatory interactions in gamma-proteobacterial genomes. *Nucleic Acids Res* **35**, D132-136
2. Meng, X., Zhu, C., Wang, H., Wang, J., Nie, J., Hardwidge, P. R., and Zhu, G. (2013) The RNA chaperone Hfq regulates expression of fimbrial-related genes and virulence of *Salmonella enterica* serovar Enteritidis. *FEMS Microbiol Lett* **346**, 90-96
3. Yamamoto, K., and Ishihama, A. (2006) Characterization of copper-inducible promoters regulated by CpxA/CpxR in *Escherichia coli*. *Biosci Biotechnol Biochem* **70**, 1688-1695
4. Ogasawara, H., Shinohara, S., Yamamoto, K., and Ishihama, A. (2012) Novel regulation targets of the metal-response BasS-BasR two-component system of *Escherichia coli*. *Microbiology* **158**, 1482-1492
5. Ogasawara, H., Ishida, Y., Yamada, K., Yamamoto, K., and Ishihama, A. (2007) PdhR (pyruvate dehydrogenase complex regulator) controls the respiratory electron transport system in *Escherichia coli*. *J Bacteriol* **189**, 5534-5541
6. Fuentes, A. M., Díaz-Mejía, J. J., Maldonado-Rodríguez, R., and Amábile-Cuevas, C. F. (2001) Differential activities of the SoxR protein of *Escherichia coli*: SoxS is not required for gene activation under iron deprivation. *FEMS Microbiol Lett* **201**, 271-275
7. Gillette, W. K., Martin, R. G., and Rosner, J. L. (2000) Probing the *Escherichia coli* transcriptional activator MarA using alanine-scanning mutagenesis: residues important for DNA binding and activation. *J Mol Biol* **299**, 1245-1255
8. Chen, Y. P., Lin, H. H., Yang, C. D., Huang, S. H., and Tseng, C. P. (2012) Regulatory role of cAMP receptor protein over *Escherichia coli* fumarase genes. *J Microbiol* **50**, 426-433
9. Kumar, R., and Shimizu, K. (2011) Transcriptional regulation of main metabolic pathways of *cyoA*, *cydB*, *fnr*, and *fur* gene knockout *Escherichia coli* in C-limited and N-limited aerobic continuous cultures. *Microb Cell Fact* **10**, 3
10. Park, S. J., and Gunsalus, R. P. (1995) Oxygen, iron, carbon, and superoxide control of the fumarase *fumA* and *fumC* genes of *Escherichia coli*: role of the *arcA*, *fnr*, and *soxR* gene products. *J Bacteriol* **177**, 6255-6262
11. Kaiser, M., and Sawers, G. (1995) Nitrate repression of the *Escherichia coli pfl* operon is mediated by the dual sensors NarQ and NarX and the dual regulators NarL and NarP. *J Bacteriol* **177**, 3647-3655

12. Sawers, G., and Suppmann, B. (1992) Anaerobic induction of pyruvate formate-lyase gene expression is mediated by the ArcA and FNR proteins. *J Bacteriol* **174**, 3474-3478
13. Sirko, A., Zehelein, E., Freundlich, M., and Sawers, G. (1993) Integration host factor is required for anaerobic pyruvate induction of *pfl* operon expression in *Escherichia coli*. *J Bacteriol* **175**, 5769-5777
14. Zheng, D., Constantinidou, C., Hobman, J. L., and Minchin, S. D. (2004) Identification of the CRP regulon using *in vitro* and *in vivo* transcriptional profiling. *Nucleic Acids Res* **32**, 5874-5893
15. Chintakayala, K., Singh, S. S., Rossiter, A. E., Shahapure, R., Dame, R. T., and Grainger, D. C. (2013) *E. coli* Fis protein insulates the *cbpA* gene from uncontrolled transcription. *PLoS Genet* **9**, e1003152
16. Partridge, J. D., Scott, C., Tang, Y., Poole, R. K., and Green, J. (2006) *Escherichia coli* transcriptome dynamics during the transition from anaerobic to aerobic conditions. *J Biol Chem* **281**, 27806-27815
17. Pilonieta, M. C., Erickson, K. D., Ernst, R. K., and Detweiler, C. S. (2009) A protein important for antimicrobial peptide resistance, YdeI/OmdA, is in the periplasm and interacts with OmpD/NmpC. *J Bacteriol* **191**, 7243-7252
18. Erickson, K. D., and Detweiler, C. S. (2006) The Rcs phosphorelay system is specific to enteric pathogens/commensals and activates *ydeI*, a gene important for persistent *Salmonella* infection of mice. *Mol Microbiol* **62**, 883-894
19. Shimada, T., Katayama, Y., Kawakita, S., Ogasawara, H., Nakano, M., Yamamoto, K., and Ishihama, A. (2012) A novel regulator RcdA of the *csgD* gene encoding the master regulator of biofilm formation in *Escherichia coli*. *Microbiologyopen* **1**, 381-394
20. Will, W. R., Bale, D. H., Reid, P. J., Libby, S. J., and Fang, F. C. (2014) Evolutionary expansion of a regulatory network by counter-silencing. *Nat Commun* **5**, 5270
21. Francez-Charlot, A., Castanié-Cornet, M. P., Gutierrez, C., and Cam, K. (2005) Osmotic regulation of the *Escherichia coli* *bdm* (biofilm-dependent modulation) gene by the RcsCDB His-Asp phosphorelay. *J Bacteriol* **187**, 3873-3877
22. Zhang, X. S., García-Contreras, R., and Wood, T. K. (2008) *Escherichia coli* transcription factor YncC (McbR) regulates colanic acid and biofilm formation by repressing expression of periplasmic protein YbiM (McbA). *ISME J* **2**, 615-631
23. Camakaris, H., and Pittard, J. (1982) Autoregulation of the *tyrR* gene. *J Bacteriol* **150**, 70-75

24. Boulanger, A., Francez-Charlot, A., Conter, A., Castanié-Cornet, M. P., Cam, K., and Gutierrez, C. (2005) Multistress regulation in *Escherichia coli*: expression of *osmB* involves two independent promoters responding either to sigmaS or to the RcsCDB His-Asp phosphorelay. *J Bacteriol* **187**, 3282-3286
25. Hermans, K., Roberfroid, S., Thijs, I. M., Kint, G., De Coster, D., Marchal, K., Vanderleyden, J., De Keersmaecker, S. C., and Steenackers, H. P. (2016) FabR regulates *Salmonella* biofilm formation via its direct target FabB. *BMC Genomics* **17**, 253
26. Beraud, M., Kolb, A., Monteil, V., D'Alayer, J., and Norel, F. (2010) A proteomic analysis reveals differential regulation of the σ (S)-dependent *yciGFE(katN)* locus by YncC and H-NS in *Salmonella* and *Escherichia coli* K-12. *Mol Cell Proteomics* **9**, 2601-2616
27. De Lay, N., and Gottesman, S. (2009) The Crp-activated small noncoding regulatory RNA CyaR (RyeE) links nutritional status to group behavior. *J Bacteriol* **191**, 461-476
28. Raivio, T. L., Leblanc, S. K., and Price, N. L. (2013) The *Escherichia coli* Cpx envelope stress response regulates genes of diverse function that impact antibiotic resistance and membrane integrity. *J Bacteriol* **195**, 2755-2767
29. Vogt, S. L., Evans, A. D., Guest, R. L., and Raivio, T. L. (2014) The Cpx envelope stress response regulates and is regulated by small noncoding RNAs. *J Bacteriol* **196**, 4229-4238
30. Martin, J. E., and Imlay, J. A. (2011) The alternative aerobic ribonucleotide reductase of *Escherichia coli*, NrDEF, is a manganese-dependent enzyme that enables cell replication during periods of iron starvation. *Mol Microbiol* **80**, 319-334
31. Torrents, E., Grinberg, I., Gorovitz-Harris, B., Lundström, H., Borovok, I., Aharonowitz, Y., Sjöberg, B. M., and Cohen, G. (2007) NrdR controls differential expression of the *Escherichia coli* ribonucleotide reductase genes. *J Bacteriol* **189**, 5012-5021
32. Wang, L., Hashimoto, Y., Tsao, C. Y., Valdes, J. J., and Bentley, W. E. (2005) Cyclic AMP (cAMP) and cAMP receptor protein influence both synthesis and uptake of extracellular autoinducer 2 in *Escherichia coli*. *J Bacteriol* **187**, 2066-2076
33. Stojiljkovic, I., Bäumlner, A. J., and Hantke, K. (1994) Fur regulon in gram-negative bacteria. Identification and characterization of new iron-regulated *Escherichia coli* genes by a *fur* titration assay. *J Mol Biol* **236**, 531-545
34. Augustus, A. M., and Spicer, L. D. (2011) The MetJ regulon in gammaproteobacteria determined by comparative genomics methods. *BMC Genomics* **12**, 558

35. Grob, P., and Guiney, D. G. (1996) *In vitro* binding of the *Salmonella* dublin virulence plasmid regulatory protein SpvR to the promoter regions of *spvA* and *spvR*. *J Bacteriol* **178**, 1813-1820
36. Cordero-Alba, M., and Ramos-Morales, F. (2014) Patterns of expression and translocation of the ubiquitin ligase SlrP in *Salmonella enterica* serovar Typhimurium. *J Bacteriol* **196**, 3912-3922
37. Ellermeier, C. D., and Slauch, J. M. (2003) RtsA and RtsB coordinately regulate expression of the invasion and flagellar genes in *Salmonella enterica* serovar Typhimurium. *J Bacteriol* **185**, 5096-5108
38. Xu, X., and Hensel, M. (2010) Systematic analysis of the SsrAB virulon of *Salmonella enterica*. *Infect Immun* **78**, 49-58
39. Altuvia, S., Almirón, M., Huisman, G., Kolter, R., and Storz, G. (1994) The *dps* promoter is activated by OxyR during growth and by IHF and sigma S in stationary phase. *Mol Microbiol* **13**, 265-272
40. Grainger, D. C., Goldberg, M. D., Lee, D. J., and Busby, S. J. (2008) Selective repression by Fis and H-NS at the *Escherichia coli* *dps* promoter. *Mol Microbiol* **68**, 1366-1377
41. Yamamoto, K., Ishihama, A., Busby, S. J., and Grainger, D. C. (2011) The *Escherichia coli* K-12 MntR miniregulon includes *dps*, which encodes the major stationary-phase DNA-binding protein. *J Bacteriol* **193**, 1477-1480
42. Yamamoto, K., Ogasawara, H., and Ishihama, A. (2008) Involvement of multiple transcription factors for metal-induced *spy* gene expression in *Escherichia coli*. *J Biotechnol* **133**, 196-200
43. Plumbridge, J., and Pellegrini, O. (2004) Expression of the chitobiose operon of *Escherichia coli* is regulated by three transcription factors: NagC, ChbR and CAP. *Mol Microbiol* **52**, 437-449
44. Zhou, X., Meng, X., and Sun, B. (2008) An EAL domain protein and cyclic AMP contribute to the interaction between the two quorum sensing systems in *Escherichia coli*. *Cell Res* **18**, 937-948
45. Wada, T., Tanabe, Y., and Kutsukake, K. (2011) FliZ acts as a repressor of the *ydiV* gene, which encodes an anti-FlhD4C2 factor of the flagellar regulon in *Salmonella enterica* serovar typhimurium. *J Bacteriol* **193**, 5191-5198

Vita

Shannon Newman is originally from St. Charles, Illinois. She graduated *summa cum laude* in course and *summa cum laude* in independent research at Lawrence University in Appleton, Wisconsin, where she earned a Bachelor of Arts in Biochemistry with a minor in German in 2011 and was inducted into the prestigious Phi Beta Kappa honor society. Shannon joined the Molecular and Cellular Biology Interdisciplinary Graduate Program at the University of Washington in the Fall of 2011. In Ferric Fang's lab, she was a two-time honorable mention of the National Science Foundation Graduate Research Fellowship and the recipient of the Cellular and Molecular Biology Training Grant. She defended her dissertation regarding the molecular and biochemical mechanisms of gene regulation in *Salmonella enterica* on June 23rd, 2017. Passionate about education and fostering meaningful learning experiences, Shannon will be beginning a position after graduation as Associate Professor at Pierce College in Puyallup, Washington. She will be working with adults to complete their high school diploma and transition into college level science courses. Outside of science, Shannon plays viola with the Puget Sound Symphony Orchestra, is an avid gardener and hiker, and enjoys organizing social dinner parties for others.